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The inadequacy of available pharmacotherapy for managing chronic pain imposes a 
huge burden on both patients, healthcare services and the economy. The exploitation of 
biologics, specifically botulinum neurotoxin A (BoNT/A), is important for the development 
of novel long-acting analgesics. BoNT/A induces analgesia in numerous chronic pain 
models, via the disruption of SNARE-mediated cellular processes. To aid translation into 
humans, reengineering BoNT/A can eliminate its paralytic effects and improve its safety 
profile. BiTox/A, an elongated version of BoNT/A, was generated using SNARE-stapling 
technology and effectively reduced mechanical hypersensitivity in multiple pain models, 
presumably via actions at the A-nociceptors. Producing a chimera as efficacious against 
other clinical features of pain, including thermal hyperalgesia, requires the retargeting of 
BoNT/A’s catalytic activity to different sensory neuron subpopulations. The light chain-
translocation domain of BoNT/A (LcTd/A) was thus conjugated to the receptor binding 
domain (Rbd) of alternate BoNT serotypes, /C to /E. Staining of cultured sensory neurons 
revealed that conjugation of LcTd/A to BoNT/D-derived Rbd produced SNAP25 cleavage 
in a subpopulation of smaller myelinated neurons. Unexpectedly, intraplantar injection of 
the chimera into an inflammatory pain model potentially prolonged thermal hyperalgesia 
and failed to alter mechanical hypersensitivity. Conversely, LcTd/A conjugated to cholera 
toxin-derived binding domain attenuated the development of, and reversed, mechanical 
hypersensitivity in a post-operative pain model and a chemotherapy-induced peripheral 
neuropathy model, yet remained ineffective against thermal hyperalgesia.  
BoNT/A’s analgesic effect is hypothesised to be predominantly centrally-mediated. To 
determine whether this theory was also relevant to BiTox/A, the chimera’s in vivo activity 
was examined. Cleaved SNAP25 was revealed in the ipsilateral ventral horn with sparse 
labelling in the dorsal horn, as well as in the peripheral afferent terminals, thus implying 
that a peripheral and central action contribute to the analgesic effect. After demonstrating 
penetration of the central nervous system, the application of toxin chimeras for drug 
delivery to the spinal cord was investigated using tetanus binding domain (Tbd). Tbd 
successfully chaperoned fluorescent tags and LcTd/A to the spinal cord. Attachment of 
a second Tbd to chimeras significantly increased the detectable fluorescence and 
amount of cleaved SNAP25 in the ventral horn. In conclusion, the smaller Aδ-
nociceptors, targeted by BoNT/D-derived Rbd, likely contribute to the resolution of 
inflammation and the recovery of normal thermal sensation. Targeting of LcTd/A by 
cholera toxin resulted in a functional analgesic that displayed less penetration of the 
ventral horn, indicating a reduced motor effect. This chimera should thus be pursued as 
a potential long-lasting analgesic. Equally, tetanus proved an efficacious tool for spinal 
cord delivery. Attaching a second binding domain successfully increased its potency, 
emphasising the versatility and technical advancement of the SNARE-stapling approach.  
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SNI Spared Nerve Injury 
SV2 Synaptic Vesicle Protein 2 
SV2/A Synaptic Vesicle Protein 2 Isoform A 
SV2/B Synaptic Vesicle Protein 2 Isoform B 
SV2/C Synaptic Vesicle Protein 2 Isoform C 
Syn Syntaxin 
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TetBot SNARE-stapled chimera constructed from LcTd/A conjugated to Tbd 
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v/v Volume/Volume percentage 
VAMP Vesicle-Associated Membrane Protein 
VAS Visual Analogue Scale 
w/v Weight/Volume percentage 
WB Western Blot 
WDR Wide Dynamic Range 
α-BTX Alpha Bungarotoxin 











Chapter 1. Introduction 
 
Chronic pain is generally defined to be pain that outlasts the normal recovery period, 
following injury or damage. Clinically, it is recognised as pain that persists beyond 3 to 6 
months (Treede et al., 2015). It is estimated that 19% of the European population suffer 
from chronic pain (Breivik et al., 2006). Analogous statistics have been reported within 
the Australian population with 17% of males and 20% of females identifying as chronic 
pain sufferers (Blyth et al., 2001). For approximately 40% of these chronic pain sufferers, 
pharmacological intervention provides inadequate pain relief (Breivik et al., 2006). This 
primarily results from a lack of medication, specifically intended for use in chronic pain 
conditions. Instead, pharmacological management of chronic pain relies upon a 
combination of anti-inflammatories, anti-epileptics, anti-depressants and opioids to 
acutely manage pain conditions (Dworkin et al., 2007). Often, these medications are 
associated with significant adverse effects which thus limits their use.  
The huge economic burden imposed by chronic pain combined with its increased 
prevalence, associated with age, raises great concern about the future impact that 
chronic pain may have on healthcare services and society, given the aging population 
(Sleed et al., 2005; Phillips, 2009; Kaye et al., 2010). This concern has consequently led 
to an increased interest in developing novel pain therapeutics. Many avenues are being 
explored in order to produce therapeutics that selectively target pain signalling pathways. 
The use of Botulinum neurotoxin (BoNT) represents one such avenue being pursued. 
Specifically, when retargeted through protein modification, BoNT can be used to silence 
distinct populations of neuronal cell types for several months, following localised injection 
(Arsenault et al., 2013; Ferrari et al., 2013; Ma et al., 2014). 
This introduction will now proceed to discuss chronic pain and the mechanisms by which 
it is hypothesised to arise before introducing BoNT subtype A (BoNT/A) and its clinical 
applications in pain at present. In addition, the protein engineering approaches being 
used to improve efficacy of BoNT/A as an analgesic, as well as its safety profile, and the 
success of these techniques will be described. 
 
1.1 Chronic Pain 
 
1.1.1 The epidemiology of chronic pain 
1.1.1.1 Inflammatory Pain 
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Chronic pain forms an umbrella term for a multitude of pain conditions. Chronic 
inflammatory pain is the most prevalent with arthritis being the leading cause of pain, 
accounting for 40% of chronic pain sufferers in Europe (Breivik et al., 2006). 
Inflammatory pain is unique in comparison to other chronic pain conditions because it is 
largely nociceptive, meaning that there is an on-going stimulus which elicits the pain 
response. Inflammatory pain does, however, begin to comprise some neuropathic 
components as the disease progresses which result from the continuous activation of 
the pain signalling pathways (van Laar et al., 2012).  
 
1.1.1.2 Neuropathic Pain 
In contrast to inflammatory pain, neuropathic pain conditions feature pain signalling and 
pain sensation which persist in the absence of a noxious stimulus. Historically, 
neuropathic pain was referred to as “pain initiated or caused by a primary lesion or 
dysfunction in the nervous system” (Merskey and Bogduk, 2012). This definition has now 
been revised and neuropathic pain is instead specified as “pain caused by a lesion or 
disease of the somatosensory system” (Jensen et al., 2011). The latter definition 
prevents complications caused by whether pain is initiated by a primary or secondary 
lesion and also avoids conditions, such as complex regional pain syndrome with more 
complex aetiology, being misappropriated as neuropathic pain conditions (Backonja, 
2003). Current estimates indicate that the prevalence of neuropathic pain is 7-10% in the 
UK population (van Hecke et al., 2014). 
Within the neuropathic pain bracket there are several distinct conditions. For example, 
2.4% of the population are estimated to suffer from peripheral neuropathies. The most 
prominent being painful diabetic peripheral neuropathy (PDPN) which presents in 26.4% 
of all type 2 diabetic patients (Martyn and Hughes, 1997; Davies et al., 2006). This 
statistic then increases to over 50% of type 2 diabetic patients over the age of 60 
experiencing PDPN (Young et al., 1993). Peripheral neuropathies are also commonly 
developed following chemotherapy in cancer patients. They are estimated to occur in 
90% of all cases due to the neurotoxic damage of nerves (Fallon, 2013). Both of these 
peripheral neuropathies typically present with a ‘gloves and stocking’ distribution due to 
the increased vulnerability of the longer peripheral nerves to neurotoxic damage (Said et 
al., 1983; Starobova and Vetter, 2017). 
Alternatively, neuropathic pain can affect a specific body region, resulting from damage 
to a specific nerve. For example, trigeminal neuralgia, a rarer condition, which affects 
0.03%- 0.3% of people, is believed to result from the focal demyelination of the trigeminal 
nerve due to compression of the nerve, most likely by blood vessels (Love and Coakham, 
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2001; De Toledo et al., 2016). Damage to nerves, typically the brachial plexus, commonly 
occurs following road traffic accidents. Brachial plexus injuries were identified in 1.2% of 
trauma patients and were  particularly prevalent in patients involved in motor cyclist 
accidents (Midha, 1997). Notably, brachial plexus injuries account for 36% of all 
traumatic peripheral nerve injuries (Ciaramitaro et al., 2010).  
Additionally, nerve damage can be inflicted by viral infection. For example, post-herpetic 
neuralgia is frequently experienced following herpes zoster infection. An Icelandic study 
stated that pain persisting past 3 months was reported in 1.8% of patients, aged below 
60, infected with herpes zoster, whereas approximately 7% of patients aged over 60 had 
pain persisting beyond 3 months (Helgason et al., 2000). Conversely, an American study 
described post-herpetic neuralgia in 25%-50% of patients aged over 50 who had incurred 
herpes zoster (Schmader, 2002). Both studies, however, emphasised an increased 
severity and incidence associated with age. Postherpetic neuralgia presents in the 
infected nerve and the associated dermatome or dermatomes. This consequently 
produces a focal neuropathy rather than a global neuropathy, as is classically observed 
in PDPN and chemotherapy-induced peripheral neuropathy (Rowbotham et al., 1998). 
 
1.1.1.3 Chronic Post-Surgical Pain 
Post-operative pain occurs following 10–50% of surgical cases. It is most commonly 
associated with surgical procedures such as breast surgery, limb amputation, 
thoracotomy and major heart surgery (Kehlet et al., 2006). The highest incidence for 
post-surgical pain occurs after limb amputation (Kehlet et al., 2006; Macrae, 2008). 
Mastectomy is a frequently used surgical intervention for treating breast cancer. 22–72% 
of breast cancer patients experience postmastectomy pain syndrome, a post-surgical 
pain condition (Gottrup et al., 2000; Andersen and Kehlet, 2011). Within the UK, post-
surgical pain is responsible for introducing an additional 140,000 patients with disabling 
chronic pain each year (Werner and Kongsgaard, 2014). 
The pathophysiology of chronic post-surgical pain is not well understood. It is generally 
accepted that it must arise from a combination of local inflammation due to the cutting of 
tissue at the surgical site causing direct activation of nociceptors, as well as nerve 
damage due to the severing of nerves, or damage inflicted to nerves, during the surgical 
procedure. This subsequently introduces a neuropathic component (Macrae, 2008; 
Reddi and Curran, 2014). There is also a large role for psychological factors in post-
surgical pain, such as catastrophising and attribution of blame, which are known to 
impact the development of chronic post-surgical pain and patient responsiveness to 
intervention (Macrae, 2008; Reddi and Curran, 2014). 
19 
 
1.1.2 Pathophysiology of chronic pain 
Although chronic inflammatory pain conditions and neuropathic pain conditions can 
present differently clinically and arise from contrasting aetiologies, the same fundamental 
mechanisms are believed to underlie the development of all subclasses of chronic pain 
(Xu and Yaksh, 2011). 
. 
1.1.2.1 Pain signalling pathways 
Acute nociception relies upon the activation of nociceptors, namely the high-threshold 
unmyelinated C-fibres and the lightly myelinated Aδ-fibres (Fig.1.1A). C-fibre nociceptors 
are polymodal and respond to thermal, mechanical and chemical stimuli, however, some 
 
Figure 1.1 The properties of sensory neuron 
subtypes relate to the different pain qualities 
experienced. (A) The table describes the three main 
classification groups for sensory neurons. Notably, the 
axon diameter (Pocock et al., 2018) and conduction 
velocity (Abraira and Ginty, 2013) are much greater in 
the Aβ-fibres than the other sensory subtypes. These 
properties correspond to the level of myelination. (B) 
Analysis of the compound action potential from a 
peripheral nerve reveals that the quality of pain 
experienced is dependent upon which sensory 
subpopulations are activated and their respective 
conduction velocities. Activation of Aδ-nociceptors 
correlates to a sharp pain (first pain), whereas activation 
of C-nociceptors produces the dull, aching, diffuse pain 
(second pain). Graph from Julius and Basbaum (2001).   
20 
 
populations only respond to a subset of these stimuli (Caterina and Julius, 1999; Almeida 
et al., 2004). Additionally, C-fibres can be classified as either peptidergic or non-
peptidergic, depending on their expression of neuropeptides (Caterina and Julius, 1999). 
Whilst Aδ-fibre nociceptors can also be polymodal, they are more commonly responsive 
to either mechanical or thermal stimuli, exclusively (Dubin and Patapoutian, 2010). In 
contrast the large diameter, myelinated Aβ-sensory afferents are low threshold 
mechanoreceptors and are responsive to innocuous stimuli,  for instance, touch (Fig. 
1.1A) (Abraira and Ginty, 2013). 
All sensory neurons, including nociceptors, are pseudopolar neurons whose cell soma 
reside in the dorsal root ganglia, located outside of the spinal cord. The axons of sensory 
neurons project to the dorsal horn of the spinal cord where they form synapses with 
interneurons and wide dynamic range (WDR) neurons. Specifically, the C-fibre 
nociceptors terminate in lamina I-IIo (outer), known as the substantia gelantinosa, and 
the Aδ- nociceptors terminate in lamina I and V (Fig 1.2) (Todd, 2010). Conversely, the 
low threshold mechanoreceptors, the Aβ-fibre sensory afferents, project to lamina IIi 
(inner)-V  (Todd, 2010). Whilst interneurons terminate locally within the spinal cord, the 
wide dynamic range neuron relay information from the peripheral nociceptive afferents 
to the higher regions of the central nervous system, including the somatosensory cortical 
areas, mainly via the lateral spinothalamic tract (Fig 1.3) (Todd, 2017).  
 
 
Figure 1.2 Primary afferents terminate within distinct laminae of the dorsal horn. The central 
terminals of the sensory afferents project to the dorsal horn of the spinal cord. C-fibres terminate 
within the substantia gelatinosa. Specifically, the peptidergic C-nociceptors project to lamina I and 
lamina IIo (outer), whereas the terminals of non-peptidergic C-fibres remain confined to Lamina 
II. Aδ-nociceptors terminate in Lamina I, with some collaterals projecting to Lamina V. Additionally, 
Aδ-fibres which innervate the hair follicles, terminate in Lamina IIi (inner) and Lamina III, however, 
these are not relevant when studying the glabrous skin. The low-threshold Aβ mechanoreceptors 
conversely terminate between laminae IIi and V. Although not shown, projection neurons are 
predominantly found in lamina I, as well as being present in lamina III–VI. The interneurons are 
located largely within Laminae I-III. From Todd (2010).  
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 Figure 1.3 The lateral spinothalamic 
tract. Nociceptors propagate noxious 
information from the periphery to the dorsal 
horn of the spinal cord (green pathway). 
Here, they synapse on to, and activate, 
second order projection neurons. Notably, 
the projection neurons decussate at the 
level of the spinal cord and access the 
contralateral lateral spinothalamic tract, 
before ascending to the ventral 
posterolateral nucleus of the thalamus. 
Information is then conveyed to the 
somatosensory cortices by third order 
neurons. Importantly, many of the projection 
neurons have collaterals which terminate 
within other central areas implicated in pain 
processing. Namely, the rostral ventral 
medulla and periaqueductal gray which are important for the descending inhibitory and facilitatory 
control of pain (orange arrows). Other collaterals project to the parabrachial nucleus and 
contribute to the emotional aspect of pain due to the subsequent activation of the amygdala and 
insula cortex (blue pathway). From Basbaum et al. (2009).  
 
Dissimilar to other the signalling tracts, the wide dynamic range neurons, the projection 
neurons, first decussate to the contralateral lateral spinothalamic tract, via the anterior 
white commissure of the spinal cord, before ascending to the thalamus. Specifically, 
upon reaching the thalamus, the projection neurons terminate within the ventral 
posterolateral nucleus of the thalamus where they synapse on to third order neurons. It 
is the third order neurons which are then responsible for transmitting sensory information 
to the higher cortical regions, such as the somatosensory cortices (Steeds, 2016). There 
is also evidence that within the spinothalamic tract, there are axon collaterals which 
project to other central structures involved in pain processing, such as the periaqueductal 
grey and the lateral brachial nucleus (Al-Khater and Todd, 2009).  
 
1.1.2.2 Peripheral Sensitisation 
1.1.2.2.1 Sensitisation of the peripheral terminal 
It is changes that occur within the pain signalling pathway that lead to the chronification 
of pain. Peripheral sensitisation specifically refers to the increased excitability and 
reduced activation threshold of nociceptive neurons, within the peripheral nervous 
system (Julius and Basbaum, 2001). This is most commonly initiated by either nerve or 
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tissue damage which produces a local inflammatory response, resulting in the release of 
inflammatory mediators, including Adenosine triphosphate (ATP), histamine, bradykinin 
and nerve growth factor (NGF), as well as the recruitment of inflammatory cells (Okuse, 
2007). The inflammatory mediators released bind to and directly activate the nociceptors 
(Amaya et al., 2013) whilst simultaneously stimulating the nociceptors to release their 
own subset of inflammatory mediators, including Substance P and Calcitonin gene-
related peptide (CGRP) (Schaible et al., 2011). The additional release of inflammatory 
mediators from the nociceptors augments the local inflammation by promoting plasma 
extravasation and vasodilation. This process is referred to as neurogenic inflammation 
(Xanthos and Sandkühler, 2014). 
Upon binding to nociceptive neurons, local inflammatory mediators promote the 
activation of intracellular signalling pathways that result in post-translational 
modifications being made to receptors and ion channels, such as phosphorylation, as 
well as increased gene expression and receptor trafficking (Bhave and Gereau IV, 2004). 
One of the best characterised targets of peripheral sensitisation is the capsaicin receptor, 
TRPV1 (transient receptor potential vanilloid receptor-1), which is specifically implicated 
in  the development of thermal hyperalgesia (Huang et al., 2006). For example, it has 
been shown that NGF, a key component of the inflammatory soup, activates mitogen-
activated protein (MAP) kinase signalling pathways in C-fibre nociceptors, resulting in 
increased trafficking of TRPV1 to the peripheral terminal (Ji et al., 2002). Meanwhile, 
other inflammatory mediators, for example, bradykinin, activate the Protein Kinase C 
(PKC) pathway which leads to the sensitisation of TRPV1 receptors already located at 
the plasma membrane, by increasing the probability of the channel opening, thus 
increasing the excitability of the neuron (Premkumar and Ahern, 2000; Huang et al., 
2006).  
Similar mechanisms have been demonstrated with respect to the ion channels. For 
example, prostaglandin E2 (PGE2) causes activation of the PKC and Protein Kinase A 
(PKA) kinases within the nociceptive afferents (Gold et al., 1998). The activation of these 
kinases results in an increased tetrodotoxin-resistant sodium current via the voltage 
gated sodium channels which precipitates in a decreased current threshold, required for 
neuronal firing (England et al., 1996; Gold et al., 1998). Additionally, the increased 
expression of sensory neuron specific tetrodotoxin-resistant PN3 sodium channel has 
been implicated in the development of mechanical allodynia and thermal hyperalgesia 
after injury in rat models of both neuropathic and inflammatory pain  (Porreca et al., 1999) 
Collectively, modifications made to receptors and ion channels, including their increased 
plasma membrane insertion, consequently impact the overall excitability of nociceptors. 
These changes in excitability correspond to the clinical features of chronic pain, such as 
23 
 
allodynia and hyperalgesia. The reduced activation threshold of nociceptors means that 
previously innocuous stimuli become sufficient to activate nociceptors, and thus, are now 
perceived to be noxious, analogous to allodynia. Conversely, the increased 
responsiveness of nociceptive neurons results in nociceptors eliciting a much larger 
neuronal response to a noxious stimuli, perceived as primary hyperalgesia, localised to 
the injury site (von Hehn et al., 2012). Additionally, if hyperexcitability develops in the 
neuron, then this can result in ectopic firing, associated with spontaneous pain attacks 
(von Hehn et al., 2012). 
 
1.1.2.2.2 Recruitment of silent nociceptors 
In addition to the increased excitability of neurons, peripheral sensitisation also features 
the recruitment of so called “silent nociceptors” (Gold and Gebhart, 2010). Silent 
nociceptors are insensitive to thermal and mechanical stimuli when in a non-pathological 
state and are estimated to account for nearly a quarter of all C-fibre nociceptors (Schmidt 
et al., 1995). After exposure to a chemical irritant, i.e. capsaicin or mustard oil, a 
proportion of these normally insensitive C-fibre nociceptors gain responsiveness to a 
sensory modality (Davis et al., 1993; Schmidt et al., 1995). Furthermore, within the 
population of C-fibre nociceptors already either exclusively mechano- or thermo-
sensitive, a subset develop an additional sensory modality responsiveness to become 
mechano-heat-sensitive (Schmidt et al., 1995).  Interestingly, Kress et al. (1992) reported 
a higher yield of recruited silent nociceptors after exposure to inflammatory mediators, 
compared with exposure to chemical irritation. This could be due to the physiological 
relevance of inflammatory mediators, compared to chemical irritants. Regardless, the 
activation of these previously unresponsive neurons act to increase the peripheral input 
and drive to the central synapse, providing spatial summation of the nociceptive signal 
(Kress et al., 1992; Schmidt et al., 1995).  
 
1.1.2.3 Central Sensitisation 
The enhanced activity of the peripheral nociceptive afferents, resulting from peripheral 
sensitisation, drives potentiation at the central synapse. This consequently augments the 
synaptic efficacy of the synapse which, in turn, causes increased excitability of the 
second order neurons in the central nervous system. The subsequent hyperexcitability 
of the pain signalling pathways, induced by the changes that occur within the central 
nervous system to amplify pain signalling, is thus referred to as central sensitisation. 
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This central mechanism for persistent pain was first realised by Woolf (1983). In the 
study, the flexor reflex withdrawal response, normally elicited to noxious stimuli, was 
measured in the α-motor neurons innervating the biceps femoris muscle in rats. Under 
normal physiological conditions, innocuous stimuli to the hindpaw did not produce a 
reflex response. Only with the application of noxious stimuli was the reflexive response 
observed. Conversely, after repeated application of a noxious heat source to the hindpaw 
that was of sufficient intensity to induce mild localised inflammation, innocuous stimuli 
were then able to elicit a reflex response from the motor neurons of the biceps femoris 
muscle. Additionally, an increased excitability and a reduced activation threshold was 
noted in the motor neurons, as well as an enlarged receptive field, and these changes 
persisted for several hours. 
It was confirmed that the changes identified were due to a central mechanism after 
anaesthetic block, administered locally to the site of injury, failed to reverse the enlarged 
receptive fields of the motor neurons. This indicated that it could not be a peripherally-
mediated mechanism otherwise the receptive fields would have immediately returned to 
their original size. Instead, it demonstrated that the enlarged fields were being centrally 
maintained. Furthermore, electrical stimulation of the low threshold Aβ- sensory neurons, 
normally irresponsive to noxious stimuli, caused the reflex to occur suggesting that Aβ-
fibres were able to access the nociceptive pathway at the central level, again, implying 
a central mechanism. Additionally, the results could be replicated by low-frequency 
stimulation of the sural nerve, specifically at the frequency at which to activate C-fibre 
nociceptors. This stimulation again caused the reflexive response to be elicited by 
innocuous stimuli and provided evidence that it was the repeated activation of the C-fibre 
nociceptors that was driving plasticity within the central nervous system to enable 
nociceptive responses to Aβ-fibre stimulation. Woolf (1983) had inadvertently discovered 
the first evidence for long-term potentiation, a mechanism by which synaptic strength is 
increased and sustained over a period of time, in the dorsal horn.  
 
1.1.2.3.1 Synaptic potentiation 
The primary neurotransmitter used by sensory afferents is glutamate. Under normal 
physiological conditions, the amount of glutamate released is sufficient to cause post-
synaptic depolarisation, however, it does not normally induce any long-term changes to 
the synapse. In contrast, in a pathological state were peripheral sensitisation has already 
been established, the nociceptors display an increased firing rate as well as an increased 
magnitude of action potentials. This consequently results in increased glutamate release 




Figure 1.4 Heterosynaptic facilitation promotes 
allodynia and secondary hyperalgesia (A) In 
homosynaptic facilitation, the conditioning stimulus 
(red arrow) activates and potentiates a single 
synapse (red). Adjacent synapses, which are not 
activated by the conditioning stimulus, remain 
unpotentiated (green). Homosynaptic potentiation is 
most commonly associated with primary 
hyperalgesia. (B) During heterosynaptic facilitation, 
activation of one synapse (red) by a conditioning 
stimulus (red arrow) results in facilitation of both the 
activated synapse and non-activated, adjacent 
synapse (green). Consequently, the synapse that 
did not receive the conditioning stimulus (green) displays augmented activity to subsequent 
stimulation (green bars in neuron output). From Latremoliere and Woolf (2009). (C) 
Heterosynaptic facilitation is initiated by the repeated or sustained activation of C-nociceptors at 
the site of injury and potentiates the synapses between the projection neurons and the Aβ low-
threshold mechanoreceptors (LTM) and Aδ-nociceptors (A-fibre noci) that innervate the adjacent 
areas (secondary zone). Facilitation of the Aβ-fibre synapses produces noxious responses to 
innocuous touch (allodynia) whereas facilitation of Aδ-fibre synapses results in enhanced 
activation, following application of noxious stimuli (secondary mechanical hyperalgesia). C-fibres 
innervating the secondary zone do not display potentiation, hence explaining the absence of 
secondary thermal hyperalgesia. From Ziegler et al. (1999).  
 
both WDR projection neurons and interneurons. The increased glutamate release then 
produces a greater activation of amino-3-hydroxy-5-methyl-4-isoxazole propionate 
(AMPA) receptors to promote a much larger post-synaptic depolarisation. The 
simultaneous release of neuropeptides, such as Substance P and CGRP, can also 
contribute to this enhanced depolarisation. Consequently, the larger depolarisation leads 
to the removal of the voltage-dependent Mg2+ block from N-methyl-D-Aspartate (NMDA) 
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receptors which results in the influx of calcium into the neuron, as well as activating 
intracellular calcium stores to be released (Latremoliere and Woolf, 2009). The increase 
in cytosolic calcium initiates many intracellular signalling cascades, similar to peripheral 
sensitisation, mainly resulting in the activation of protein kinases (Basbaum et al., 2009). 
One of the most well-characterised cellular targets of the activated signalling cascades 
is the AMPA receptors. Phosphorylation of AMPA receptors at the GluR1 subunit by PKC 
leads to their increased membrane insertion (Boehm et al., 2006) whilst phosphorylation 
of GluR1 by active CaMKII  (Ca 2+ /calmodulin-dependent protein kinase II) converts 
AMPA receptors to a higher conductance state (Derkach et al., 1999). Likewise, 
activation of PKC has also been shown to induce the trafficking of NMDA receptors to 
the plasma membrane and to increase the frequency of channel opening (Lan et al., 
2001). The increased availability of receptors, as well as their potentiated state, means 
that a larger post-synaptic current can generated by the same original level of 
stimulation, and consequently, a greater depolarisation of the neuron is observed. The 
synapse is thus regarded to be potentiated. The increased synaptic efficacy also means 
that the post-synaptic neuron can be activated by previously subthreshold stimuli and 
this attributes to the maintenance of the potentiation (Latremoliere and Woolf, 2009).  
The mechanism described so far mainly refers to homosynaptic potentiation which is 
when synaptic efficacy is enhanced specifically in the conditioned synapse, meaning the 
synapse which receives and is being activated by the noxious conditioning stimulus (Fig 
1.4A). Homosynaptic potentiation thus amplifies the signal being received directly from 
the activated peripheral afferent and therefore contributes to primary hyperalgesia, the 
exaggerated response to a noxious stimulus, applied to the site of injury (Ikeda et al., 
2006). Heterosynaptic potentiation is more clinically relevant as it is responsible for the 
development of secondary hyperalgesia and allodynia, the additional pain phenotypes 
which cannot be fully accounted for by peripheral sensitisation (Fig 1.4C) (Woolf, 2011).  
Heterosynaptic potentiation occurs when adjacent synapses, that are not activated by 
the conditioning stimulus, display altered synaptic efficacy such that subsequent 
activation of the unconditioned synapse results in an augmented postsynaptic response 
(Fig 1.4B). It has been suggested that diffusible nitric oxide, released from a synapse 
which has been facilitated by homosynaptic potentiation, could promote neurotransmitter 
release from locally situated synapses, that were not activated by the conditioning 
stimulus, to then induce potentiation (Jacoby et al., 2001). Allodynia specifically results 
from the heterosynaptic potentiation of the Aβ-fibre input to the dorsal horn projection 
neurons (Baba et al., 1999). Following heterosynaptic facilitation, information conveyed 
by the Aβ-fibres, regarding innocuous stimuli, now infiltrates and engages the 
nociceptive signalling pathways, due to the potentiation of the synapse. As a result, a 
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previously innocuous stimulus is therefore consequently perceived to be noxious. This 
phenomenon was observed by Woolf (1983) and has been replicated in subsequent 
studies (Thompson et al., 1993).  
Conversely, it is the heterosynaptic potentiation of the central synapses of both Aβ- and 
Aδ-fibres, innervating the areas adjacent to the site of injury or inflammation, that is 
responsible for the development of secondary hyperalgesia (Ziegler et al., 1999; Magerl 
et al., 2001). Again, this potentiation relies upon the activation of C-fibre nociceptors to 
induce heterosynaptic facilitation at the central synapse of Aβ- and Aδ-fibres to dorsal 
horn second order neurons (Ziegler et al., 1999; Magerl et al., 2001). This has been 
demonstrated in human subjects whereby compression block of the A-fibres, confirmed 
by electrophysiological recordings, blocked the perception of secondary hyperalgesia, 
elicited by application of punctate mechanical stimuli, following intradermal injection of 
capsaicin (Ziegler et al., 1999; Magerl et al., 2001). Moreover, even when compression 
blockade of A-fibre conduction was performed, prior to the injection of capsaicin, and 
was then maintained for a period of time after capsaicin injection, mechanical secondary 
hyperalgesia was still perceived once the block was removed. This thus demonstrates 
that secondary hyperalgesia is still able to develop, despite the blockade of A-fibre 
volleys, and confirms that the development of secondary hyperalgesia relies upon the 
activation of C-fibre nociceptors at the immediate site of injury whose signalling remained 
intact throughout. It is the firing of these fibres that ensures that central changes are still 
induced and allows for these synaptic modifications to become effective once the A-fibre 
blockade is removed (Ziegler et al., 1999). This was further confirmed by the 
demonstration that anaesthetic block administered to the skin, prior to injection of 
capsaicin, and used to effectively block the firing of the C-fibres innervating the inflamed 
area, prevented the development of secondary hyperalgesia showing that it is C-fibre 
initiated (LaMotte et al., 1991). 
Essentially, heterosynaptic facilitation results in the recruitment of subthreshold inputs      
by increasing the synaptic efficacy meaning that activity within these inputs is now 
sufficient to generate action potentials in second order neurons. This consequently 
manifests in the wide dynamic range neurons having enlarged receptive fields. They 
hence begin to respond to neurons that are either normally insufficiently activated by 
certain sensory modalities to elicit a response, or that innervate areas outside of the 
normal receptive field (Woolf and King, 1990; Latremoliere and Woolf, 2009).  
  
1.1.2.3.2 Disinhibition within the dorsal horn 
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This understanding of central sensitisation has been expanded to not only acknowledge 
the contribution of synaptic potentiation as the sole cause of hyperexcitability in the pain 
signalling pathways, but now also incorporates the role of disinhibition within the dorsal 
horn. Disinhibition is specifically implicated in the presentation of allodynia and 
secondary hyperalgesia. The dorsal horn is densely populated by GABAergic and 
glycinergic inhibitory interneurons (Todd, 2017). When this inhibitory modulation is 
removed by application of GABA antagonists, an enhancement of A-fibre mediated 
excitation of the second order neurons in the superficial dorsal horn is observed (Baba 
et al., 2003). Reduced inhibitory neurotransmission is consistently demonstrated in 
models of nerve injury (Moore et al., 2002), alongside reports of apoptotic death of 
GABAergic inhibitory interneurons within the dorsal horn (Scholz et al., 2005). It was 
suggested that this apoptosis results from NMDA receptor-mediated excitotoxicity after 
MK-801, an NMDA antagonist, significantly reduced the number of apoptotic neurons 
(Scholz et al., 2005). 
The death of inhibitory interneurons as the cause of reduced inhibitory modulation 
remains contentious as subsequent studies have failed to replicate this finding (Polgár 
et al., 2004). Instead, others have argued that although inhibition is decreased, 
specifically following nerve injury, the inhibitory circuitry remains intact, thus explaining 
why GABA analogues, such as pregabalin, are able to deliver analgesia in chronic pain 
conditions (Basbaum et al., 2009). 
Similarly in inflammatory pain conditions, there is disinhibition of the dorsal horn neurons, 
however, it is instead associated with the loss of glycinergic inhibitory tone (Hösl et al., 
2006). Following peripheral inflammation, PGE2 is produced by cyclo-oxygenase 
enzymes within the spinal cord. Here, PGE2 acts locally to cause the activation of the 
PGE2 receptor subtype, EP2, which subsequently promotes activation of PKA (Reinold 
et al., 2005). Activated PKA then phosphorylates the glycine receptor subtype, GlyRα3, 
which consequently inhibits the activity of the receptor, thus disrupting glycinergic 
inhibition (Harvey et al., 2004). Mice lacking EP2 receptors displayed significantly 
reduced mechanical hyperalgesia compared to wild type mice following direct injection 
of, and induced production of, PGE2 (Reinold et al., 2005). More impressively, mice 
lacking GlyRα3 receptor failed to develop any pain sensitivity after intrathecal injection 
of PGE2 (Harvey et al., 2004). This mechanism of disinhibition is unique to chronic 
inflammatory pain and does not contribute to hyperalgesia developed following 
peripheral nerve injury (Hösl et al., 2006). 
Regardless of the mechanism or cause of the disinhibition in the dorsal horn, the lack of 
inhibitory currents further augments the hyperexcitability observed in the pain signalling 
pathways, initiated by synaptic potentiation, by failing to inhibit the newly facilitated 
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inputs. The disinhibition of these circuits also contributes to the subsequent maintenance 
of the facilitated state as it fails to reverse the increased activity of the synapses and 
allows previously subthreshold inputs to continue to activate pain signalling pathways.  
 
1.1.2.4 Alterations in the central processing of pain 
In addition to the multiple changes to pain processing and signalling that have been 
described within the peripheral nervous system and the central spinal cord, altered pain 
processing has also been demonstrated in the central brain regions, most notably the 
“pain matrix”. The “Pain Matrix” constitutes the areas of the brain involved in the 
processing and subjective experience of pain. These areas include, but are not limited 
to: the somatosensory cortices, the prefrontal cortices, the nucleus accumbens, the 
anterior cingulates cortex, the insula, the amygdala, the periaqueductal gray (PAG), the 
locus coerulus and the rostrovental medulla (Legrain et al., 2011). 
Investigations of the pain matrix have highlighted altered activation patterns in chronic 
pain states. Functional neuroimaging techniques have specifically emphasised that there 
is increased activation of the anterior cingulate cortex, the insula and the prefrontal cortex 
observed in chronic pain patients (Tracey and Mantyh, 2007; Friebel et al., 2011). These 
brain regions all contribute to the emotional element of pain. Furthermore, structural MRI 
scans have consistently revealed reduced gray matter volume within the brains of 
chronic pain patients, compared to healthy controls. The most frequently affected areas 
are the anterior cingulate cortex, the insula and the dorsal pons, all of which are brain 
regions implicated in the pain matrix (May, 2008). Comparatively, cortical reorganisation 
has also been demonstrated specifically within the motor representation of body regions 
affected by chronic pain (Moxon et al., 2014; Nurmikko et al., 2016). Although, historically 
motor cortex reorganisation has been associated almost exclusively with phantom limb 
pain (Karl et al., 2001), more recent studies have shown that this reorganisation is 
apparent across multiple pain conditions, for example, in trigeminal neuropathy 
(Nurmikko et al., 2016).  
Additional supraspinal mechanisms for the development and maintenance of chronic 
pain are attributed to the loss of inhibition and increased facilitation within the descending 
modulatory pathways, originating from the PAG and rostral ventromedial medulla (RVM) 
(Vanegas and Schaible, 2004). Reduced sensitivity to opioids has been identified in the 
PAG and the thalamus within a chronic constriction injury neuropathic pain model in mice 
(Hoot et al., 2011). Responsiveness to opioids is required for the activation of the PAG 
to stimulate descending inhibitory pathways within the RVM (Park et al., 2010). Notably, 
silencing the descending inhibition from the RVM by local application of lidocaine has 
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been shown to precipitate allodynia in wildtype rats (De Felice et al., 2011). The RVM 
also exhibits a descending facilitatory function, whereby it is able to augment and 
facilitate pain signalling in the spinal cord. In appreciation of this function, administrating 
lidocaine to the RVM in allodynic rats, following spinal nerve ligation, reversed allodynia 
(De Felice et al., 2011). This emphasises how an imbalance in the activity of the inhibitory 
and facilitatory pathways, originating from the RVM, can occur in chronic pain and thus 
can be implicated in its maintenance (Porreca et al., 2002; Vanegas and Schaible, 2004). 
 
1.2 Botulinum Neurotoxin in chronic pain 
The mechanisms of peripheral and central sensitisation, discussed above, both heavily 
rely upon SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment Protein 
Receptor) dependent exocytosis. Primarily, SNARE-mediated exocytosis is required for 
the release of neurotransmitters and neuropeptides (Welch et al., 2000; Lisman et al., 
2007; Dolly and O’Connell, 2012). Moreover, SNARE-mediated exocytosis is also 
necessary for the membrane insertion of receptors, implicated in the establishment of 
persistent pain, most notably TRPV1, AMPA and NMDA receptors (Lan et al., 2001; Lu 
et al., 2001; Morenilla-Palao et al., 2004).  
Botulinum neurotoxin (BoNT) inhibits SNARE-mediated exocytosis by cleaving specific 
SNARE- proteins, dependent on the serotype, to thus prevent the formation of SNARE-
complexes and the subsequent fusion of the vesicular and plasma membranes 
(Montecucco et al., 2005). Consequently, BoNT provides a tool by which to block the 
SNARE-dependent neurotransmitter release and membrane insertion of receptors that 
occurs during the induction and maintenance of chronic pain.  
 
1.2.1 The structure of Botulinum Neurotoxin 
Botulinum neurotoxin (BoNT) is produced by anaerobic Clostridium botulinum bacteria 
and exists in seven distinct serotypes, BoNT/A-G (Davletov et al., 2005).  All botulinum 
neurotoxin serotypes are synthesised as a single polypeptide which is then cleaved by 
either bacterial or host cell proteases to form a heavy and a light chain. The two chains 
are linked by a disulphide bond, providing the characteristic multidomain protein structure 





Figure 1.5 The 3D structure and amino acid sequence of Botulinum Neurotoxin A. (A) 
BoNT/A is expressed as an inactive single polypeptide. Post-translational proteolysis leads to the 
formation of the disulphide bond between the light and heavy chain, producing the active dichain. 
The black brackets indicate where a disulphide bond exists. Noticeably, there is another 
disulphide bond present in the receptor binding domain. (B) A backbone trace of the 3D structure 
of BoNT/A illustrates the catalytic domain (purple), featuring a zinc ion (white sphere) and zinc-
binding motif (red), required for the zinc-endopeptidase activity. The central pair of α-helices 
(green) indicate the translocation domain. The N-terminal of the receptor binding domain (pink) is 
assumed to aid the function of the c-terminal subdomain (blue) which contains the ganglioside 
binding site (orange) and mediates receptor binding. From Lacy and Stevens (1999). (C) The 
amino acid sequence of BoNT/A, determined by Thompson et al. (1990), delineates the catalytic 
domain (purple), translocation domain (green) and receptor binding domain (pink). The sequence 
contains 8 cysteines (C), 4 of which contribute to the disulphide bonds shown in (A).  
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All seven botulinum neurotoxin serotypes share a molecular mass of 150 kDa. This mass 
is split across the heavy chain (HC, Mr ~100 kDA), comprising both the receptor binding 
domain (Rbd, Mr ~50 kDa) and the translocation domain (Td, Mr ~50 kDa), and the light 
chain (Lc, Mr ~50 kDa), which contains the zinc-endopeptidase activity, necessary for 
the cleavage of SNARE-proteins (Schiavo et al., 2000) (Fig. 1.5B).  
 
1.2.2 Mechanism of action 
The Rbd, contained within the heavy chain, provides the neuron specific binding 
associated with the BoNTs. The majority of the serotypes, namely BoNT/A, -B, -E, -F 
and -G, utilise a dual receptor binding mechanism whereby the Rbd selectively binds to 
a protein receptor and a complex ganglioside, found on the membrane of neurons (Fig. 
1.6A) (Rummel, 2012). In contrast, it has been demonstrated that BoNT/C and BoNT/D 
do not require a protein receptor and instead only bind to either gangliosides or 
phospholipids (Tsukamoto et al., 2005). The different serotypes bind to distinct complex 
gangliosides, enriched in neuronal membranes (Montal, 2010). The exact combination 
of protein receptors and gangliosides bound is dependent on the serotype and is 
discussed more in-depth in chapter 4.1.  
The dual receptor binding of surface receptors and gangliosides, specifically, produces 
high affinity binding that allows BoNT to undergo receptor-mediated endocytosis and be 
internalised into cells (Fig 1.6B) (Montecucco, 1994). Once the holotoxin is captured 
inside the endosome, the acidic environment induces a pH-dependent conformational 
change to the Td, such that the Td inserts itself into the endosomal membrane, forming 
a channel that allows the Lc to translocate into the cytosol (Fig 1.6C). Concomitantly, the 
Lc unfolds from its globular structure which enables it to translocate through the narrow 
channel, produced by the insertion of Td (Koriazova and Montal, 2003). The Td thus acts 
a chaperone to allow the endosomal escape of the Lc, and additionally stabilises the Lc 
in its unfolded inactive state, during translocation (Fischer et al., 2008; Pirazzini et al., 
2011).  
Following endosomal escape, reduction of the disulphide bond, connecting the HC and 
the Lc, occurs (Fischer and Montal, 2007). It has been hypothesised that this reduction 
is performed by thioredoxin reductase-thioredoxin, located on the cytosolic surface of the 
endosomes (Pirazzini et al., 2014). The reduction of the disulphide bond results in the 
cytosolic release of the Lc. Subsequently, the return of the Lc to the neutral pH of the 





Figure 1.6  Schematic depicting the mechanism of action of Botulinum Neurotoxin (BoNT) 
at the neuromuscular junction. (A) The BoNT receptor binding domain (Hc, blue) binds to the 
relevant gangliosides and protein receptors located on the presynaptic membrane. (B) This 
initiates receptor-mediated internalisation of BoNT into vesicles. (C) The ATPase pump, located 
on the vesicle membrane, generates an acidic environment. This induces a conformational 
change to promote the insertion of the translocation domain (HN, green) into the vesicular 
membrane, thus allowing the light chain (LC, yellow) to translocate across the membrane, into 
the cytosol, where reduction of the disulphide bond occurs. (D) The LC then diffuses through the 
cytosol to cleaves its SNARE-protein target, via its zinc-endopeptidase activity. The SNARE target 
varies dependent on the BoNT serotype. BoNT/A and -/E cleave SNAP-25 whilst BoNT/ B, -/D, -
/F and -/G cleave VAMP (synaptobrevin). BoNT/C cleaves both syntaxin and SNAP-25. The 
cleavage of SNARE proteins prevents the formation of the SNARE-complex and prevents 
exocytosis of acetylcholine (ACh). Consequently, acetylcholine receptors (AChR) located on 
muscle fibres are no longer activated, producing flaccid paralysis. From Turton et al. (2002).  
 
Once returned to its active form, the Lc is able to mediate the proteolytic cleavage of 
SNARE-proteins via its intrinsic zinc-endopeptidase activity (Fig 1.6D). The specific 
SNARE-target is determined by the BoNT serotype. BoNT/A and -/E both cleave SNAP-
25 (Synaptosomal associated protein 25) whereas BoNT/B, -/D, -/F and -/G cleave 
synaptobrevin, also referred to as vesicle-associated membrane protein (VAMP). In 
contrast, BoNT/C has two SNARE-targets as it cleaves both syntaxin and SNAP-25 
(Davletov et al., 2005).  
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Intact SNARE proteins are necessary for vesicle fusion at the neuronal plasma 
membrane, which is essential for the release of neurotransmitter (Söllner et al., 1993). 
The action of BoNTS is historically associated with the blockade of neurotransmitter 
release from cholinergic presynaptic terminals, situated at the neuromuscular junction 
(Simpson, 1981). In this instance, cleavage of the SNARE proteins prevents vesicle 
fusion thus preventing the release of acetylcholine. This blockade of cholinergic 
neurotransmission consequently results in the failure to initiate muscle contraction and 
therefore produces the clinical manifestation of flaccid paralysis (Turton et al., 2002).  
BoNTs are, however, known to inhibit the release of other neurotransmitters and 
neuropeptides due to the fundamental role of SNARE-proteins in all release mechanisms 
(Purkiss et al., 2000; Welch et al., 2000; Cui et al., 2004; Durham et al., 2004). 
 
1.2.3 Clinical evidence for the antinociceptive effect of BoNT/A 
In addition to targeting different SNARE proteins, the seven BoNT serotypes also vary in 
their duration of action and their potency (Aoki and Guyer, 2001). Specifically, Botulinum 
Neurotoxin A (BoNT/A) has the longest duration of action of the seven serotypes and 
consequently, has been the serotype most frequently utilised for clinical applications 
(Foran et al., 2003). Notably, it is BoNT/A, specifically, that has been approved for the 
clinical management of chronic migraine (Dodick et al., 2010). Consequently, the use of 
BoNT/A in other pain chronic conditions is now being pursued (Drinovac et al., 2013). 
The most clinical and preclinical literature therefore exists with respect to BoNT/A, 
compared to the other serotypes (Pickett, 2010; Matak and Lacković, 2014). Accordingly, 
there has been a much more thorough investigation of its mechanism of action and a 
more comprehensive understanding reached. For the purposes of this project, the 
introduction will now mainly focus on discussing BoNT/A for the reasons detailed above.  
The potential analgesic effect of BoNT was first recognised in conditions characterised 
by excessive muscle contractions and neuromuscular hyperexcitability. Treatment of 
conditions such as cervical and axial dystonia with BoNT/A effectively reduces the 
frequency and intensity of involuntary muscle contractions whilst concomitantly reducing 
the pain experienced in these disorders. In one study by Jankovic et al. (1990), 90% of 
patients with cervical dystonia reported significant global improvement in their condition, 
encompassing both spasms and pain. Furthermore, 93% of cervical dystonia patients 
who reported pain as a feature of their cervical dystonia described a marked reduction. 
On average, patients rated their pain as almost completely resolved, as indicated by an 
average pain response of 3.5 with 0 representing no improvement and 4 representing a 
complete resolution of pain. Likewise, Brin et al. (1987) demonstrated that 64% of 
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patients suffering cervical dystonia benefited from local injection of BoNT/A, reporting 
improved motor symptoms. A further 74% of these patients similarly described 
significantly reduced pain. Additionally, a study focused on the treatment of lower-limb 
spasticity in children with cerebral palsy, using BoNT/A, found that all 26 patients 
included in the study demonstrated significantly reduced pain according to pain scores 
collected at 3 months post-treatment (Lundy et al., 2009). 
It was primarily assumed that the marked reduction in pain observed in spasticity 
disorders related to the paralytic properties of BoNT/A. Excessive muscle contractions 
can cause compression of the local blood vessels resulting in ischemia of the supplied 
tissue. Ischemia initiates an inflammatory response that includes the release of 
inflammatory mediators which, as detailed earlier, results in the activation and 
sensitisation of peripheral nociceptors (Mense, 2004; Pickett, 2010). Similarly, 
adenosine-5-triphosphate, released from cells suffering ischemic damage, will activate 
and sensitise neurons expressing the P2X purinoceptor 3 (P2X3) (Cook and McCleskey, 
2002). Additionally, ischemia can also lead to a decrease in pH which can cause acid-
sensing ion channels to activate and can eventually sensitise chemical-responsive 
nociceptors (Mense, 2004; Pickett, 2010). 
Contrary to this explanation, however, there is evidence that the analgesic effect of 
BoNT/A exists beyond its muscle relaxant properties. For example, pain relief can persist 
after normal muscle contractility has returned. Freund and Schwartz (2003) showed that 
although the onset of muscle relaxation and analgesia occurred concurrently following 
intramuscular injection of BoNT/A to the masseter and temporalis muscles in 
temporomandibular disorder, the pain relief experienced continued after bite force, the 
measure of muscle contractility, returned to, and even surpassed, basal values. 
Conversely, in another study, Relja and Klepac (2002) observed significant pain relief in 
patients with cervical dystonia after injection of doses as low as 50 U BoNT/A, and as 
early as one week post-treatment. Improvement in spasticity, however, was only 
revealed two weeks post-treatment and, furthermore, required higher dosages, 100 and 
150 U BoNT/A, to be observed. Notably, BoNT is more commonly measured in units 
when used in a clinical setting. A unit of BoNT refers to the median lethal dose (LD50) 
following intraperitoneal administration and is determined using a standardised mouse 
lethality assay (Dressler et al., 2012). One Unit is roughly equivalent to 28 pg of BoNT/A 
(Frevert, 2010). 
Moreover, pain relief has been described in conditions with little or no association with 
muscular hyperactivity, for example, in chronic migraine, where BoNT/A is FDA-
approved for clinical use (Dodick et al., 2010). This has led to further investigation of the 
possible applications of BoNT/A in other chronic pain conditions, namely in neuropathic 
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pain. Attal et al. (2016) conducted a randomised, placebo-controlled, multicentre clinical 
trial investigating the efficacy of BoNT/A in peripheral neuropathic pain, primarily 
resulting from either trauma or surgery. Patients were asked to rate their pain according 
to an 11-point numerical rating scale, 0 meaning no pain to 10 meaning maximum pain 
imaginable. Attal et al. (2016) reported an average pain reduction of almost 30% 
following two separate administrations of BoNT/A subcutaneous injections to the painful 
area, 12 weeks apart. Impressively, 50% of patients receiving BoNT/A treatment were 
deemed to be responders, meaning that they experienced an average pain reduction of 
greater than 50%. Interestingly, the severity of allodynia, as assessed using quantitative 
sensory testing, was the best predictor of whether a patient would be a responder. Brush 
evoked allodynia was significantly reduced by treatment with BoNT/A compared to 
placebo. Attal et al. (2016) reported that there was no effect of BoNT/A on normal 
sensation, similarly assessed using quantitative sensory testing (QST).  
This observation of unaltered sensation, combined with the anti-allodynic effect of 
BoNT/A observed, has some important implications for the potential mechanism of action 
for BoNT/A in neuropathic pain. The lack of effect against normal sensation suggests 
that BoNT/A cannot be acting at the peripheral nerve terminals. If this was the case, one 
might expect to observe hypoesthesia, a reduction in normal sensation, resulting from 
reduced activation by stimuli. As described earlier, allodynia results from central 
sensitisation whereby normal activation of Aβ-fibres begins to initiate activity in pain 
signalling pathways, via changes that occur at the central synapse (Baba et al., 1999). 
This therefore implies that BoNT/A must be acting within the central spinal cord to 
somehow interrupt this signalling.  
In contrast, a systematic review regarding the pharmacological management of 
neuropathic pain, conducted by the same research group a year earlier, highlighted that 
subcutaneous injection of BoNT/A should be only used as a third line option for the 
management of neuropathic pain (Finnerup et al., 2015). They advised that BoNT/A is 
particularly applicable for use in peripheral neuropathies that are predicted to result from 
a peripheral insult. Finnerup et al. (2015) did, however, specify that the conclusion of 
BoNT/A’s efficacy was based on, and limited by, the low number of randomised 
controlled trials conducted, as well as their small sample size. These studies did, 
nevertheless, consistently report a therapeutic effect of BoNT/A. Additionally, Finnerup 
et al. (2015) included a larger, unpublished study in the meta-analysis that, in contrast to 
the small studies, reported no analgesic effect of BoNT/A in neuropathic pain. The size 
of this study relative to the others thus greatly impacted the overall perceived efficacy of 
BoNT/A. This led the research group to conduct their own clinical trial, detailed above, in 
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which they demonstrated a clear therapeutic effect, thus supporting the overall 
effectiveness of BoNT/A in neuropathic pain (Attal et al., 2016).  
Such clinical observations verify that BoNT has analgesic properties, separate from its 
actions as a muscle relaxant. This has led to the hypothesis that BoNT/A may act directly 
at nociceptors. The preclinical evidence supporting this hypothesis will now be 
discussed. 
 
1.2.4 Pre-clinical evidence for BoNT/A’s analgesic effect 
Preclinical investigations of the anti-nociceptive effect of BoNT/A in chronic migraine 
were able to elucidate a direct action at the nociceptors. Importantly, it is the meningeal 
afferents, a subpopulation of trigeminal neurons, that receive and propagate sensory 
information from the dura mater, where headaches and migraine are believed to 
originate, to the trigeminal nucleus caudalis (Melin et al., 2017). Incubation of cultured 
trigeminal ganglion neurons with BoNT/A did not affect the basal release of CGRP, 
however, significantly reduced CGRP release evoked by stimulation with potassium, as 
well as the chemical irritant, capsaicin (Durham et al., 2004). This effect was observed 
at clinically relevant doses of BoNT/A and after incubations as short as 3 hours.  
Additional evidence for a direct effect of BoNT/A at the meningeal afferents is provided 
by the reduced trafficking of TRPV1 receptors noted in the trigeminal neurons after 
administration of BoNT/A (Shimizu et al., 2012). Notably, increased trafficking and 
membrane insertion of TRPV1 receptors is specifically implicated in the peripheral 
sensitisation of nociceptors (Ji et al., 2002). Following subcutaneous injection of BoNT/A 
to rats, reduced immunoreactivity for TRPV1 was observed at the soma and the nerve 
terminals of trigeminal ganglion neurons. It was shown that this was not due to decreased 
receptor expression, but instead resulted from decreased trafficking of TRPV1 receptors 
to the membrane. The reduced trafficking consequently rendered receptors to the cytosol 
where they were increasingly vulnerable to proteolytic degradation by the proteasome, 
thus explaining the perceived reduction in immunoreactivity (Shimizu et al., 2012).  
Both studies highlight potential mechanisms by which BoNT/A could be mediating its 
analgesic effect in chronic migraine, predominantly showing that BoNT/A specifically 
acts by preventing modifications that occur during sensitisation. Accordingly, other 
preclinical studies have replicated these findings and recognised similar mechanisms in 
other pain conditions and in vitro models. It is believed that the pathophysiology of pain 
conditions arising from injury or insult to the trigeminal and dorsal root ganglion neurons 
is shared (Dolly and O’Connell, 2012). Consequently, any elucidated mechanisms for 
the analgesic action of BoNT/A in chronic migraine should be equally applicable to pain 
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conditions originating from distal peripheral sites that are instead innervated by DRG 
neurons.  
This hypothesis appears to be valid. When added to DRG cultures, it was demonstrated 
that BoNT/A inhibited calcium-dependent release of substance P in response to both 
capsaicin and potassium stimulation, similar to the reduction of evoked-CGRP release 
observed in trigeminal ganglion cultures (Purkiss et al., 2000; Welch et al., 2000). 
Substance P and CGRP are both neuropeptides that are released from the central 
terminal of sensory afferents and contribute to central sensitisation (Basbaum et al., 
2009). Notably, mice who lack the gene for either substance P or the substance P 
receptor, NK1, fail to display BoNT/A-mediated analgesia when subjected to 
inflammatory or neuropathic pain (Matak et al., 2017). 
Moreover, comparable to Shimizu et al. (2012), Xiao et al. (2013) reported reduced 
immunoreactivity for TRPV1 receptors in the DRG, following intraplantar injection of 
BoNT/A in a rat neuropathic pain model. In the latter study, however, this was attributed 
to the reduced expression of TRPV1 receptors. Nevertheless, it has been repeatedly 
shown that BoNT/A does not alter the expression of TRPV1 but does impact its 
trafficking, mainly by interfering with PKC-induced translocation of TRPV1 receptors to 
the plasma membrane (Morenilla-Palao et al., 2004; Shimizu et al., 2012). It is thus likely 
that the reduced immunoreactivity, recognised by Xiao et al. (2013), was misinterpreted 
as reduced expression of TRPV1, but instead resulted from increased degradation of 
TRPV1 receptors, secondary to reduced receptor trafficking (Shimizu et al., 2012).  
The effects so far described are largely confined to the primary nociceptive afferents, i.e. 
the trafficking of receptors to the peripheral terminal and the release of neuropeptides at 
the central terminal. Both changes are, however, integral to peripheral and central 
sensitisation which underlie the induction and maintenance of chronic pain conditions. It 
is therefore hypothesised that BoNT/A prevents the development of hyperexcitability in 
the pain signalling pathways, rather than simply blocking neurotransmission in 
nociceptive neurons, as might be expected given its silencing effects within the motor 
neurons. This hence explains why BoNT/A does not alter sensory thresholds or acute 
nociception in non-pathological states (Ji et al., 2002; Cui et al., 2004; Bach-Rojecky and 
Lacković, 2005, 2009; Attal et al., 2016).  
The lack of effectiveness of BoNT/A against acute nociception is well demonstrated by 
the application of BoNT/A in the formalin model of inflammatory pain. Intraplantar 
injection of BoNT/A to rats, prior to formalin challenge, is ineffective against the first 
phase of inflammation, however, significantly reduces pain behaviour during the second 
phase (Cui et al., 2004). The first phase of inflammation represents the direct chemical 
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activation of nociceptors, immediately after injury, thus showing that BoNT/A does not 
block neurotransmission in the peripheral nociceptors. In contrast, the second phase 
reflects the hyperexcitability of the pain signalling pathways, resulting from peripheral 
and central sensitisation, indicating a more sustained pain state. Again, this illustrates 
that BoNT/A is acting to prevent the changes that induce sensitisation. The observed 
reduction in pain behaviour during the second phase corresponds to an inhibition of 
glutamate release from the peripheral afferents (Cui et al., 2004). Glutamatergic 
neurotransmission is essential for central sensitisation, thus emphasising that BoNT/A 
prevents the pain signalling necessary for the establishment of persistent pain, rather 
than affecting acute pain nociception (Woolf & Thompson, 1991). 
This study again highlights the effectiveness of BoNT/A against mechanisms of 
sensitisation, specifically those initiated within the primary afferents. It does not, 
however, specify whether BoNT/A is most efficacious at preventing modifications which 
occur at the peripheral or central terminal of sensory afferents. There is now, however, 
a significant amount of literature gathered from in vivo studies, that places a greater 
emphasis on the effectiveness of BoNT/A against changes that occur at the central 
terminal, rather than at the peripheral terminal. 
BoNT/A has been shown to produce analgesia in a number of animal models for a range 
of chronic pain conditions, including: inflammatory pain (Cui et al., 2004; Matak et al., 
2017), orofacial pain (Matak et al., 2011), trigeminal neuropathy (Filipović et al., 2012), 
trigeminal neuralgia (Wu et al., 2016), muscle hyperalgesia “mirror pain” (Bach-Rojecky 
and Lacković, 2009; Drinovac et al., 2016), peripheral neuropathy (Bach-Rojecky et al., 
2010; Marinelli et al., 2012; Drinovac et al., 2013; Matak et al., 2017), cancer tumour pain 
(Olbrich et al., 2017) and chemotherapy-induced peripheral neuropathy (Favre-Guilmard 
et al., 2009). In a number of these studies, intraneural injection of colchicine, an axonal 
transport blocker, consistently abolished the analgesia observed after peripheral 
injection of BoNT/A (Bach-Rojecky and Lacković, 2009; Matak et al., 2011; Filipović et 
al., 2012; Wu et al., 2016). This consequently indicates that axonal transport of BoNT/A 
to the central nervous system is essential for it to mediate its analgesic effect and 
suggests that the perceived analgesia does not result from the actions of BoNT/A at the 
peripheral terminal.  
Further to this, it has been suggested that transcytosis of BoNT/A into second order 
neurons might contribute to its perceived analgesic effect. This hypothesis has mainly 
arisen after the observation of bilateral analgesia in global pain conditions, namely DPN 
and chemotherapy-induced peripheral neuropathy, following unilateral peripheral 
injection of BoNT/A (Favre-Guilmard et al., 2009; Bach-Rojecky et al., 2010). 
Accordingly, immunohistochemical studies have confirmed transcytosis of BoNT/A 
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(Antonucci et al., 2008; Restani et al., 2011). In one study, cleaved SNAP25 was 
produced in the tectum of rats following intravitreal injection of BoNT/A (Restani et al., 
2011). Within the tectum, cleaved SNAP25 was not present in the terminals of the retinal 
ganglion cells but was instead detected in the adjacent structures, thus implying that 
cleaved SNAP25 was contained within the terminals of the second order tectal cells 
(Restani et al., 2011). The appearance of cleaved SNAP25 was prevented by injection 
of colchicine, highlighting that cleavage was due to the axonal transport of BoNT/A, and 
not via systemic diffusion, whilst an additional experiment confirmed that it was the active 
protease that undergoes axonal transport, and not the cleavage product (Restani et al., 
2011).  
In support of these claims, cleaved SNAP25, the cleavage product of BoNT/A, has been 
detected at the level of the lumbar spinal cord, following intraplantar injection of BoNT/A. 
Specifically, cleaved SNAP25 was visible in the ipsilateral ventral horn, surrounding the 
motor neurons, and in single nerve fibres, labelled in the ipsilateral dorsal horn (Matak 
et al., 2011, 2012; Drinovac et al., 2016). This demonstrates that the axonal transport of 
BoNT/A, and possibly the transcytosis, might also occur within the motor system and is 
likely to not be exclusively observed in the visual system.  
Behavioural studies have also elucidated how BoNT/A might interact with inhibitory 
networks, thus contributing to the theory of its centrally-mediated analgesic effect. 
GABA-mediated inhibition was implicated in the anti-nociceptive effect of BoNT/A after 
intraperitoneal injection of GABA-A receptor antagonist, bicuculline, reversed the 
BoNT/A-associated analgesia in a formalin-induced inflammatory pain model and in a 
partial sciatic nerve transection neuropathic pain model (Drinovac et al., 2014). 
Importantly, in this study, as well as in a consequent study, intraplantar, intraperitoneal 
and intrathecal injection of bicuculline all successfully prevented the BoNT/A-induced 
anti-nociceptive effect, however, intracisternal injection of bicuculline, used to gain 
access to the brain regions where the descending inhibitory pathways originate from, did 
not (Drinovac et al., 2014, 2016). It was thus concluded that BoNT/A alters GABAergic 
transmission at the level of the spinal cord, and not supraspinally, in chronic pain 
conditions. 
It has, however, been documented that intrathecal administration of antagonists to 
GABAergic and glycinergic receptors does precipitate a pain phenotype, akin to that 
observed following peripheral injury, most notably featuring tactile allodynia (Sivilotti and 
Woolf, 1994; Malan et al., 2002; Drew et al., 2004; Basbaum et al., 2009). Given that this 
assumed interaction between BoNT/A and the GABAergic network is solely based on 
the use of bicuculline, and provided that the pronociceptive effect of bicuculline is so 
pronounced even in naïve animals, it is possible that bicuculline could be acting 
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separately, away from interfering with the mechanism by which BoNT/A mediates 
allodynia, to still induce a pain phenotype.  
There is, however, evidence to suggest that BoNT/A also influences the endogenous 
opioid system, present within the spinal cord (Drinovac et al., 2013, 2016). The activation 
of opioid receptors is an important mechanism by which inhibition is again initiated within 
the spinal cord (Dickenson, 1995). Injection of non-specific opioid receptor antagonist, 
naltrexone, prior to behavioural testing, prevented the observed anti-nociceptive effect 
of BoNT/A in both formalin-induced inflammatory pain and the partial sciatic nerve 
transection model of neuropathic pain (Drinovac et al., 2013). Moreover, injection of the 
selective µ-opioid receptor antagonist, naloxonazine, inhibited BoNT/A-induced 
analgesia in formalin-induced inflammatory pain and in carrageenan-induced mirror pain, 
hence emphasising the predominant involvement of µ-opioid receptors (Drinovac et al., 
2016). This is not surprising given that µ-receptors represent 70% of the opioid receptors, 
present in the dorsal horn (Dickenson, 1995). Finally, similar to that demonstrated with 
bicuculline, a central action, specifically confined to the level of the spinal cord, was 
confirmed after intrathecal injection effectively abolished the analgesic effect in 
carrageenan-induced mirror pain whereas intercerebroventricular injection of 
naloxonazine failed to prevent the perceived analgesia (Drinovac et al., 2016). This again 
highlights a potential link between BoNT/A-mediated analgesia and the inhibitory 
networks of the spinal cord. It subsequently generates a more convincing argument of 
how BoNT/A might correct this disinhibition, characteristic of pain conditions.  
In contrast to the neuron-specific actions so far described, some studies have suggested 
that BoNT/A might somehow interact with non-neuronal inflammatory cells to elicit an 
anti-inflammatory effect. Cleaved SNAP25 has been detected colocalised with markers 
of astrocytes and microglia following intraplantar injection of BoNT/A to mice (Marinelli 
et al., 2012). Another study demonstrated, using western blot, that intraplantar injection 
of BoNT/A to rats prevented the upregulation of pro-inflammatory interleukins, important 
to microglia activation, however, no immunohistochemical staining was either conducted 
or eluded to in order to confirm the colocalisation of cleaved SNAP25 with microglia 
(Zychowska et al., 2016). Similarly, it was highlighted that intraplantar injection of 
BoNT/A can reduce astrocyte expression and activation at the spinal cord of rats (Vacca 
et al., 2012). Again, although this study used immunohistochemistry to quantify the 
expression and activation of astrocytes, it did not investigate the colocalisation with 
cleaved SNAP25.  
Interestingly, this inflammatory theory remains contentious as many studies have failed 
to detect any colocalisation between cleaved SNAP25, indicative of BoNT/A activity, and 
inflammatory cells, for example, astrocytes (Restani et al., 2011; Matak et al., 2012; Cai 
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et al., 2017). This is not unexpected given that astrocytes and other glial cells are known 
to express SNAP23, which is resistant to BoNT/A cleavage, rather than the neuronal 
SNAP25  (Hepp et al., 1999). It is thus logical to assume that any anti-inflammatory effect 
associated with BoNT/A, is most likely due to an indirect effect, resulting from the 
reduced neurotransmitter and neuropeptide release at the afferent terminals. This would 
then consequently prevent the recruitment and activation of inflammatory cells.  
 
1.2.5 Protein engineering to optimise BoNT/A’s anti-nociceptive activity 
Despite the discrepancy on whether the actions of BoNT/A responsible for its anti-
nociceptive effect are restricted to the primary afferents, or whether it does transcytosis 
into second order neurons of the spinal cord, the studies detailed above clearly and 
consistently demonstrate that BoNT/A does have an important action within the 
nociceptive pathway. All of these findings are, however, based on the use of BoNT/A in 
its native form whereby it is still able to access and block neurotransmission at the 
neuromuscular junction and, therefore, retains its paralytic activity. This thus limits the 
dosage of BoNT/A which can be safely used to induce analgesia without eliciting a 
paralytic effect. Reengineering techniques seek to remove the paralytic activity of 
BoNT/A and redirect its binding specifically to sensory neurons. In theory, this can be 
effectively achieved by replacing the Rbd of BoNT/A with an alternative targeting 
molecule, which displays greater affinity and specificity for subpopulations of sensory 
neurons, selective to pain pathways. 
One method by which this is achievable is recombinant protein expression. This 
technique has been used to express a novel protein by fusing the gene that encodes 
BoNT/A, purposely excluding the gene section which encodes the C-terminal of the Rbd 
and that constitutes the ganglioside-binding pocket, with a gene encoding a single-chain 
variable fragment antibody against P2X purinoceptor 3 (P2X3), a receptor specific to 
nociceptive neurons (Ma et al., 2014). Accordingly, the protein produced specifically 
bound to cultured DRG neurons expressing P2X3. Cleaved SNAP-25 was successfully 
detected in DRG cultures after exposure to 0.1 nM of the chimera. Furthermore, the 
percentage of SNAP25 cleaved correlated with the degree of inhibition of CGRP release 
from treated DRG cultures, compared to untreated cultures. This indicates that the 
recombinant protein was successfully internalised via the intended target and retained 
BoNT/A’s endopeptidase activity to provide a functional pain-specific outcome. 
Additionally, the reengineered protein displayed a 2 × 108 greater LD50 than native 
BoNT/A, indicating a much improved safety profile (Ma et al., 2014).  
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Recombinant expression is limited by the size of protein that can be produced, alongside 
additional issues with protein misfolding (Rosano and Ceccarelli, 2014). An alternative 
method for protein engineering is chemical conjugation. This method was previously 
used to conjugate LcTd/A to a lectin isolated from Erythrina cristagalli (ECL), after it was 
established that the lectin specifically bound gangliosides found on nociceptive neurons 
(Duggan et al., 2002). In this case, a protein cross-linking reagent was used to introduce 
reactive sulphydryl groups to both LcTd/A and ECL to enable the formation of a 
disulphide bond between the two components. The novel protein was able to internalise 
into neurons, and subsequently inhibited both substance P and glutamate release from 
embryonic DRG cultures. Additional in vivo lumbar recordings, following intrathecal 
injection, revealed that the LcTd/A-ECL conjugate reduced C-fibre responses by 75.8% 
and Aδ-fibre activity by 42.3% at the injection site, while Aβ-fibre responses were 
unaffected, highlighting selectivity for pain pathways (Duggan et al., 2002). Notably, 
however, neither of the two studies so far described attempted to assess the analgesic 
effect of the respective chimeras in behavioural pain models (Drew et al., 2004; Ma et 
al., 2014). It is therefore unknown whether their efficacy translates in vivo. 
Another popular method of chemical conjugation is maleimide conjugation. This method 
was used by a separate group to conjugate the light chain of BoNT/A (Lc/A) to Substance 
P, thus deliberately excluding both the Rbd and the translocation domain of BoNT/A from 
the construct (Mustafa et al., 2013). The novel chimera was reportedly internalised by 
cultured diencephalon neurons and retained the ability to cleave SNAP25. This finding 
is surprising given that the translocation domain is required for the endosomal release of 
the Lc (Koriazova and Montal, 2003). It consequently suggests that the Lc can reach the 
cytosol unaided, and therefore, negates the importance of the translocation domain. 
Unconjugated Lc/A failed to internalise into cells, however, thus emphasising that a 
targeting domain is required for internalisation. Additionally, intracisternal injection of the 
Lc/A-Substance P construct significantly reversed thermal hypersensitivity in mice 
subjected to the paclitaxel-induced peripheral neuropathy model, compared to vehicle 
(Mustafa et al., 2013). Although not definitely shown, this implies that Lc/A-Substance P 
remained functional in vivo and indicates that the ability of Lc to access the cytosol, in 
the absence of the translocation domain, is not an artefact of culture.  
Unfortunately, although maleimide conjugation produces uncleavable bonds, there are 
concerns about the long-term stability of the chimeras generated, specifically when 
subjected to blood plasma (Christie et al., 2015). Chemical reactions, such as thiol 
exchange, can promote instability in chimeras and are also capable of affecting the 
efficacy of the therapeutic unit of the chimera, even within a stable chimera. This issue 
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has even been recognised to affect certain FDA-approved maleimide conjugated drugs 
(Fontaine et al., 2015).  
 
1.2.5.1 SNARE-stapling for protein engineering 
The limitations associated with the current methods of recombinant protein expression 
and chemical conjugation have encouraged others to establish novel methods by which 
to achieve protein reengineering. Our own research group developed a ‘stapling’ 
technology which combines and exploits the two platforms of protein engineering, 
recombinant and protein conjugation, whilst acting within their limitations to overcome 
the issues so far described (Darios et al., 2010).  
For this technique, individual functional protein domains are tagged with short SNARE-
peptides, namely synaptobrevin and SNAP25, using recombinant protein expression 
(Darios et al., 2010; Ferrari et al., 2012). Since only single subunits are being expressed 
at one time, the protein size of the individual subunits remains within the constraints of 
recombinant protein expression. Once successfully expressed with the fused SNARE-
tags, the individual subunits can then be assembled into a single multidomain protein by 
the addition of the SNARE-staple, syntaxin. The SNARE-peptides assemble into an 
irreversible, correctly orientated, tetrahelical complex, known as the SNARE-complex 
(Fig 1.7A). This assembly occurs within an hour at room temperature. Specifically, the 
assembly of the SNARE-complex does not require a chemical reaction and therefore is 
not susceptible to other reactive groups. The resultant complex is resistant to harsh 
detergents, including Sodium dodecyl sulphate (SDS), and therefore the assembled 
chimera can be detected by SDS-page gel (Fig 1.7B) (Darios et al., 2010). Additionally, 
this method enables a combinatorial approach to protein engineering. When all of the 
subunits of interest have been expressed with the relevant SNARE-tags, numerous 
combinations of distinct subunits can be produced which can then be tested to identify 




This stapling method has so far been used to produce two novel chimeras that have both 
demonstrated analgesic properties in behavioural pain models. One of the chimeras, 
TetBot, was produced by conjugating the LcTd/A, expressed with the fused SNAP25 tag, 
to the Rbd of tetanus toxin, fused to the synaptobrevin tag, by addition of the syntaxin 
staple (Fig 1.7A) (Ferrari et al., 2013). Native Tetanus toxin undergoes retrograde  
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Figure 1.7 The modular assembly of botulinum 
neurotoxin A- tetanus toxin chimera by SNARE-
tagging. (A) The schematic illustrates the 
conjugation of LcTd/A, fused to SNAP25 (Botulinum 
Enzyme), to the tetanus binding domain (Tbd), fused 
to synaptobrevin, by addition of a staple, syntaxin. 
Central to the chimera (right), the tetrahelical 
SNARE-complex can be seen. (B) The coomassie-
stained SDS-page gel shows that the conjugation 
reaction only occurs in presence of the staple and is 
successful at producing an irreversible, SDS-page 
resistant product. From Ferrari et al. (2013).  
 
transport to the spinal cord to elicit spastic paralysis (Surana et al., 2017). TetBot was 
therefore generated with the intention of targeting the active domain of BoNT/A to central 
neurons, whilst attempting to exclude its normal paralytic activity.  
The introduction of the SNARE-complex into the centre of the chimera produced an 
elongated protein of approximately 23 nm which is almost double the length of native 
BoNT/A (Ferrari et al., 2013). When applied to isolated mouse hemidiaphragm muscles, 
TetBot was shown to be 11000 less effective at blocking muscle twitches than native 
BoNT/A. Impressively, intramuscular injection of 500 ng TetBot to mice did not produce 
any signs of motor paralysis and was not associated with any lethality. Consequently, it 
can be confirmed that TetBot displays a LD50 that is at least 105 fold greater than the 
LD50 of native BoNT/A. It has therefore been inferred that the chimera has restricted 
access to the neuromuscular junction (NMJ), resulting from the increased size of the 
protein combined with the tight synaptic cleft and ensheathing, characteristic of the NMJ 
(Ferrari et al., 2011). 
TetBot was applied to hippocampal neuron cultures to examine its efficacy at central 
neurons. TetBot was imaged internalised into the synaptic terminals of hippocampal 
neurons and was shown, by western blot, to successfully cleave SNAP25 and thus 
retained the catalytic activity of BoNT/A (Ferrari et al., 2013). Furthermore, brain slices 
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containing the suprachiasmatic nucleus displayed significantly reduced circadian 
rhythms following incubation with TetBot, indicating a functional effect.  
After confirming the lack of paralysis and retained functionality of the chimera, TetBot 
was trialled in the complete Freund's adjuvant (CFA)-induced inflammatory pain model. 
100 ng TetBot was injected intrathecally to rats prior to induction of the pain model. 
TetBot did not influence basal mechanical sensitivity, however, significantly attenuated 
the mechanical hypersensitivity developed after intraplantar injection of CFA (Ferrari et 
al., 2013). Importantly, this analgesic effect was still apparent at 11 days post-CFA when 
the experiment was terminated, emphasising a long-lasting effect. Again, the analgesia 
occurred in the absence of any motor impairment.  
In the experiments detailed, TetBot was administered directly to the target neurons. For 
example, intrathecal injection was used when targeting the central neurons of the spinal 
cord in the CFA-induced inflammatory pain model. This delivery method would have 
therefore provided direct access to the target neurons. Consequently, the experimental 
conditions did not attempt to exploit the axonal transport, associated with Tetanus toxin, 
although this was the original aim. Ideally, TetBot should have been injected to a 
peripheral site to investigate whether it would then undergo retrograde transport to 
penetrate the central neurons. Additionally, the vast majority of humans are immunised 
against tetanus toxin, and consequently, TetBot would most likely not be suitable for use 
in human medical care (Maple et al., 2000). Instead, TetBot would be most applicable 
for pain management in animals.  
 
1.2.5.1.2 BiTox 
The other chimera generated was BiTox which is an elongated version of native BoNT/A 
(Ferrari et al., 2011). BiTox was again constructed from the LcTd/A fused to the SNAP25 
SNARE-peptide tag. The fused-subunit was then conjugated to the Rbd of BoNT/A, 
tagged with synaptobrevin, by addition of the SNARE-staple, syntaxin. This once more 
led to the formation of a truncated SNARE-complex within the chimera, which hence 
significantly increased the length of the protein. Accordingly, BiTox demonstrated 
reduced potency at blocking neurotransmission at the NMJ, similar to TetBot. 
Specifically, 75 minute incubation with 190 pM BiTox was required to reduce the 
amplitude of contractile responses in mouse hemidiaphragm preparations by 50% 
(Darios et al., 2010). By contrast, it has been separately shown that 2 pM of native 
BoNT/A was sufficient to reduce the amplitude of muscle twitches in hemidiaphragm 
preparations by 50%, within the same time allowance (Ferrari et al., 2013). This again 
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highlights that the paralytic activity of BoNT/A is greatly impaired by the SNARE-stapling 
approach.  
Correspondingly, BiTox demonstrated greatly reduced lethality compared to native 
BoNT/A. Lethality with native BoNT/A was observed within 24 hours in mice after 
intraperitoneal injection of doses as low as 2 ng/kg (Ferrari et al., 2011). In contrast, mice 
receiving intraperitoneal injection of up to 200 ng/kg BiTox did not display any indication 
of muscular paralysis or compromised well-being. Again, this reveals an increased safety 
profile, associated with the reengineered proteins.  
Subsequent in vitro investigations confirmed the functionality of BiTox. Specifically, 
incubation of isolated brain synaptosomes with BiTox inhibited both calcium-dependent 
and potassium-evoked glutamate release (Darios et al., 2010). The impairment of 
glutamate release was equivalent to that observed following incubation with BoNT/A, 
therefore emphasising that BiTox is as efficacious as native BoNT/A at blocking 
neurotransmission and neuronal function of central neurons. The compromised efficacy 
of BiTox is instead exclusive to the encapsulated NMJs.  
The selectivity of BiTox for silencing other neuronal populations in preference to the 
motor neurons, in addition to its improved safety profile, encouraged the antinociceptive 
potential of BiTox to be assessed. Similar to native BoNT/A, intraplantar injection of 
BiTox did not affect basal mechanical or thermal sensory thresholds in naïve rats 
(Mangione et al., 2016). 200 ng BiTox administered via intraplantar injection, 1 day after 
pain model induction, produced only a partial and transient recovery of the basal 
mechanical withdrawal threshold in both CFA-induced inflammatory pain and the plantar 
incision post-operative pain model, compared to vehicle control. 
By contrast, in a subsequent experiment, CFA was instead injected into the ankle joint, 
rather than intraplantar, while the mechanical withdrawal threshold continued to be 
measured at the plantar surface of the ipsilateral hindpaw. Under these conditions, 
intraplantar injection of BiTox 3 days after CFA-injection, significantly reduced 
mechanical hypersensitivity. Likewise, intraplantar injection of BiTox, prior to exposure 
to capsaicin, failed to alter primary thermal hyperalgesia, localised to the capsaicin 
injection site. Injection of BiTox did, however, effectively reduce secondary mechanical 
hyperalgesia in the adjacent area on the plantar surface of the hindpaw. The study did 
not, however, measure mechanical primary hyperalgesia following capsaicin injection. It 
is therefore not clear from this experiment whether BiTox is more effective against the 
sensory modality, i.e. thermal or mechanical pain, or the site of hyperalgesia, primary or 
secondary. Mechanical threshold was, however, assessed in both CFA-models and this, 
therefore, consequently implies that BiTox exhibits an effectiveness specifically against 
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secondary hyperalgesia, highlighting a potential action against central sensitisation 
(Mangione et al., 2016).  
Separately, when intraplantar injection of 200 ng BiTox was administered 3 days post-
spared nerve injury (SNI), a model of peripheral neuropathic pain, a significant reversal 
of the developed mechanical hypersensitivity was observed whereby the mechanical 
threshold returned to basal values. In contrast, vehicle-injected SNI rats continued to 
develop further mechanical hypersensitivity. Additionally, intraplantar injection of BiTox, 
14 days prior to SNI, greatly attenuated the development of mechanical hypersensitivity. 
Notably, only a marginal decrease in mechanical threshold from basal values was 
detected in BiTox-injected rats, compared to vehicle injected rats (Mangione et al., 2016).  
Mechanical hypersensitivity in neuropathic pain, likewise, results from central 
sensitisation (Nickel et al., 2012). Collectively, it suggests that, similar to native BoNT/A, 
BiTox might produce its analgesic effect predominantly via a centrally-mediated 
mechanism. In agreement with this, a delay in the analgesic effect following intraplantar 
injection of BiTox was consistently noted hence suggesting that this time might be 
necessary to allow for the axonal transport of the chimera. Opposingly, however, western 
blot analysis failed to reveal cleaved SNAP25 at the level of the dorsal horn in BiTox-
injected animals (Mangione et al., 2016). Furthermore, evidence was provided for a 
peripheral mechanism after reduced capsaicin-induced plasma extravasation was 
observed in the BiTox-injected hindpaw compared to the uninjected contralateral paw 
(Mangione et al., 2016). A direct action at A-nociceptors was also suggested after 
mechanical, but not thermal hypersensitivity, was reduced, as thermal nociception is 
communicated by C-fibre nociceptors (Mangione et al., 2016). As a result of the 
conflicting evidence, it is currently unclear how BiTox mediates its analgesic effect and 
subsequently still remains to be clarified.  
 
1.3 Hypotheses and Aims 
Chronic pain represents a huge unmet clinical need. Whilst no chronic pain-specific 
pharmacotherapy exists, and while the aging population proceeds to grow, chronic pain 
will continue to place massive strain on both present and future healthcare services, as 
well as imposing ever-increasing pressure on the economy. In order to resolve this issue, 
it is important that therapeutics specifically intended for use in chronic pain conditions 
are developed. Between them, the studies described here illustrate how chemical and 
recombinant protein engineering methods can be utilised to design chimeras that 
incorporate the potent BoNT/A, in order to provide novel analgesics.  
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Within these studies, several important aims have already been achieved. Novel 
chimeras have repeatedly been demonstrated to effectively retain the catalytic activity of 
BoNT/A, via the detection of cleaved SNAP25 (Mustafa et al., 2013; Ma et al., 2014). 
Furthermore, the novel chimeras have displayed functionality by inhibiting pain mediator 
release from cultured neurons, and by producing analgesia in behavioural pain models 
(Duggan et al., 2002; Mustafa et al., 2013; Ma et al., 2014). Specifically, the chimeras 
generated using the pioneered SNARE-stapling technique exhibited reduced potency at 
the neuromuscular junction, thus circumventing the motor paralysis and lethality 
associated with BoNT/A, whilst simultaneously continuing to provide long-lasting pain 
relief (Ferrari et al., 2013; Mangione et al., 2016). It is essential that the mechanisms of 
action of these chimeras begin to be understood. From this perspective, Chapter 3 will 
focus on elucidating the in vivo activity of BiTox/A, the most successful chimera so far 
produced using the SNARE-stapling technology.  
It is also important that novel chimeras continue to be developed. This is required in 
order to assess whether alternative combinatorial chimeric designs are more effective at 
producing analgesia in other pain conditions or are more efficacious at treating certain 
clinical presentations of chronic pain, e.g. thermal versus mechanical hypersensitivity. 
By maintaining the inclusion of LcTd/A, the future resultant chimeras will persist to cleave 
SNAP25 in neurons, and consequently block SNARE-mediated cellular processes. 
However, by combining LcTd/A with alternative targeting domains, using the 
combinatorial approach, possible with the SNARE-stapling technology, the catalytic 
activity of BoNT/A can be retargeted to separate subpopulations of sensory neurons. 
Based on the distinct combinations of gangliosides and protein receptors bound by the 
alternative BoNT serotypes, it is hypothesised that the Rbd of the respective serotypes, 
conjugated to LcTd/A, will retarget the catalytic activity to distinct populations of sensory 
neurons, whilst continuing to avoid action at the NMJ (Chapter 4). The in vitro binding 
profile of BiTox, henceforth referred to as BiTox/A, due to the inclusion of Rbd/A, will thus 
be assessed and then compared to the binding profile of chimeras composed of the 
alternative BoNT Rbds, to investigate whether they do exhibit preferential binding to 
distinct sensory neuron subpopulations and whether this consequently conveys an 
alternate therapeutic effect in vivo. There is also the possibility of utilising the binding 
domains of unrelated toxins, such as cholera toxin. This will be investigated using the 
same technique in Chapter 6. 
Additionally, a potential alternative clinical application for chimeras, separate from the 
management of chronic pain, will be explored (Chapter 5). Axonal transport to the central 
terminal of neurons has been either demonstrated or suggested for both native and re-
engineered clostridial neurotoxins (Bach-Rojecky and Lacković, 2009; Mangione et al., 
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2016; Matak et al., 2017), however, it is already known and accepted that tetanus toxin 
does undergo retrograde transport to reach the inhibitory interneurons, located in the 
spinal cord (Surana et al., 2017). It will therefore be investigated whether the binding 
domain of tetanus toxin can be exploited for the drug delivery of therapeutics to the 
central nervous system, as a proof of principle experiment, and whether optimisation and 
advancement of the SNARE-stapling method can augment this delivery. Furthermore, 
cholera toxin is similarly able to undergo axonal transport and therefore is well-
established as a neuronal tracer (Angelucci et al., 1996). For this reason, the use of 
cholera toxin binding domain for drug delivery will also be examined. 
The ultimate objective of this thesis does, however, remain the development of a novel 
pain therapeutic for use in chronic pain conditions. This will again be the investigated in 
Chapter 6, subsequent to findings made in Chapter 5, regarding a novel chimera 
constructed from the binding domain of cholera toxin conjugated to LcTd/A. In Chapter 
6, the analgesic potential of the novel chimera, which utilises the binding domain of a 
non-clostridial toxin, will be determined. 
Collectively, this thesis will demonstrate how the SNARE-stapling conjugation approach 
allows for the production of safe, long-lasting, non-paralytic analgesics, with the potential 




















All the chimeras and proteins that were used for either treating cell cultures or that were 
injected into animals are listed in the table below: 
 
Table 2.1 Details of chimeras used. 









BiTox/A LcTd/A Rbd/A 
Recombinant 
(Expressed and purified 
by Dr Charlotte Leese) 




BiTox/C LcTd/A Rbd/C 
Recombinant 
(Expressed and purified 
by Dr Charlotte Leese) 
 
BiTox/D LcTd/A Rbd/D 
Recombinant 
(Expressed and purified 
by Dr Charlotte Leese) 
 
BiTox/E LcTd/A Rbd/E 
Recombinant 
(Expressed and purified 
by Dr Charlotte Leese) 
 
ChoBot LcTd/A AB5 
Recombinant 
(Expressed and purified 










No. C34775)  
(Conte et al., 
2009) 
Tbd-Cy3 - Tbd 
Recombinant 
(Expressed and purified 
by Dr Charlotte Leese) 
(Mavlyutov et 
al., 2016) 
2xTbd-Cy3 - 2xTbd 
Recombinant 
(Expressed and purified 
by Dr Charlotte Leese) 
 
TetBot LcTd/A Tbd 
Recombinant 
(Expressed and purified 
by Dr Charlotte Leese) 
(Ferrari et al., 
2013) 
2xTetBot LcTd/A 2x Tbd 
Recombinant 
(Expressed and purified 





Below is a table documenting all the primary antibodies used for immunocytochemistry, 
immunohistochemistry and western blot. 
 
 Table 2.2 Details of all primary antibodies used including the relevant dilutions used for 






























































Peripherin Peripherin Mouse 1:200 (ICC) MAB1527 
Merck 
Millipore 
SNAP25 SNAP25 Mouse 
1:1000 
(IHC) 
SMI 81 Biolegend 
SNAP25 SNAP25 Rabbit 1:3000 (WB)  In-house 
Syntaxin 1 Syn1 Rabbit 1:2000 (WB)  In-house 
 
 
The specificity of the in-house anti-cleaved SNAP25 antibody has been repeatedly 
verified within the laboratory (Fig. 2.1). Similarly, the inhouse anti-Neurofilament 200 
antibody has been validated by Dr Ciara Doran who demonstrated that immunolabelling 
produced by the inhouse antibody colocalised to that produced by a commercial anti-
Neurofilament 200 antibody (data not shown).  
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All secondary antibodies used for immunocytochemistry, immunohistochemistry and 
western blot are listed in the table below: 
 
Table 2.3 Details of all secondary antibodies used including the relevant dilutions used for 






















A11029 Life Technologies 
Anti-rabbit IgG (H+L) 





A11034 Life Technologies 
Anti-mouse IgG (H+L) 





A11005 Life Technologies 
Anti-rabbit IgG (H+L) 





A11012 Life Technologies 
Anti-rabbit IgG HRP 
linked 




A protein conjugate was also used for immunohistochemistry. Its details are documented 
in the table below. 
 
Table 2.4 Details of the protein conjugate used.  
 





Alexa Fluor 488 
Conjugate 




Figure 2.1 The anti-cleaved SNAP25 
antibody is specific for the BoNT/A- 
cleavage product. (A) Western blot analysis 
of dissociated dorsal root ganglion cultures, 
incubated with multiple concentrations of 
Botulinum neurotoxin A (BoNT/A), display 
dose-dependent cleavage of SNAP25. When 
the western blot is probed with the total 
SNAP25 antibody, immunoreactive to both 
whole, uncleaved SNAP25 and cleaved 
SNAP25, two bands are detected in each lane 
of the treated cultures. The top band 
represents full length, uncleaved SNAP25 whilst the bottom band represents the shorter, BoNT/A-
cleavage product. Accordingly, only one band is detected in the untreated sample, representing 
whole SNAP25 and indicating that no cleavage of SNAP25 has occurred. (B) In contrast, probing 
using the specific anti-cleaved SNAP25 antibody reveals only one band. Thus, highlighting the 
specificity of the antibody for the BoNT/A-cleavage product and the lack of immunoreactivity for 
whole SNAP25. Resultantly, no band is detected in the untreated sample. Data provided courtesy 
of Dr C. Leese.  
 
2.1.3 Media and solutions used 
All medias used are detailed in the table below, alongside their composition. 
 
Table 2.5 Details of the medias used. 
 Media Components 
DRG wash 
media 
DMEM/F12 with Glutamax (31331, Life Technologies), 10% heat-
inactivated Horse serum (26050, Life Technologies) and 1% penicillin-
streptomycin (P0781, Sigma) 
DRG low-
serum media 
Neurobasal A medium (10888, Life Technologies), 1% heat-
inactivated Horse serum (26050, Life Technologies), 1% penicillin-
streptomycin (P0781, Sigma), 20 ng/ml NGFβ (SRP4304, Sigma), 1x 
B27 (17504-044, Life Technologies), 1% Glutamax (35050-061, Life 
Technologies) 20 μM uridine (U3003, Sigma), 20 μM 5'-Fluoro-2'-




Neurobasal medium (21103, Life Technologies), 1% penicillin-
streptomycin (P0781, Sigma), 1x B27 (17504-044, Life Technologies), 
1% Glutamax (35050-061, Life Technologies) 
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All solutions used are documented in the table below, alongside their composition.  
 
Table 2.6 Details of the solutions used.  
 
Solution Composition 
Blocking solution for 
Immunohistochemistry 
5% (v/v) Goat serum (005-000-121, Jackson 
ImmunoResearch Laboratories, Inc), 0.3% (v/v) Triton X-100 
(BP151-500, Fisher BioReagents) in 1x PBS. 
Blocking solution for 
Western Blot 
5% (w/v) Skim milk powder (70166, Sigma), 0.1% (v/v) 
Tween 20 (B337-500, Fisher BioReagents) in 1x PBS. 
15% Bovine Serum 
Albumin 
15% (w/v), DMEM/F12 with Glutamax (31331, Life 
Technologies), 10% heat-inactivated Horse serum (26050, 
Life Technologies) and 1% penicillin-streptomycin (P0781, 
Sigma). 
DRG Lysis Buffer 
50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1.5 mM MgCl2, 
10% glycerol, 1% Triton-X100 and 1:40 protease inhibitor in 
deionised water (Gift from Dr M. A. Nassar’s Lab). 
70% Ethanol 





1 mg/ml Dispase II (D4693, 0.85 U/mg, Sigma), 0.6 mg/ml 
Collagenase XI (C7657,1594 U/mg Sigma) in 155 mM NaCl 
(S/3160/60, Fisher Scientific), 4.8 mM HEPES sodium salt 
(H8651,Sigma), 5.6 mM HEPES (B299-500, Fisher 
BioReagents), 1.5 mM KH2PO4  (P/5240/53, Fisher Scientific) 
and 10 mM D-(+)-Glucose (G7528, Sigma) in deionised 
water.  
Laminin 10 μg/ml laminin (L2020, Sigma), Sterile PBS 
Membrane Transfer 
Buffer 
20% (v/v) methanol and 10% (v/v) 10x transfer buffer (Fluka) 
in deionised water. 
MES SDS running 
buffer 
5% (v/v) 20x NuPAGE MES SDS running buffer (Life 
Technologies) in deionised water. 
4% Paraformaldehyde 
(pH 7.4) 
4% (w/v) Paraformealdehyde (A11313, Alfa Aesar and 





Buffered saline (PBS) 
10% (v/v) 10x Phosphate-Buffered saline (1.37 M Sodium 
chloride, 0.027 M Potassium Chloride and 0.119 M 
Phosphate buffer) (BP399-20, Fisher Scientific) in deionised 
water (pH 7.4).  
4x SDS Lysis Buffer 
224 mM SDS, 250 mM Tris-HCl pH 6.8, 6.4 mM EDTA, 25% 
(v/v) glycerol, 1 mM MgCl2 (223210010, ACROS organics) 
and 0.1 % (v/v) Benzonase nuclease (E1014-2KU, Sigma) 
and traces of bromophenol blue (BDH Chemical) in deionised 
water. 
5% Sucrose 5% (w/v) sucrose (S/8600/53, Fisher Scientific) in 1x PBS. 
30% Sucrose 30% (w/v) sucrose (S/8600/53, Fisher Scientific) in 1x PBS. 
0.3% Triton in PBS 
0.3% (v/v) Triton X-100 (BP151-500, Fisher Bioreagents) in 
1x PBS. 
0.1% Tween in PBS 
0.1% (v/v) Tween 20 (B337-500, Fisher BioReagents) in 1x 
PBS. 
Working solution for 
immunohistochemistry 
2% (v/v) Goat serum (005-000-121, Jackson 
ImmunoResearch Laboratories, Inc), 0.3% (v/v) Triton X-100 
(BP151-500, Fisher BioReagents) in PBS. 
 
 
2.2 Dorsal Root Ganglion Culture 
 
2.2.1 Coating plates 
μClear 96-well plates (655090, Greiner Bio-One) were used for imaging experiments. 
96-well plates were coated with 40 μl per well of 10 μg/ml laminin in PBS and left for 1 
hour at 37 oC. Alternatively, for western blot experiments using dissociated dorsal root 
ganglion cultures, 24-well plates (3526, Costar) were used. 120 μl of 10 μg/ml laminin 
was added per well and again plates were then left for 1 hour at 37 oC. After 1 hour, the 
laminin solution was aspirated from the wells and the wells were then washed twice, 




2.2.2 Dissection of dorsal root ganglia 
3-5 week old Sprague Dawley rats were culled by schedule 1 method (cervical 
dislocation followed by exanguination) in accordance with the UK Animals (Scientific 
Procedures) Act 1986. The skin overlying the spinal column was removed and the 
excess adipose tissue trimmed away using a blade (15C, Swann-Morton). The spinal 
column was excised from situ using iris scissors (WPI) and a dorsal laminectomy was 
performed using microscissors (WPI) to remove the dorsal roof and expose the spinal 
cord. The ventral body of the spinal column was then hemisected, again using iris 
scissors (WPI). The spinal cord was gradually pulled away from each hemisection to 
reveal the dorsal root ganglia. Each dorsal root ganglion was dissected out using fine 
tweezers (Dumont) and microscissors (WPI) and the central and peripheral spinal root 
were trimmed away. Trimmed DRG were collected into 1 ml PBS in a 1.5 ml eppendorf 
tube. 
 
2.2.3 Preparation of culture 
The PBS was removed from the DRGs in a culture hood (Class II biological safety 
cabinet, Airstream) and 1 ml of 1 mg/ml Dispase II (D4693, 0.85 U/mg, Sigma) and 0.6 
mg/ml Collagenase XI (C7657,1594 U/mg Sigma) in HEPES-buffered dissociation 
solution was added (Baker and Bostock, 1997). The DRGs were incubated at 37 oC for 
1.5 hour in a carbon dioxide incubator to allow for dissociation (Galaxy 170 S CO2 
Incubator, New Brunswick). After 1.5 hr, DRGs were transferred to a 15 ml falcon tube 
and triturated rapidly in 1 ml of DRG wash media. The resuspended DRG mixture was 
then carefully pipetted and transferred to form a separate layer on top of 3 ml 15% BSA 
(in DRG Wash Media) and centrifuged for 10 minutes at 1500 rpm (21 oC, Asc 9, Desc 
2) using a Rotina 46 R centrifuge (Hettich) centrifuge. The supernatant containing both 
DRG wash media and 15% BSA was next removed leaving a pellet of DRG neurons. 4 
ml of DRG wash media was then added, the pellet resuspended, and the spin repeated 
(10 mins at 1500 rpm, 21 oC, Asc 9, Desc 2) using the same centrifuge. The supernatant 
was again removed, and the pellet was resuspended in the appropriate amount of DRG 
low-serum media to allow the cells to plated in 200 µl per well. 
 
2.2.4 Incubation with chimeras 
Dissociated dorsal root ganglia cultures were grown for 2 days prior to the addition of 
chimeras. Half (100 μl) of the low serum media was removed and replaced with fresh 
low serum media, containing the chimera, to give an end concentration of 10 nM of 
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chimera. The culture was then incubated with the chimera for 65 hours at 37 oC, 5% CO2 
in the cell culture incubator.  
 
2.2.5 Immunocytochemistry 
After 65 hours incubation with the respective chimeras, 170 μl of the media containing 
the chimera was removed from the wells and the cells were washed with 150 μl of ice 
cold PBS for 5 minutes before 10 minute fixation with 150 μl 4% PFA. Both steps were 
carried out on ice. The wells were then washed once with 150 μl PBS for 5 min before 
permeabilising the cells with 150 μl of 0.3% triton in PBS. The wells were then washed 
a further two times with 150 μl PBS (first wash 2 minutes, second wash 5 minutes). The 
cells were then incubated in 150 μl blocking solution for immunocytochemistry for 1 hour. 
Next, the blocking solution was removed from the wells and the cells were incubated for 
a further 1 hour with primary antibodies diluted in 150 μl immunocytochemistry specific 
blocking solution. This was again followed by two washes with 150 μl PBS, the first for 2 
minutes and the second for 5 minutes, before incubation with the respective secondary 
antibodies and DAPI (Sigma), again diluted in 150 μl blocking solution, for 45 minutes. 
The cells were then washed at least 3 times with 150 μl PBS (the first wash for 2 minutes 
and then subsequent washes for 5 minutes), prior to imaging.  
 
2.2.6 Epifluorescence microscopy of cell cultures  
Images were acquired on a Leica DM IRB epifluorescence microscope at 20x 
magnification using MicroManager software. Three fields of view were imaged per well. 
To avoid investigator bias, the fields of view were selected by viewing the well at 5x 
magnification and positioning the field of view to be central to each of three set positions 
per well (Fig. 2.2), before then increasing the magnification to 20x. Each experiment was 
completed in triplicates.  
 
Figure 2.2 Selection of the fields of view when imaging 
dissociated dorsal root ganglion cultures. The well of the 
96 well plate was first viewed under 5x magnification to 
position the centre of the field of view at one of the three 
positions depicted. The magnification was then increased to 
20x and the epifluorescent image was taken. This process 
was repeated until epifluorescent images had been taken at 




2.2.7 Image analysis 
Image analysis and quantification was performed using FIJI. Cells were judged to be 
neurons if they labelled positively with β-Tubulin-III (or Neurofilament 200 or Peripherin, 
dependent on the neuronal marker used) with an intact, healthy nucleus, assessed using 
the DAPI stain, and an intact cell membrane. The region of interest (ROI) of healthy 
neurons was then marked on the brightfield image, using the FIJI freehand selections 
tool (Fig 2.3). The multi-measure function was used to measure the area of the marked 
ROIs and the mean gray value intensity of the pixels contained within the individual ROIs, 
across the multiple image slices. This produced an Excel sheet which was then 
transferred to Microsoft Excel. Here, the cell diameter of neurons was calculated from 
the measured ROI area using the equation “=2*(SQRT(CELL/PI()))”.  
Colocalisation of cleaved SNAP25 with the neuronal markers was determined by a 
thresholding technique. The mean gray value threshold for each antibody stain is listed 
in Table 2.5. A higher threshold was set for the cleaved SNAP25 stain because this 
antibody produced a much brighter, more intense stain than the neuronal markers, 
possibly due to the use of the Anti-mouse IgG (H+L) Cross adsorbed Alexa Fluor 594 
secondary antibody, opposed to Alexa Fluor 488, used to label the neuronal markers. 
The conditional formatting function within Microsoft Excel was used to highlight neurons 
whose immunofluorescence exceeded the set threshold. 
 
  
Figure 2.3 Marking of neurons and image quantification using FIJI. Neurons were identified 
using the βIII-Tubulin stain (left panel). The health of neurons was then determined by identifying 
a DAPI-stained nucleus (3rd panel). Only the healthy neurons with intact nuclei were then outlined 
in the brightfield image (4th panel), using the freehand selection tool. The arrows indicate cells 
which appeared weakly positive for βIII-Tubulin but did not have a nucleus when viewing the DAPI 
image. The dead cells can be seen to produce non-specific immunofluorescence in the Cleaved 




Table 2.7 The mean gray value threshold applied to 







2.2.8 Statistical Analysis of DRG culture images 
One-way analysis of variance (ANOVA) was used to assess the statistical relevance of 
immunocytochemistry data. Statistical significance was defined as P<0.05. In Chapter 4, 
Dunnett’s multiple comparisons was used to specifically compare the binding of BiTox/A 
to each of the alternative botulinum chimeras. In chapter 6, however, the binding profile 
of three chimeras, BiTox/A, TetBot and ChoBot, was compared against each other. This 
meant that all pairwise comparisons were conducted, and therefore the Tukey’s multiple 
comparisons test was used instead. All statistical analysis was conducted using 
GraphPad Prism 7. Results are presented as mean ± S.E.M. 
 
2.3 Animals 
All animal experiments were conducted under a UK Home Office Project License and 
complied with the UK Animals (Scientific Procedures) Act, 1986. Male and female rats 
were purchased from Charles River and breeding pairs were established. Male Sprague-
Dawley rats (150-200 g) from the subsequent litters were then used in experiments. All 
animals were housed in a 12 hour light/dark cycle at 21 oC and in 55% relative humidity. 
Food and water was available ad libitum. 
 
2.4 Injections 
2.4.1 Preparation of clostridial chimeras for injection 
Chimeras were prepared courtesy of Dr C. Leese. The appropriate amount of chimera 
was dissolved in the relevant volume of Buffer A to achieve the desired injection volume, 
most commonly 30 or 50 μl. For the vehicle control, the equivalent volume of 0.4% OG 
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(Octyl β-D-glucopyranoside) used to prepare the chimera, was diluted in Buffer A. Prior 
to injection, both solutions were maintained on ice to ensure their stability. 
 
2.4.2 Intraplantar injection 
Rats were individually anaesthetised in an induction chamber with 4% isoflurane (IsoFlo, 
Zoetis) in oxygen. Once immobile, the rat was then moved to an anaesthesia mask and 
placed in the prone position. The depth of anaesthesia was confirmed by loss of the 
pedal withdrawal reflex in the right hindpaw. The left hindpaw was next cleaned using 
70% ethanol and a 0.3 ml U-100 Insulin syringe (Terumo), coupled to a 29-gauge needle, 
was inserted subcutaneously into the plantar aspect of the left hindpaw. The desired 
volume was then injected into the centre of the footpad, over approximately 5-10 
seconds. The animal was then placed in a recovery cage and monitored for several 
minutes before being returned to its normal cage.  
 
2.4.3 Intraperitoneal injection 
Rats were anaesthetised with 4% isoflurane (in oxygen) in an induction chamber. Once 
anaesthetised, the rats were then removed and gently restrained whilst a 1ml syringe 
coupled to a 27-gauge needle (302200, BD Microlance) was inserted into the posterior 
quadrant of the abdomen, in order to access the peritoneum. The needle was angled so 
that it ran parallel to the line of the hind leg, as to avoid the abdominal organs. The 
necessary volume of substance was then delivered, and the needle withdrawn.  
 
2.5 Experimental pain models 
2.5.1 Chronic inflammatory pain model 
Either 15 μl (Chapter 6) or 30 μl (Chapter 4) of Complete Freund’s Adjuvant (F5881, 
Sigma) was delivered via intraplantar injection (as described in 2.4.1) to the central 
footpad to produce a stable inflammatory state (Stein et al., 1988).  
 
2.5.2 Incisional post-operative pain model 
For the post-operative pain model, rats were deeply anaesthetised in an anaesthesia 
induction chamber, using 4% isoflurane in oxygen, before being secured to an external 
anaesthesia mask in the prone position. The depth of anaesthesia was confirmed by loss 
of the pedal withdrawal reflex in the right hindpaw. The left hindpaw was then cleaned 
62 
 
thoroughly using 70% ethanol. An incision, approximately 1 cm in length, was then made 
to the left hindpaw, using a sterile blade (15A, Swann-Morton), extending from the centre 
of the foot pad towards the heel of hindpaw (Brennan et al., 1996). Pressure was then 
applied to the hindpaw for 1-2 minutes until any bleeding had stopped and the incision 
was sealed using VetBond tissue adhesive (3M). The rat was then returned to a recovery 
cage and monitored for 20 minutes to ensure the incision was effectively sealed before 
being returned to a clean cage. 
 
2.5.3 Chemotherapy-induced peripheral neuropathy pain model 
Rats were injected intraperitoneally (described in 2.4.2) with 2 mg/kg paclitaxel (10461, 
Cayman Chemicals), delivered in an injection volume of 1 ml/kg, as described previously 
(Polomano et al., 2001). The correct concentration of paclitaxel was prepared by diluting 
paclitaxel to 2 mg/ml in saline and then injecting the calculated volume, dependent on 
the weight of the individual rat. Rats received a total of 4 intraperitoneal injections of 
paclitaxel, administered on alternate days (day 0, 2, 4 and 6), providing a cumulative 
dose of 8 mg/kg paclitaxel per animal. A separate group of animals simultaneously 
received 4 IP doses of Cremophor EL (C5135, Sigma)/ Ethanol (1:1), used to dissolve 
paclitaxel, to provide a vehicle only group.  
 
2.6 Behavioural studies 
2.6.1 Hargreaves Test 
Rats were placed in clear plastic boxes (20 cm x 20 cm x 14 cm) on top of a glass surface 
and allowed 30-45 minutes to acclimatise. Longer, however, specifically up to 1 hour, 
was allowed during initial baseline measurements. During the acclimatisation period, the 
rats were observed for exploratory behaviour. Only once this behaviour seized and rats 
appeared calm and less mobile, with only occasional bouts of grooming, was the test 
started. Thermal thresholds were determined by Hargreaves test using the Plantar 
Hargreaves' Test Apparatus (37370, Ugo Basile) (Hargreaves et al., 1988). Here, a laser 
heat source (60 IR), situated beneath the glass surface, was positioned under the central 
footpad of both the affected and unaffected hind paw. Once correctly positioned, a switch 
was used to activate the heat source and start an in-built electronic timer. The withdrawal 
latency for when the rat removed its paw from the heat source was electronically 
measured and confirmed by observation. To ensure that no tissue damage occurred 
during testing, a maximum withdrawal latency cut-off value of 20 seconds was imposed. 
A total of four readings were taken for each hindpaw and recorded with a minimum wait 
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of 5 minutes between each consecutive reading. The average withdrawal latency was 
then calculated from the four readings. 
Urine and faeces were cleared for the duration of the test. Urine, especially, interferes 
with the heat absorption of the plantar surface of the paw, and with the reflection of the 
infrared beam, thus disrupting the reading (Ugo Basile, 2013). 
 
2.6.2 Electronic von Freys 
Rats were placed in individual plastic chambers (15cm x 36 cm x 18 cm) on top of an 
elevated wire mesh. Rats were allowed 30-45 minutes to acclimatise, however, a longer 
acclimatisation period was allowed during the initial baseline measurements. Once 
exploratory behaviour had stopped, and rats were still with only occasional short 
grooming periods, the test was started. Mechanical thresholds were assessed using 
electronic Von Frey equipment (EVF3, BioSeb) applied to the centre of the footpad of 
the affected and unaffected hind paw (Ängeby Möller et al., 1998). Pressure was evenly 
applied until the rat withdrew its hindpaw. The force at which the paw was removed was 
then electronically recorded. Four readings were taken per paw and a minimum interval 
of 5 minutes was imposed between consecutive readings. The average mechanical 
withdrawal threshold was then calculated from the four readings for each individual rat. 
 
2.6.3 Evaluation of motor function 
Two separate methods were used to assess motor function. Firstly, hindpaw digit 
spreading, following tail suspension, was used to examine motor innervation. Successful 
digit spreading of the hindpaw indicated sufficient intact motor innervation of the hindpaw 
(Wen et al., 2015). Secondly, a suspension test was used to assess muscle weakness 
and loss of muscle tone (Mangione et al., 2016). During this test, the rats were placed 
on a wire mesh. The mesh was then inverted and held approximately 30 cm over a 
cushioned cage. It was recorded whether rats were able to successfully grip the wire 
mesh or whether they fell immediately. Additionally, rats were observed for any signs of 
limping or dragging of the hindlimb, indicative of muscular paralysis, during normal 
exploratory behaviour.  
 
2.6.4 Statistical Analysis  
Two-way ANOVA was used to determine the statistical significance of the behavioural 
results. Sidak’s multiple comparisons test was used, post-hoc, to determine whether any 
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statistical differences existed between treatment groups at each individual time point. 
Statistical significance was defined as P<0.05. All statistical analysis was conducted 
using GraphPad Prism 7. Results are presented as mean ± S.E.M.  
  
2.7 Immunohistochemistry 
2.7.1 Transcardial Perfusion 
Rats were euthanized by an overdose of anaesthetic via intraperitoneal injection 
(described in 2.4.2) of pentobarbital (150 mg/kg) (JML), delivered under 4% isoflurane. 
Loss of the pedal withdrawal reflex and corneal reflex was used to confirm the depth of 
anaesthesia before proceeding with the perfusion. The rat was then placed in the supine 
position and a midline incision was made, extending up to the chest. The heart was 
accessed by cutting through the diaphragm and removing the ribcage using iris scissors 
(WPI). Once exposed, a 19-gauge needle (BD Microlance) was inserted into the left 
ventricle of the heart and secured using a needle holder (Arnold). Microscissors (WPI) 
were used to make an incision to the right atrium to allow the exit of fluids. The animal 
was perfused with 300 ml PBS followed by 300 ml 4% PFA. The animal was then 
released from the perfusion system and the relevant tissues were collected. These 
included the spinal cord, the dorsal root ganglia and glabrous skin, taken from the plantar 
surface of both hindpaws.  
 
2.7.2 Preparation of tissue 
Following the dissection, the tissues were post-fixed in 4% PFA for 4 hours at room 
temperature. The tissues were then transferred to 30% sucrose and stored at 4oC until 
sectioned. Additionally, with regards to the spinal cord collected, an incision was made 
to the contralateral ventral horn using a blade (15C, Swann-Morton) to enable 
identification of the contralateral spinal cord during image analysis. 
 
2.7.3 Sectioning of tissue 
All tissue specimens to be processed were emerged in Cryo-M-Bed OCT embedding 
medium (53581-1, Bright) and frozen at -40 oC. 30 μm sections were prepared using a 
cryostat (OFT5000, Bright Instruments). Transverse spinal cord sections and glabrous 
skin sections were collected and consequently stored at 4 oC in 5 % sucrose in PBS as 
free-floating sections. Conversely, dorsal root ganglion sections were mounted directly 
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onto SuperFrost plus slides (ThermoFisher) and then stored at -20 oC until further 
immunohistochemical processing. 
 
2.7.4 Immunohistochemical staining  
Free-floating sections received three 10 minutes washes in PBS. Sections were then 
incubated with blocking solution (5% Goat serum, 0.03% Triton X-100 in 1x PBS) for one 
hour at room temperature before overnight incubation at 4 oC with the relevant primary 
antibodies, diluted in working solution (2% Goat serum, 0.03% Triton X-100 in 1x PBS). 
The next day, the sections were washed a further three times in 1x PBS. Again, each 
wash was 10 minutes long. Sections were then incubated with the corresponding 
secondary antibodies, diluted in the working solution for 2 hours. DAPI (Sigma) was also 
added at this stage. Sections underwent an additional three 10 minute washes in PBS 
before being mounted onto SuperFrost plus slides (ThermoFisher). The DRG slide-
mounted sections were processed identically except for each set of three 10 minutes 
washes, the slides were instead washed 5 times for 5 minutes. PBS was again used for 
the washes. In both instances, the slides were allowed to air dry before adding 
Fluoromount aqueous mounting medium (Sigma) and applying a 22x64 mm coverslip 
(401/0188/52, BDH) to the slides, ready for immunofluorescent and confocal microscopy.  
 
2.7.5 Imaging and microscopy of sections 
Sections were imaged on a Leica DM IRB epifluorescence microscope at 5x, 10x, 20x 
and 40x magnifications, using MicroManager software. Where specified, images were 
acquired on a Nikon A1 TIRF confocal microscope at 40x magnification. 
  
2.7.6 Image analysis 
Image analysis and quantification was performed using FIJI. Similar to that described in 
2.2.8, thresholding was again applied to quantify in vivo images. This technique is 
specifically used in Chapter 5. A predetermined threshold was first applied to the chosen 
image to select either the motor neurons of the ventral horn (5.3.2), or the whole of the 
tissue section (5.3.3). The FIJI analyse particles function was then used to generate an 
outline and calculate the area contained within the marked outline (tissue section, 5.3.3) 
or outlines (motor neurons, 5.3.2). Another threshold was then applied to highlight the 
area containing the other relevant immunofluorescent stain. Again, the analyse particles 
function was executed to create, outline and measure the area of the selected 
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immunofluorescence. This generated a summary excel sheet, detailing the total area 
measured within the outlines, which was then exported to Microsoft excel. The 
immunofluorescence was subsequently expressed as a percentage of the total area, 
either of the tissue section or of the motor neurons. A working example is shown in 
Figure. 2.4. 
 
2.8 Western Blot 
2.8.1 Protein extraction from whole Dorsal Root ganglia 
Dorsal root ganglia from L3-L6 were collected as described in 2.2.2. In this instance, 
however, they were collected into ice cold PBS in individually labelled 1.5 ml Eppendorf 
tubes. Once the dissection was complete, the eppendorf tubes containing the individual 
DRGs were centrifuged at 13200 RPM for 1 minute and the excess PBS was removed. 
Each DRG was then individually transferred to a 0.1ml homogeniser and 40 μl of DRG 
lysis buffer was added. The DRG was homogenised for several minutes whilst being 
maintained on ice. Once sufficiently homogenised, the lysate was transferred back into 
an eppendorf tube which was then placed on a rotator for 1 hr and vortexed every 15 
mins, whilst kept at 4 oC. The eppendorf tubes containing the lysate were then 
centrifuged at 13200 RPM for 1 minute. The supernatants were then collected into fresh 
eppendorfs before being placed in a heat block, set at 90 oC, for 3 minutes. The 
supernatant was then either loaded immediately onto a gel or stored in -20 oC until 
required. 
 
2.8.2 Protein extraction from cultured neurons  
1x SDS sample buffer was prepared by diluting 4x SDS buffer in deionised water and 
then adding 1 mM MgCl₂ and 0.1 % benzonase nuclease (Sigma). All media was 
aspirated from the wells of the 24-well plate. 60 μl of 1x sample buffer was added per 
well and the plate was then shaken for 10 minutes at 650 rpm, at room temperature, to 
lyse cells. The lysates were then collected into 1.5 ml eppendorf tubes and boiled for 3 
minutes (>90 oC) before being centrifuged at 13200 RPM for 1 minute. Lysates were 
then either immediately loaded into a gel for western blot or stored at -20 oC for later use. 
 
2.8.3 Western Blot 
NuPAGE 12 % Bis-Tris pre-cast gels (Life Technologies) were loaded with a 5 μl Dual 
Colour protein ladder (Biorad) in the first lane and 13 μl of sample in the subsequent 
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Figure 2.4 Thresholding to 
quantify in vivo images. (A) An 
epifluorescent image of cleaved 
SNAP25 (green) in the lumbar 
spinal cord, following intraplantar 
injection of 2xTetBot (Chapter 5). 
(B) A low threshold was applied 
to the epifluorescent image to 
select the whole of the tissue 
section (left). The FIJI analyse 
particles function was then used 
to generate an outline and 
calculate the area contained 
within (right). (C) A higher 
threshold was then applied to 
highlight only the area containing 
the cleaved SNAP25 stain (left). 
Again, the analyse particles 
function was performed to 
create, outline and measure the 
area of the cleaved SNAP25 
stain (right). (D) The 
measurements were transferred 
to Microsoft excel to express the 
cleaved SNAP25 stain as a 







lanes. Gels were run at 180 V constant and 300 W for 1 hour 50 min in an XCell SureLock 
system (Life Technologies) filled with NuPAGE MES SDS running buffer. Approximately 
5 minutes before completion, an immunoblot PVDF membrane (BioRad) was activated 
by soaking it in methanol for 10-20 seconds. The membrane was then soaked in transfer 
buffer, along with two pieces of Whatmann paper. Once ran, the gel was then loaded 
into a transfer cassette and placed into a transfer tank (BioRad), filled with transfer buffer. 
The transfer cassette was ordered such that it contained: a foam sponge, whatmann 
paper, gel, a methanol-activated Immuno-Blot PVDF membrane, a second whatmann 
paper and a foam sponge. A freezer block was placed in the transfer tank and the transfer 
was run for 1 hour at constant 250 mA, 300 V and 300 W.  
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Once the transfer was complete, the membrane was gently washed with deionised water 
before incubation with 12 ml western blot blocking solution for 30 minutes at room 
temperature. The primary antibodies were then added directly to the blocking solution 
for overnight incubation at 4 oC. For all incubation and wash steps, the membrane was 
placed on a rocker. The following day, the membrane was rinsed and then received three 
5 minutes washes in PBS with 0.1 % Tween-20. Next, the membrane was incubated with 
the respective secondary antibodies, again diluted in western blot blocking solution, for 
30 minutes at room temperature. The membrane was then rinsed and underwent a 
further three 5 minutes washes in PBS with 0.1 % Tween-20. 0.4 ml of chemiluminescent 
solution (SuperSignal West Dura extended duration substrate, Thermo Scientific) was 
then added per membrane. The subsequent luminescence was visualised by exposing 
X-ray film (Amersham) to the membrane and then developing the X-ray film using an 

























BiTox/A has been shown to be analgesic in neuropathic pain conditions, however, it is 
not yet clear how BiTox/A is producing these therapeutic effects. It has been suggested 
that BiTox/A binds to, and is enzymatically active in, A-nociceptors (Mangione et al., 
2016). This theory is largely based on the observation that native BoNT/A, when added 
to dorsal root ganglion (DRG) cultures, inhibits calcium-dependent release of substance 
P in response to both capsaicin and potassium stimulation (Purkiss et al., 2000; Welch 
et al., 2000). It is namely the C-fibre and the Type I Aδ-fibre mechano-heat sensitive 
nociceptors that are responsive to capsaicin stimulation (Magerl et al., 2001). For this 
reason, it was assumed that one of these fibres types must be targeted by BiTox/A.  
Data generated by Mangione et al. (2016) then demonstrated that administration of 
BiTox/A specifically attenuated secondary hyperalgesia in pain models whilst primary 
hyperalgesia remained unaffected. This again indicates the involvement of Aδ- 
nociceptors, as well as possibly, Aβ- sensory neurons. Secondary hyperalgesia arises 
from increased input from the low threshold mechanoreceptors, the Aβ-fibre neurons, 
and the Aδ-nociceptors, to the pain signalling pathways, such that they begin to drive, 
and augment, the activity of these pain pathways (Ziegler et al., 1999). This occurs at 
the level of the central spinal cord and is believed to result from heterosynaptic 
facilitation, as a consequence of central sensitisation (Treede et al., 1992; Ziegler et al., 
1999; Woolf, 2011). From the collective evidence, it was thus suggested that the A-
nociceptors must be implicated in the analgesic effects of BiTox/A (Mangione et al., 
2016).  
Regardless of which sensory neuron subtypes are involved, it still remains unclear 
whether these analgesic effects are peripherally or centrally mediated. A central effect 
was suggested due to the perceived delay noted in the therapeutic effect of BiTox/A 
(Mangione et al., 2016). Western blot analysis of tissue taken from BiTox/A-injected 
animals, nevertheless, failed to detect cleaved SNAP25 at the central level of dorsal horn 
in the spinal cord, or in the dorsal root ganglia, implying a peripherally-mediated effect 
(Mangione et al., 2016). Skin tissue from the plantar surface of the injected hindpaw was 
not, however, included in the western blot analysis. It is therefore unknown whether 
cleaved SNAP25 would have been detected in the periphery either. As a result, this data 
does not completely discredit a central effect.  
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Consequently, here, the binding profile of BiTox/A will be investigated in vivo, using the 
in-house anti-cleaved SNAP25 antibody as a marker of BiTox/A’s enzymatic activity, and 
as an indirect reporter to determine the location of BiTox/A. This method will be used to 
confirm whether BiTox/A is active in the A-nociceptors in vivo, and potentially, will help 
to elucidate the mechanism by which BiTox/A-induced analgesia is produced. 
Specifically, whether this is by blocking neurotransmission in the peripheral afferents, or 
by preventing the development of central sensitisation at the level of the spinal cord.  
 
3.2 Results 
3.2.1 Cleaved SNAP25 is visualised in the sensory neurons of the glabrous skin 
following intraplantar injection of BiTox/A 
Immunohistochemical processing of glabrous skin sections, isolated from the plantar 
surface of the BiTox/A-injected hindpaw, revealed SNAP25 cleavage within the sensory 
neurons (Fig. 3.1A). Briefly, the sensory neurons were identified using pan-neuronal 
marker, βIII-Tubulin, which labels all nerve fibres, including both sensory and motor 
fibres. The location of the nerve terminals can, however, be used to distinguish the 
sensory nerve fibres from the motor nerve fibres. Sensory nerve fibres terminate more 
superficially within the dermis. Specifically, sensory nerve terminals are concentrated 
proximal to the epidermis. Motor neurons instead project to muscle fibres which are 
located much deeper in the skin, beneath the dermis.  
Cleaved SNAP25 was not visualised in the sensory neurons of the contralateral hindpaw 
or in ipsilateral paw of vehicle-injected animals. Neither was cleaved SNAP25 observed 
in the paw skin tissue of naïve animals.  
Further immunostaining indicated that cleaved SNAP25 colocalises with neurofilament 
200 (NF200) -positive nerve fibres, a marker of myelinated neurons (Fig. 3.1B, Top 
panel), as well as IB4 (Fig. 3.1B, Middle panel) which labels non-peptidergic neurons 
(Stucky and Lewin, 1999). Cleaved SNAP25 was visualised within a subset of CGRP 
positive neurons (Fig. 3.1B, Bottom panel). Subjective observations, however, suggest 
that cleaved SNAP25 colocalised most readily with NF200. Importantly, the labelling for 
cleaved SNAP25 was shown to colocalise with the staining produced by the anti-
SNAP25 antibody, which is immunoreactive to both whole and cleaved SNAP25, in 








Figure 3.1 Cleaved SNAP25 is detected in the sensory nerve terminals of the glabrous skin 
after intraplantar injection of BiTox/A. 4-5 week old male Sprague-Dawley rats received 
intraplantar injection of either 200 ng/ 30 µl BiTox/A (N=3) or 30 µl vehicle (N=2). 7 days post-
injection rats were perfused and glabrous skin tissue was taken from both hindpaws. (A) 
Epifluorescent images of 30 µm glabrous skin sections, isolated from the ipsilateral hindpaw, 
revealed cleaved SNAP25 (red) in the sensory neurons, marked using βIII-Tubulin (green), within 
the dermis (N=3). Cleaved SNAP25 was not detected in the contralateral hindpaw of BiTox/A-
injected rats (N=3), in the ipsilateral hindpaw of vehicle-injected rats (N=2) or in naïve rats (N=2). 
Scale bar = 100 µm (B) Cleaved SNAP25 (red) colocalised with both NF200 (top panel, green, 
N=2) and IB4 labelled neurons (middle panel, green, N=2) and was also observed in a subset of 
CGRP-positive neurons (bottom panel, green, N=2) in the BiTox/A-injected hindpaw. Scale bar = 
100 µm (C) Cleaved SNAP25 staining (red) also colocalised with staining produced by a SNAP25 
antibody, reactive to both full length and cleaved SNAP25 (green). Scale bar = 50 µm. Positive 
cleaved SNAP25 staining is indicated by the white arrowheads. The large, intense area of green 
and red fluorescence visible at the superior edge of the images is due to autofluoroscence 




3.2.2 Cleaved SNAP25 is visualised at the neuromuscular junctions of the glabrous 
skin following intraplantar injection of BiTox/A 
In agreement with previous studies, no motor paralysis was observed following 
intraplantar injection of 200 ng BiTox/A (Ferrari et al., 2011; Mangione et al., 2016). Rats 
continued to span the digits of their hindpaws normally when elevated and continued to 
be able to successfully grasp and remain suspended from an inverted wire mesh. 
Despite the perceived lack of motor paralysis, cleaved SNAP25 staining was detected at 
the neuromuscular junction (NMJ), labelled using α-Bungarotoxin-AlexaFluor488 (αBTX-
488), and moreover, could also be seen in the nerve fibres innervating the NMJ (Fig. 
3.2A, Top panel). Unexpectedly, SNAP25 cleavage was similarly visualised at the NMJ 
in skin isolated from the contralateral hindpaw (Fig. 3.2A, Second panel). Cleaved 
SNAP25 was not, however, present at the neuromuscular junction of vehicle-injected 
rats or naïve rats (Fig. 3.2A, Third and Bottom panel). 
Again, cleaved SNAP25 was shown to colocalise with whole SNAP25 labelling following 
BiTox/A injection, confirming that the cleaved SNAP25 antibody is labelling neurons 





Figure 3.2 Cleaved SNAP25 is detected at the neuromuscular junction of the hindpaw after 
intraplantar injection of BiTox/A. (A) Cleaved SNAP25 immunolabelling (red) was detected at 
the neuromuscular junction, marked using α-bungarotoxin-488 (green), in the ipsilateral (N=3) 
and contralateral hindpaw (N=3) in 200 ng/ 30 µl BiTox/A-injected animals. Cleaved SNAP25 was 
not detected in the ipsilateral paw of vehicle-injected rats (N=2) or naïve animals (N=2). Scale bar 
= 50 µm (B) Immunolabelled cleaved SNAP25 (red) colocalised with SNAP25 staining (green), 
immunoreactive to both full length and cleaved SNAP25, at the neuromuscular junction. Scale 
bar = 50 µm. 
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3.2.3 Cleaved SNAP25 is detected in other innervated structures contained within 
the skin 
Cleaved SNAP25 was also found localised to other structures within the skin. Namely, 
cleaved SNAP25 was detected at the sweat glands (Fig. 3.3, Top panel) and blood 
vessels (Fig. 3.3, Bottom panel). Both of which receive neuronal innervation from the 
sympathetic nervous system. 
 
3.2.4 SNAP25 cleavage is not detected in the lumbar dorsal root ganglia following 
intraplantar injection of BiTox/A  
Although SNAP25 cleavage was detected in the peripheral sensory nerve terminals, 
cleaved SNAP25 could not be detected at the level of the dorsal root ganglia (DRGs). 
Multiple methods were used to confirm this. Firstly, DRG cultures were produced from 
ipsilateral and contralateral DRG, taken from the lumbar levels L3-L5, of rats which, 5 
days previously, had received intraplantar injection of 300 ng BiTox/A. Staining of these 
cultures did not reveal positive labelling for cleaved SNAP25 in any of the DRG from the 
investigated lumbar levels, ipsilateral or contralateral to the injected paw (Fig. 3.4A). To 
confirm that this was not a result of cells potentially being lost during the culturing 
protocol,
  
Figure 3.3 Cleaved SNAP25 is detected at the sweat glands and blood vessels of the 
glabrous skin after intraplantar injection of BiTox/A. Cleaved SNAP25 immunolabelling (red) 
is found colocalised with SNAP25 staining (green), labelling both whole and cleaved SNAP25, at 
the sweat glands and the blood vessels located in the glabrous skin of the 200 ng/ 30 µl BiTox/A-






Figure 3.4 Cleaved SNAP25 is absent in the dorsal root ganglia following intraplantar 
injection of BiTox/A. (A) A 6 week old female Sprague-Dawley rat (N=1) received intraplantar 
injection of 300 ng/ 30 µl BiTox/A and was culled 5 days later. Dissociated dorsal root ganglia 
cultures were prepared from the ipsilateral and contralateral L3-L6 DRGs. Cleaved SNAP25 
immunofluorescence (red) was not detected in any sensory neurons, marked by βIII-Tubulin 
(green), in DRG cultures from any level, either ipsilateral or contralateral to the injected paw. 
Scale bar = 50 µm. (B) Cleaved SNAP25 (red) was not detected in 30 µm DRG sections, prepared 
from the ipsilateral L4 and L5 DRG, taken from a 4 week old male rat (N=1) which had received 
intraplantar injection of 100 ng/ 20 µl BiTox/A 8 days previously. NeuN marks the sensory neuron 
soma (green). Scale bar = 50 µm. (C) Western blot analysis was performed on lysates prepared 
from ipsilateral and contralateral DRGs (L3-L6) dissected from a 6 week old female Sprague-
Dawley rat (N=1) which had received intraplantar injection of 300 ng/ 30 µl BiTox/A 5 days earlier. 
Western blot, probed with an antibody immunoreactive to whole and cleaved SNAP25, displayed 
bands for whole SNAP25 for each DRG. No bands for cleaved SNAP25 were detected. Syntaxin 
was included as a loading control. 
 
protocol, the DRG of 100 ng BiTox/A-injected rats were removed and cryosectioned. 
Immunolabelled DRG sections were also negative for cleaved SNAP25 (Fig. 3.4B). 
Finally, lysates were prepared from individual DRGs, again taken from the lumbar levels 
L3-L5, both ipsilateral and contralateral to the 300 ng BiTox/A-injected hindpaw. Western 
blot, likewise, failed to recognise any cleaved SNAP25 in DRG isolated from the lumbar 
region (Fig. 3.4C). 
 
3.2.5 Cleaved SNAP25 is observed in the ventral horn of the lumbar spinal cord 
following intraplantar injection of BiTox/A. 
Again, despite the lack of motor paralysis observed, cleaved SNAP25 was detected 
within the ventral horn of the lumbar spinal cord of rats receiving intraplantar injection of 
BiTox/A. Specifically, cleaved SNAP25 was identified between levels L3-L5 of the spinal 
cord, as well as at the sacral region, S1 (Fig. 3.5A) with the strongest labelling visualised 
at L5. This staining was absent at L5 in vehicle-injected and naïve rats (Fig. 3.5B).  
Labelling of the spinal cord sections with SNAP25 showed that although SNAP25 is 
expressed globally across the spinal cord, both in the dorsal and ventral horn, cleaved 
SNAP25 is only detected in a proportion of these nerve fibres and these fibres centre 
around the ipsilateral motor neurons of Lamina IX (Fig. 3.6A). Specifically, cleaved 
SNAP25 is not detected within the motor neuron soma themselves and is not present at 






Figure 3.5 Cleaved SNAP25 is detected in the lumbar spinal cord after intraplantar injection 
of BiTox/A 4-5 weeks old male Sprague-Dawley rats (N=3) received intraplantar injection of 200 
ng/ 30 µl BiTox/A. (A) Representative images were taken of cleaved SNAP25 staining (green) at 
L3-6 and S1 of the spinal cord. NeuN was used to label the neuronal soma (red). Cleaved 
SNAP25 staining was most intense at L5. (B) Cleaved SNAP25 staining is not observed in the 
lumbar spinal cord of vehicle-injected or naïve rats. Scale bar = 0.5 mm. 
 
interneurons, which synapse on to the motor neurons (Fig. 3.6B). This is clearly 
demonstrated by the absence of any overlap between the cleaved SNAP25 and NeuN 
stains when images are taken at different slices throughout a single spinal cord section 
(Fig. 3.6C). 
 
3.2.6 Small amounts of cleaved SNAP25 are observed in the dorsal horn following 
intraplantar injection of BiTox/A 
With regards to the dorsal horn, cleaved SNAP25 was sparsely detected in the dorsal 
horn in comparison to large area of SNAP25 cleavage visualised in the ventral horn (Fig. 
3.6B). Specifically, single neurites containing cleaved SNAP25 were detected in the 
ipsilateral dorsal horn (Fig. 3.7, Top panel) which were largely absent in the contralateral 
dorsal horn (Fig. 3.7, Bottom panel). 
 
3.3. Discussion 
Here, the experimental conditions of Mangione et al. (2016) were replicated by injecting 
200ng BiTox/A intraplantar into the hindpaw of Sprague-Dawley rats, with the intent to 
elucidate the mechanisms by which BiTox/A elicits its analgesic effect. 
Immunohistochemical staining revealed SNAP25 cleavage, considered to be indicative 
of BiTox/A’s enzymatic activity, concentrated in the sensory and motor neurons of the 
glabrous skin of the injected hindpaw and in the ipsilateral ventral horn of the lumbar 
spinal cord. 
 
3.3.1 BiTox/A cleaves SNAP25 in myelinated sensory neurons in vivo 
Specifically, cleaved SNAP25 was visualised in both the NF200-positive neurons and 
the IB4-positive neurons, contained within the glabrous skin. This labelling suggests that 
BiTox/A internalises into myelinated, non-peptidergic neurons. Cleaved SNAP25 was 






Figure 3.6 Cleaved SNAP25 is found concentrated around the motor neuron soma in 
lamina IX of the lumbar spinal cord. (A) Spinal cord sections produced from a 4.5 weeks old 
male Sprague-Dawley rat (N=1) injected intraplantar with 200 ng/ 30 µl BiTox/A 7 days previously, 
displayed cleaved SNAP25 (green) colocalised with SNAP25 staining (red), immunoreactive to 
full length and cleaved SNAP25. Scale bar = 0.5 mm. (B) Higher magnification image of the 
ipsilateral L5 spinal cord, isolated from 200 ng/ 30 µl BiTox/A injected rats (N=3), acquired using 
a Nikon A1 TIRF confocal microscope. Cleaved SNAP25 (green) is observed surrounding the 
lateral lamina IX (dashed line) motor neuron pool (NeuN, red). Scale bar = 50 µm. (C) Stacked 
images were acquired using the Nikon A1 TIRF confocal microscope throughout the depth of a 
L5 lumbar spinal cord section and illustrate that cleaved SNAP25 (red) is excluded from the motor 
neuron soma (red). Scale bar = 20 µm. 
 
neuropeptide, CGRP, indicates that these neurons are peptidergic. This is in keeping 
with other in vitro studies that have reported reduced CGRP release from neuronal 
cultures which have been incubated with BiTox/A (Durham et al., 2004) . Similarly, in 
vivo studies have demonstrated decreased CGRP release from the sensory afferents of 
the bladder following intravesical delivery of BoNT/A (Chuang et al., 2004).  
Subjective observation of the skin sections suggested that there was a higher 
colocalisation of cleaved SNAP25 staining with NF200 labelling than CGRP labelling in 
sensory nerve terminals. These observations are subjective and purely speculative. The 
immunofluorescence in sensory neurons was unable to be quantified as it was not clear 
following immunostaining, whereabout in the plantar surface the skin section had been 
isolated from. Additionally, cleaved SNAP25 was not consistently detected within every 
skin section, therefore, a method could not be standardised to allow for a fair comparison 
to be made. Despite this, within a single slice, cleaved SNAP25 would be routinely 
visualised within every NF200 positively labelled neuron present. In contrast, cleaved 
SNAP25 would only be detected within a subset of CGRP-positive nerve fibres, even 
when investigating one individual skin section.  
Regardless, the detection of cleaved SNAP25 at the peripheral injection site suggests 
that the analgesic effect of BiTox/A should at least partially be due to a peripheral 
mechanism. The Aδ- and Aβ- neurons, labelled by NF200, are more strongly implicated 
in central sensitisation (Latremoliere and Woolf, 2009). It is thus possible that the 
cleavage of SNAP25 in these neurons could be having an indirect effect on central 
sensitisation by removing the peripheral drive which leads to increased excitability at the 
central synapse, thus explaining the effectiveness of BiTox/A against secondary 







Figure 3.7 Cleaved SNAP25 is detected in single, sparse nerve fibres in the dorsal horn of 
the lumbar spinal cord. Higher magnification images of the dorsal horn of spinal cord sections 
prepared from 4-5 week old Sprague-Dawley rats (N=3), 7 day after intraplantar injection of 200 
ng/ 30 µl BiTox/A, show single nerve fibres displaying immunolabelling for cleaved SNAP25 
(green) in the ipsilateral dorsal horn (top panel). Neuronal soma are labelled by NeuN (red). 
Cleaved SNAP25 is not readily detected in the contralateral dorsal horn (bottom panel). A single, 
small cleaved SNAP25- positive nerve fibre can be seen around lamina VI, at the base of the 
dorsal horn. Scale bar = 100 µm. 
 
Cleaved SNAP25 detected in a subset of CGRP-expressing neurons could likely explain 
the reduced plasma extravasation and inflammatory oedema, measures of local 
inflammation, observed in inflammatory models after intraplantar injection of BiTox/A 
(Mangione et al., 2016). CGRP is released from the peripheral nerve terminals of sensory 
afferents and contributes to neurogenic inflammation. It is hence logical that blocking this 
release would reduce local inflammation (Kilo et al., 1997). Surprisingly, however, C-fibre 
mediated thermal hyperalgesia at the site of inflammation remains unaffected by 
intraplantar injection of BiTox/A (Weng et al., 2012; Mangione et al., 2016). This would 
suggest that the reduction in CGRP release is primarily mediated via actions at the Aδ- 
nociceptors, which also display expression of CGRP, although less so than the C-
nociceptors, as C-fibre signalling does not appear to be affected (McCarthy and Lawson, 
1990). This could provide explanation for why, despite the reduction in local inflammation 
by BiTox/A observed, that C-fibre mediated thermal hyperalgesia is still developed. 
 
3.3.2 The possible significance of SNAP25 cleavage detected at autonomic 
structures 
Notably, SNAP25 cleavage was also detected at the blood vessels and sweat glands, 
located in the glabrous skin, following intraplantar injection of BiTox/A. Cleaved SNAP25 
is normally reported at these structures following administration of native BoNT/A 
(Rhéaume et al., 2015) and represents the internalisation of BoNT/A into cholinergic 
autonomic neurons (McCorry, 2007). Accordingly, BoNT/A is used to treat conditions 
such as axillary hyperhidrosis, characterised by excessive sweating (Heckmann et al., 
2001; Mirkovic et al., 2018).  
The SNAP25 cleavage noted in the autonomic nervous system could potentially 
represent another, yet unexplored, possible therapeutic mechanism for the analgesic 
effect of BiTox/A. Sympathetic blockade and sympathectomy have been used to treat 
chronic pain conditions, such as complex regional pain syndrome (Straube et al., 2013; 
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O’Connell et al., 2016) and post-herpetic neuralgia (Kumar et al., 2004). Xie et al. (2016) 
demonstrated that performing a microsympathectomy reduced local inflammation and 
subsequent pain behaviour in a model of lower back pain in Sprague-Dawley rats. During 
this procedure, the ipsilateral gray rami, containing the postganglionic sympathetic fibres 
that project to the L4 and L5 sensory nerve branches, were severed. BiTox/A could be 
eliciting a similar effect by blocking neurotransmission in the sympathetic neurons, 
specifically those which innervate the hindpaw, thus limiting the inflammation which 
occurs in, and augments, pain conditions. 
Native botulinum neurotoxin has already been used to successfully prolong the analgesic 
effect of a sympathetic nerve block (Choi et al., 2015). Importantly, however, this finding 
was based on a case study including only two patients. Furthermore, although 
sympathetic blockade has been routinely used to treat chronic pain conditions, its 
efficacy remains questionable (Straube et al., 2013; O’Connell et al., 2016). Lack of 
adequate controls and the poor quality of data consequently generated by these trials, 
means that conclusions about the efficacy of sympathetic blocks cannot be made. 
Moreover, Xie et al. (2016) noted the beneficial effect of microsympathectomy 
specifically with reference to a condition with a large inflammatory component. The 
analgesic effect of BiTox/A was most prominent in neuropathic conditions which do not 
have a strong inflammatory component (Mangione et al., 2016). Overall, it is therefore 
unlikely that an action at autonomic neurons is the mechanism by which BiTox/A is 
eliciting its analgesic effect.  
 
3.3.3. The absence of cleaved SNAP25 in the dorsal root ganglia 
Despite the SNAP25 cleavage detected at the peripheral nerve terminals, cleaved 
SNAP25 was not detected in dorsal root ganglia where the somas of the pseudopolar 
sensory neurons are located. Although all three methods used to detect SNAP25 
cleavage employed only an N of one, each method repeatedly confirmed the absence of 
cleaved SNAP25 within the dorsal root ganglia, thus increasing the overall validity of this 
observation. This finding is not entirely surprising given that SNAP25 is a synaptic 
protein, involved in the release of neurotransmitter, and is thus more localised to the 
axons and axonal terminals, rather than the neuronal soma (Oyler et al., 1989; Tao-
Cheng et al., 2000). Consequently, high levels of SNAP25 would not be expected in the 
dorsal root ganglia which could explain the absence of SNAP25 cleavage. It would thus 
be recommended to investigate the distribution of the SNAP25 in the dorsal root ganglia, 
by immunolabelling with the SNAP25 antibody, to determine whether this is the case.  
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Interestingly, Matak et al. (2011) investigated the analgesic effect of BoNT/A, following 
intraganglionic injection, after observing that peripheral injection of BoNT/A to the 
whisker pad of rats reduced formalin-induced orofacial pain and produced cleaved 
SNAP25 in the dorsal horn of the ipsilateral trigeminal nucleus caudalis. While they 
similarly observed a reduction in formalin-induced orofacial pain behaviours following 
intraganglionic injection, this effect was only observed when BoNT/A was injected two 
days prior to formalin challenge. BoNT/A injected 24 hours before the formalin test, or 
co-administered with colchicine, which blocks axonal transport, failed to elicit an 
antinociceptive effect. This consequently implies that the dorsal root ganglia are not the 
site of action for BoNT/A. Instead, the delay necessary to observe the analgesic effect 
indicates that BoNT/A still requires axonal transport to another area to produce 
analgesia, thus supporting the absence of cleaved SNAP25 in the DRG reported here.  
 
3.3.4 BiTox/A does produce SNAP25 cleavage at the central spinal cord 
In contrast, whilst investigating whether BiTox/A might have a centrally-mediated 
analgesic effect, cleaved SNAP25 was found readily detected at the level of the spinal 
cord, specifically concentrated around lamina IX of the ipsilateral ventral horn, as 
reported previously following intraplantar injection of native BoNT/A (Matak et al., 2012, 
2017; Drinovac et al., 2016). Comparable to other studies that investigated native 
BoNT/A, sparse individual nerve fibres, displaying cleaved SNAP25 immunolabelling, 
were identified within the ipsilateral dorsal horn after intraplantar injection of BiTox/A 
(Matak et al., 2011, 2012, 2017; Drinovac et al., 2016). This strongly suggests that axonal 
transport of BiTox/A to the central nervous system does occur. Notably, cleaved SNAP25 
was not detected within the motor neuron cell bodies, as delineated by NeuN, but instead 
appeared to be present in a network of nerve fibres, surrounding the motor neurons, 
hypothesised to be interneurons.  
Cai et al. (2017) dispute this observation, claiming that cleaved SNAP25 is instead 
confined within the dendritic arborisations of the motor neuron pool. They were able to 
demonstrate this by injecting Cholera toxin B subunit Alexa Fluor 488 conjugate (CTB-
488), a neuronal tracer, used to label the motor neurons of the ventral horn, and showed 
that this colocalised with the cleaved SNAP25 immunostain. There were, however, many 
fibres displaying cleaved SNAP25 that did not colocalise with CTB-488. Similar to the 
findings reported here, cleaved SNAP25 was visualised adjacent to the plasma 
membrane, outside of the external edge of the NeuN stain here, and the CTB-488 stain 
in their study. This cleaved SNAP25 staining appeared to look like end-feet, projecting 
to the motor neurons, which they did not acknowledge or account for. As stated earlier, 
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SNAP25 is a synaptic protein and therefore it would be expected that SNAP25 would be 
concentrated at the axonal terminals, and not at the plasma membrane of the cell soma 
(Tao-Cheng et al., 2000) as Cai et al. (2017) suggest. 
Cleaved SNAP25 being contained solely within the motor neuron dendritic arborisations 
seems unlikely given the expanse and density of the cleaved SNAP25 stain. Specifically, 
at L5, the cleaved SNAP25 staining can be seen extending into the white matter of the 
spinal cord, as well as in single fibres projecting up to the dorsal horn. This data instead 
suggests that BiTox/A might transcytose into second order neurons. Evidence for the 
transcytosis of BoNT/A has been already provided by two separate studies (Antonucci 
et al., 2008; Restani et al., 2011). For example, Restani et al. (2011) demonstrated this 
by intravitreal injection of BoNT/A to the eye of rats which resulted in detectable cleaved 
SNAP25 in the tectum. 3 days post-BoNT/A intraocular injection, the optic nerve was 
severed, thus preventing any further axonal transport of BoNT/A protease before BoNT/E 
was then injected directly into the tectum. BoNT/E also cleaves SNAP25, however, 
BoNT/E removes 26 amino acids from the c-terminal, whereas BoNT/A only cleaves a 9 
amino acid fragment. This enables the two cleavage products to be easily distinguished. 
After injection of BiTox/E, BiTox/A-cleaved SNAP25 was no longer detected in the 
tectum. BoNT/A-cleaved SNAP25 was, however, able to be detected again after the 
duration of action for BoNT/E had passed. The re-emergence of BoNT/A- cleaved 
SNAP25 indicated that the active protease had transcytosed into these second order 
neurons, rather than simply the BoNT/A cleavage product. Moreover, in both studies they 
were able to show that the cleavage of SNAP25 resulted from the axonal transport of 
BoNT/A, and not systemic spread, as SNAP25 cleavage was no longer detected 
following pre-injection of colchicine (Antonucci et al., 2008; Restani et al., 2011). Restani 
et al. (2011) also pre-emptively administered colchicine to the ipsilateral eye to show that 
detection of cleaved SNAP25 in the contralateral dorsal horn, likewise, relied upon 
axonal transport and discredited a systemic effect, thus contradicting Cai et al. (2017) 
who attributed the distal cleavage of SNAP25 to the systemic diffusion of BoNT/A. 
Provided the limited amount of SNAP25 cleavage detected in the dorsal horn compared 
to the much larger amount of cleavage visualised in the ventral horn, the SNAP25 
cleavage localised around the motor neurons could hold significance for the analgesic 
effect of BiTox/A. Although sensori-motor connectivity is described within the spinal cord, 
it is mainly concerned with the sensory input modulating reflexive responses elicited by 
the motor neurons (Cook and Woolf, 1985; Sivilotti and Woolf, 1994). Interestingly, 
however, repetitive transcranial magnetic stimulation (rTMS), targeted to the motor 
cortex, successfully produces analgesia in approximately 40% of refractory neuropathic 
pain patients (Lefaucheur et al., 2004, 2006, 2011, 2014; Lima and Fregni, 2008; 
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Nurmikko et al., 2016) whereas rTMS is ineffective against pain when targeted to the 
sensory cortex (Hirayama et al., 2006). It could thus be a possibility that modulation of 
the motor pathways, in the case of rTMS, the descending inhibitory motor pathways, 
could be beneficial in pain conditions.  
In contrast, a range of behavioural studies have demonstrated the involvement of a 
number of neurotransmitters, specifically associated with pain signalling, in BoNT/A-
induced analgesia including Substance P and its receptor, NK1 (Matak et al., 2017), 
GABA (Drinovac et al., 2014, 2016), and µ-opioids (Drinovac et al., 2013, 2016). Others 
have identified an anti-inflammatory component to the analgesic effect of BoNT/A, 
suggesting the involvement of Schwann cells (Marinelli et al., 2012), astrocytes (Marinelli 
et al., 2012; Vacca et al., 2012) and interleukins (Zychowska et al., 2016). Multiple 
studies have, however, contradicted this theory, reporting that there was no 
colocalisation of cleaved SNAP25 with GFAP, a marker of astrocytes, during 
immunostaining (Restani et al., 2011; Matak et al., 2012; Cai et al., 2017). Additionally, 
western blot analysis has further shown that BoNT/A has no effect on the expression of 
GFAP in the spinal cord or DRG (Zychowska et al., 2016).  
The involvement of Substance P was recognised after using two strains of knockout 
mice. In one strain the gene encoding Substance P had been removed, whilst the other 
strain lacked the NK1 receptor gene (Matak et al., 2017). The anti-nociceptive effect of 
intraplantar BoNT/A in both an inflammatory pain model and a neuropathic pain model 
could not be replicated in either strain, hence implying that Substance P must have a 
role in the BoNT/A-induced analgesia. This is consistent with in vitro findings that 
incubation of neuronal cultures with BoNT/A inhibits the stimulated release of Substance 
P (Purkiss et al., 2000; Welch et al., 2000).  
Conversely, GABA and µ-opioids were both implicated in the centrally-mediated 
therapeutic action of BoNT/A after intrathecal injection of GABA-A receptor antagonist, 
bicuculline, and µ-opioid receptor antagonist, naloxonazine, in rats, prevented the 
analgesic effect of BoNT/A against mechanical hypersensitivity in a mirror pain model 
(Drinovac et al., 2016). Furthermore, intraperitoneal injection of naloxonazine was also 
able to prevent the anti-nociceptive effect of BoNT/A in both a formalin inflammatory pain 
model and a sciatic nerve partial transection neuropathic pain model (Drinovac et al., 
2013). Both experiments also demonstrated decreased formalin-evoked c-Fos activation 
in the dorsal horn of the spinal cord following intraplantar injection of BoNT/A. This effect 
was eliminated by knockout of substance P related genes (Matak et al., 2017) and 
separately, by injection of opioid antagonist, naltrexone (Drinovac et al., 2013) and  
GABA antagonist, bicuculline (Drinovac et al., 2014). None of these studies, however, 
investigated or demonstrated the colocalisation of cleaved SNAP25 with any markers of 
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the proteins mentioned. From this perspective, it would be recommended to conduct 
further immunolabelling of the spinal cord, isolated from BiTox/A-injected rats, to 
investigate whether any of the aforementioned proteins are co-expressed in the nerve 
fibres displaying cleaved SNAP25. 
One study, however, argues that regardless, the amount of SNAP25 cleavage that 
occurs at the level of spinal cord is not sufficient to block neurotransmission at the central 
synapse (Lawrence et al., 2012). This was suggested after compartmentalised exposure 
of the neurites of cultured superior cervical ganglion neurons to native BoNT/A did not 
influence synaptic transmission between the cell bodies contained within the central 
compartment, despite that, at this time point, SNAP25 cleavage was readily detected in 
the cell soma. In contrast, global administration of BoNT/A to all culture chambers, 
consequently meaning that BoNT/A would gain direct access to the cell bodies, did 
significantly reduce the frequency of spontaneous excitatory postsynaptic currents, with 
currents completely abolished in four of the seven cells recorded (Lawrence et al., 2012). 
This suggests that although BoNT/A protease does reach the soma, it does not do so in 
sufficient amounts as to block neurotransmission. 
This theory does, however, help to explain the lack of motor paralysis observed following 
intraplantar injection of BiTox/A (Ferrari et al., 2011; Mangione et al., 2016) and native 
BoNT/A (Cui et al., 2004; Matak et al., 2012; Wu et al., 2016), despite the SNAP25 
cleavage noted in the ventral horn in both instances. Nevertheless, the study was 
conducted in vitro and, therefore, might not truly represent the actions of BoNT/A in vivo. 
For example, it has repeatedly been demonstrated that the anti-nociceptive effect of 
BoNT/A requires axonal transport after observing that injection of colchicine abolished 
BoNT/A-induced analgesia (Antonucci et al., 2008; Bach-Rojecky and Lacković, 2009; 
Matak et al., 2011, 2012; Restani et al., 2011; Wu et al., 2016). This provides strong 
evidence that BoNT/A does have a centrally mediated analgesic effect and further 
suggests that, in vivo, SNAP25 cleavage at the central level is adequate to block 
neurotransmission.  
 
3.3.5 Cleaved SNAP25 is detected at the neuromuscular junction after peripheral 
injection of BiTox/A 
With regards to the absence of any motor impairments following intraplantar injection of 
BiTox/A, it is important to acknowledge that cleaved SNAP25 was, however, detected at 
the neuromuscular junction, notably, of both the ipsilateral and contralateral hindpaw. 
This observation proved contrary to the theory proposed by Ferrari et al. (2011), that the 
increased molecular size of BiTox/A, compared to native BoNT/A, would negate its 
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access to the tight cleft of the NMJ. Instead, it appears that BiTox/A must still retain the 
ability to access the NMJ but may do so on a more restricted basis, provided the lack of 
paralysis observed. Specifically, the nerve terminals of the C- and Aδ nociceptors lack 
encapsulation and therefore could be more susceptible to penetration by BiTox/A, 
consequently creating a preference for binding of the sensory neurons above the motor 
neurons (Hall and Treinin, 2011). In future, however, more sensitive methods for the 
assessment of motor function should be used. For example, using the Digit Abduction 
Scale to systematically score digit spreading rather than a more subjective all or nothing 
approach (Broide et al., 2013), or by using CatWalk gait analysis to reveal any less 
obvious alterations in gait (Kappos et al., 2017).  
The detection of cleaved SNAP25 at the NMJ of contralateral paw also raises concerns 
over systemic diffusion. It seems highly unlikely, however, that the protease would have 
arrived at the NMJ, following systemic diffusion, as cleaved SNAP25 was not detected 
in the sensory neurons of the contralateral paw. As described earlier, cleaved SNAP25 
has previously been demonstrated in structures contralateral to the injection site. The 
appearance of cleaved SNAP25, contralateral to the injection site, was successfully 
prevented by pre-injection of colchicine, thus highlighting the role of axonal transport and 
transcytosis (Restani et al., 2011). Provided the importance of interconnectivity between 
the lumbar motor neuron pools for locomotion (Cazalets et al., 1995), it is feasible that 
BiTox/A could have transcytosed across these pathways to enter the contralateral motor 
neurons. This does, however, remain to be confirmed by injection of colchicine.  
 
3.3.6 Conclusion 
In conclusion, here, the first evidence for the cleavage of SNAP25 by BiTox/A in vivo has 
been successfully demonstrated. Although not definitively shown, after considering both 
the data presented here, and the evidence discussed with respect to native BoNT/A, it 
is most likely that BiTox/A is eliciting its therapeutic effect, via both a peripheral and a 
centrally-mediated mechanism. It is likely that by blocking neurotransmission in the 
peripheral sensory afferents, BiTox/A also indirectly prevents central sensitisation (Aoki, 
2005). Future experiments are, however, necessary to effectively demonstrate this 
hypothesis. Further immunolabelling of the spinal cord sections will be required to 
determine which subtypes of central neurons BiTox/A is catalytically active in. This 
labelling should primarily be based on the observations made during the behavioural 
studies by Matak et al. (2017) and Drinovac et al. (2013, 2014, 2016) and should include 
co-staining of cleaved SNAP25 with anti-GAD65 (a marker for GABAergic neurons), anti-
NK1 (a marker for Substance P receptors) and anti-MOR (a marker for µ-opioid 
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receptors) antibodies. It would also be beneficial to repeat the behavioural studies, 
detailed in Mangione et al. (2016), whilst including a pre-emptive injection of colchicine 
to confirm that the analgesic effect of BiTox/A is at least partly dependent upon a central 
mechanism. This will also verify that any central or contralateral cleaved SNAP25 
staining observed does result from axonal transport of the active protease, and not from 
systemic diffusion. During these behavioural studies, additional motor assessments 
should also be carried out to ensure that any subtler motor impairments have not gone 
undetected. After conducting the further experiments detailed, the true significance of 























Chapter 4. The substitution of the receptor binding domain of Botulinum 
Neurotoxin A with that of alternative botulinum serotypes targets the 
enzymatic activity of Botulinum Neurotoxin A to additional subpopulations 
of sensory neurons  
 
4.1 Introduction 
It was recently demonstrated that intraplantar injection of BiTox/A, investigated in the 
previous chapter, prevents the development of, and reverses, the mechanical 
hyperalgesia observed in a rat model of peripheral neuropathic pain (Mangione et al., 
2016). Unfortunately, however, the therapeutic application of BiTox/A in inflammatory 
pain conditions appears to be more limited. BiTox/A promoted a prolonged reduction in 
secondary hyperalgesia in an inflammatory pain model but was largely ineffective at 
reversing thermal hypersensitivity at the site of injury. Secondary hyperalgesia is 
hypothesised to result from the Aβ-fibres of low-threshold mechanoreceptors gaining 
access to the nociceptive signalling pathway, as a result of central sensitisation (Cervero 
et al., 2003; Latremoliere and Woolf, 2009). This suggests that the analgesic benefits of 
BiTox/A are largely due to its actions at the large Aβ-fibres rather than C-fibre nociceptors 
which would be activated direct at the site of injury. To effectively treat inflammatory pain 
conditions, it is thus necessary to retarget BiTox/A to a different subpopulation of sensory 
neurons, namely the nociceptors. 
One way by which to achieve this is by utilising the other serotypes of Botulinum 
Neurotoxin (BoNT), of which seven exist, BoNT/A-G. The different serotypes are known 
to bind to different combinations of polysiagangliosides and membrane proteins, due to 
variations in the amino acid sequence of the Hc domain (Tsukamoto et al., 2005; Montal, 
2010; Strotmeier et al., 2010). For example, BoNT/A binds to the ganglioside GT1b, and 
preferentially, the protein receptor, synaptic vesicle 2C (SV2C), although it does retain 
affinity for all three isoforms (SV2A, SV2B and SV2C) (Rummel et al., 2004; Dong et al., 
2006; Rossetto, 2017). BoNT/E meanwhile, also displays affinity for GT1b but only binds 
two of the synaptic vesicle isoforms, SV2A and SV2B (Dong et al., 2008; Montal, 2010; 
Rossetto, 2017). Conversely, BoNT/C binds to GD1b, in addition to GT1b, but does not 
require a protein receptor for internalisation (Tsukamoto et al., 2005; Rummel et al., 
2009). Similarly, there is no known protein receptor for BoNT/D (Rummel et al., 2009) 
and it further lacks the ganglioside-binding pocket present in the other serotypes. 
Instead, BoNT/D is believed to utilise the phospholipid, phosphatidylethanolamine 
(Tsukamoto et al., 2005).  
The differential ganglioside binding profiles of the BoNT serotypes suggests that they 
would display different patterns of neuronal binding, dependent on the expression of  
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Figure 4.1 SNARE-tagging and stapling enables the production of alternative BiTox 
chimeras. (A) Native BoNT/A consists of an enzymatic domain (light chain, Lc, blue), a 
translocation domain (Td, orange) and a receptor binding domain (Rbd, red). (B) For SNARE-
stapling, BoNT/A was separated into the LcTd/A (blue, orange) and the Rbd/A (red). LcTd/A was 
expressed fused with a SNAP25 tag (green), whilst Rbd/A was expressed fused to synaptobrevin 
(blue). The chimera, BiTox/A (right), was produced after addition of the syntaxin staple (yellow). 
The assembled SNARE-complex is visible central to the chimera. (C) To generate the alternate 
BiTox chimeras, the Rbd of other serotypes were separately expressed fused to synaptobrevin (-
brevin), as depicted in the schematic. Importantly, LcTd/A-SNAP25 and syntaxin were used 
consistently in the formation of each chimera. The substitution of Rbd/A-Brevin for Rbd/C-Brevin, 
Rbd/D-Brevin and Rbd/E-Brevin produces BiTox/C, BiTox/D and BiTox/E, respectively (Right). 
The clostridial chimera molecular model was created using the following structures, accessible in 
the Protein Data Bank archive (http://www.rcsb.org): 3BTA (BoNT/A), 1N7S (SNARE complex). 
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certain gangliosides and protein receptors by different subpopulations of sensory 
neurons (Ashton et al., 1990; Bajjalieh et al., 1994). The receptor binding domains of the 
botulinum serotypes could thus be utilised to selectively retarget the enzymatic activity 
of BoNT/A to specific subpopulations of sensory neurons, including those involved in 
inflammatory pain. 
Here, it will be investigated whether retargeting BoNT/A by recombining the cleavage 
promoting, enzymatic domain of BoNT/A, with the receptor binding domain (Rbd) of 
alternative botulinum serotypes, will alter the population of sensory neurons to which 




4.2.1 Stapling the Light Chain Translocation Domain of Botulinum Neurotoxin A to 
the Receptor Binding domain of alternative botulinums results in functional toxins 
which retain the ability to cleave SNAP25 in vitro 
The Light Chain-Translocation domain of Botulinum Neurotoxin A (LcTd/A), containing 
the enzymatic domain, was recombined with the receptor binding domain (Rbd) of 
BoNT/A, using our established stapling technology, to create the previously published 
BiTox/A (Fig. 4.1B) (Ferrari et al., 2011). LcTd/A was further conjugated to the Rbd of 
alternative botulinum neurotoxin serotypes C, D and E, to produce the chimeras: 
BiTox/C, BiTox/D and BiTox/E, respectively (Fig. 4.1C). LcTd/A contains the zinc-
endopeptidase activity of BoNT/A which mediates the cleavage of SNAP25. The 
functionality of the novel chimeras was first assessed to evaluate whether they retained 
the catalytic activity of LcTd/A after reengineering.  
Western blot revealed that after 65 hour incubation with 10 nM of each chimera, all four 
novel chimeras successfully produced SNAP25 cleavage in dissociated dorsal root 
ganglion cultures (Fig. 4.2A) confirming that they retained their efficacy. Incubation with 
10 nM LcTd/A-αSNAP25, containing only the enzymatic activity of BoNT/A, without any 
targeting domain, also resulted in detectable SNAP25 cleavage, however, the 
percentage of total SNAP25 cleaved was significantly lower than that observed after 
incubation with the engineered chimeras, with the exclusion of BiTox/E (One-way 
ANOVA, F(5, 18)=22.61; BiTox/A vs. LcTd/A-αSNAP25, P<0.05; BiTox/C vs. LcTd/A-
αSNAP25, P<0.01; BiTox/D vs. LcTd/A-αSNAP25, P<0.05; BiTox/E vs. LcTd/A-
αSNAP25, P=0.18, Fig. 4.2B). No cleavage was detected following the addition of 0.4% 
OG, the vehicle control that peptide staples are dissolved in to enable the formation of 




Figure 4.2 Clostridial chimeras containing LcTd/A retain the catalytic activity of BoNT/A in 
vitro. (A) Western blots of dorsal root ganglion cultures were probed with a whole SNAP25 
antibody following 65 hour incubation with 10 nM of each Chimera (N=4). Cleaved SNAP25 was 
detectable in all cultures incubated with active chimeras but was absent in untreated cultures and 
cultures incubated with 0.4% OG vehicle control. Syntaxin was included as a loading control. (B) 
The graph shows cleaved SNAP25 expressed as a percentage of total SNAP25, after 
quantification of the immunoblots. In the chimeras BiTox/A-/D, the conjugation of a Rbd to LcTd/A 
increased the percentage of SNAP25 cleaved compared to unconjugated LcTd/A-αSNAP25. All 
data is presented as mean ± S.E.M, * p<0.05, ** p<0.01, **** p<0.0001.  
 
Notably, Syntaxin 1 was chosen as a loading control. Syntaxin is an essential component 
of the SNARE complex and therefore is indicative of the number of SNARE complexes 
in the culture (Wilhelm et al., 2014). Syntaxin levels remained consistent between culture 
conditions, thus indicating that the separate cultures had a similar level of SNARE 
proteins available for cleavage.  
 
4.2.2 The biodistribution of cleaved SNAP25 in cultured dorsal root ganglion 
neurons following incubation with alternative BiTox constructs suggests that 
substitution of Rbd/A can target the enzymatic activity of BoNT/A to additional 
sensory neuron subpopulations. 
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After confirming that the novel chimeras remained potent, it was next assessed whether 
the attachment of an alternative receptor binding domain was able to retarget the 
catalytic activity of LcTd/A to different subpopulations of sensory neurons. After 65 hour 
incubation with 10 nM of each chimera, an inhouse anti-cleaved SNAP25 antibody, 
specific for cleaved SNAP25 and lacking immunoreactivity for whole SNAP25, was used 
to report the proteolytic activity of LcTd/A in healthy, viable sensory neurons, as identified 
using anti-βTubulin III antibody, a pan-neuronal marker, in combination with DAPI, a 
nuclear marker.  
Immunolabelling of dorsal root ganglion cultures indicated that the novel chimeras, 
BiTox/C, /D and /E, did not produce SNAP25 cleavage in a significantly distinct 
population of sensory neurons, based on soma size, compared to BiTox/A (One-way 
ANOVA, F (4,154) =2.265, P=0.065, Fig. 4.3A). BiTox/C did cleave SNAP25 in neurons 
with a slightly larger mean cell diameter (29.7 ± 1.5 µm) than BiTox/A (27.6 ± 1.3 µm), 
although the difference was not significant. Cleaved SNAP25 was, however, detected in 
a smaller percentage of neurons following incubation with BiTox/C, opposed to BiTox/A 
(Fig. 4.3B). Again, this difference was not significant (One-way ANOVA, F (6,24) = 3.589, 
P=0.772).  
In contrast, SNAP25 cleavage was detected in a slightly larger percentage of neurons 
following incubation with BiTox/D than after incubation with BiTox/A (Fig. 4.3B). The 
mean cell diameter of neurons displaying SNAP25 cleavage after incubation with 
BiTox/A and BiTox/D was very similar (27.6 ± 1.3 µm and 27.3 ± 1.2 µm respectively, 
Fig. 4.3A), however, the distribution of neurons displaying cleaved SNAP25 differed 
between the two. Neurons displaying positive SNAP25 cleavage post-incubation with 
BiTox/A, as well as with BiTox/C, were mainly congregated at the upper values of the 
histogram whereas the distribution of neurons displaying SNAP25 cleavage after 
incubation with BiTox/D appeared almost bimodal with one peak visible around 18 µm 
and a second around 26-28 µm (Fig. 4.4B). Conversely, the neurons positive for cleaved 
SNAP25 after incubation with BiTox/E were evenly distributed between 20 and 30 µm. 
In accordance with this observation, the average cell diameter of neurons showing 
SNAP25 cleavage after incubation with BiTox/E was 25.0 ± 2.0 µm suggesting that 
BiTox/E binds to a population of smaller sensory neurons than BiTox/A. Incubation with 
BiTox/E, however, resulted in an approximately 60% reduction in the number of neurons 
displaying SNAP25 cleavage compared to after incubation with BiTox/A. Even so, this 




Figure 4.3 Substitution of BoNT/A Rbd with the Rbd from alternative BoNT serotypes does 
not significantly alter the targeting of the enzymatic activity BoNT/A to other 
subpopulations of sensory neurons. (A) 10 nM of each chimera was added to 2 day old dorsal 
root ganglion cultures and incubated for a further 65 hours (BiTox/A - BiTox/E, LcTd/A-αSNAP25: 
N=5, n=3; Untreated, 0.4% OG: N=3, n=3). Neurons were identified using pan-neuronal marker, 
βTubulin III. Incubation with BiTox/A resulted in SNAP25 cleavage, as detected using anti-cleaved 
SNAP25 antibody, in neurons with a soma diameter of 27.6 ± 1.3 μm. BiTox/C (29.7 ± 1.5 μm) 
and BiTox/D (27.3 ± 1.2 μm) failed to result in SNAP25 cleavage in a significantly different 
population of neurons. There was a trend for BiTox/E (25.0 ± 2.0 μm) and LcTd/A-αSNAP25 (20.8 
± 1.9 μm) to produce SNAP25 cleavage in neurons with a smaller mean cell diameter. (B) The 
number of neurons displaying detectable SNAP25 cleavage was expressed as a percentage of 
the total number of neurons identified in each culture. The percentage of neurons displaying 
SNAP25 was not significantly affected by the substitution of Rbd/A for the Rbd of another 
botulinum serotype. All data is presented as mean ± S.E.M.  
 
Similarly, 10 nM LcTd/A-αSNAP25 produced SNAP25 cleavage in neurons with a 
smaller average cell diameter (20.8 ± 1.9 µm), and in a yet smaller percentage of neurons 
(3.3 ± 1.2 %) than BiTox/A. Although, again, neither difference was significant (One-way 
ANOVA for cell diameter, F (4,155) =2.265, P=0.1054, Fig. 4.3A; One-way ANOVA for % 
of neurons displaying SNAP25 cleavage, F (6,24) = 3.589, P=0.1297, Fig. 4.3B). No trend 
in the cell diameter of neurons displaying cleaved SNAP25 was observed after 
incubation with LcTd/A-αSNAP25. Instead, cells displaying positive cleaved-SNAP25 
staining appeared randomly throughout the frequency distribution histogram, thus 
supporting the hypothesis that a receptor binding domain is required for specific binding 
and internalisation into discreet neuronal subpopulations (Fig. 4.4B). 
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In agreement, a previous study showed that the LcTd portion of BoNT alone, is sufficient 
for entering neurons (Fischer et al., 2008). The LcTd is believed to exploit the constitutive 
endocytic pathway, to gain access to cells, rather than undergoing receptor-mediated 
endocytosis, normally associated with BoNTs. This mechanism is augmented by the 
presence of the attached -αSNAP25 peptide. This would most likely interact with the 
other components of the SNARE complex that might become exposed at the cell 
membrane, post-exocytosis, thus aiding nonspecific uptake into cells. The Rbd is instead 
only necessary to act as a chaperone, mediating neuronal specificity, and increasing the 
efficiency of neuronal uptake, hence explaining the lower percentage of neurons 
displaying SNAP25 cleavage. Being satisfied by this explanation, together with only 
being interested in determining a way to direct the LcTd/A of BiTox/A to specific, alternate 
populations of neurons, the binding profile of LcTd/A-αSNAP25 was not further 
investigated. Importantly, cleaved SNAP25 staining was not observed in cultures 
incubated with vehicle or in untreated cultures, thereby confirming that SNAP25 cleavage 
resulted from the addition of active protease to the cultures.  
In summary, although certain trends were noted, none of the observed differences were 
shown to be significant. This lack of significance could be due to the negatively skewed 
distribution of the cell soma size observed in DRG cultures. This skew can be clearly 
seen in the frequency distribution histograms (Fig. 4.4B). The data sets display a natural 
bias towards smaller diameter neurons. This is because the protocol used to prepare 
DRG cultures favours the yield of smaller neurons, opposed to larger diameter neurons, 
as the larger neurons are more prone to being ruptured and lost during the trituration 
steps. Therefore, even if SNAP25 cleavage is detected in a very small proportion of small 
diameter neurons, it could severely distort the mean cell diameter of neurons displaying 
cleaved SNAP25, mitigating any perceived difference between the alternative BiTox 
constructs. For this reason, it was important to investigate the two populations of 
neurons, the larger myelinated neurons and the small unmyelinated neurons, separately. 
The neuronal markers, Neurofilament 200 and Peripherin, were used to identify and 
distinguish the two populations of neurons, respectively (Goldstein et al., 1991; Fornaro 
et al., 2008).  
 
4.2.3 Cleaved SNAP25 is detected in a subpopulation of smaller myelinated 
sensory neurons after substitution of Rbd/A for the Rbd of alternative serotypes. 
Anti-Neurofilament 200 antibody recognises heavy weight (200 kDa) neurofilament and 
is used to identify myelinated fibres. It labels large Aβ sensory neurons as well as more 





































































































































































































































































































































































































































































































































































































































































































































































neurons. It does not, however, show immunoreactivity for unmyelinated C-fibres 
(Lawson et al., 1984; Lawson and Waddell, 1991).  
After using anti-NF200 antibody to isolate only the myelinated neurons, it was shown 
that substituting the Rbd/A of BiTox/A for that of other serotypes had a significant effect 
on the mean cell diameter of NF200-positive neurons, displaying cleaved SNAP25 (One-
way ANOVA, F (3,120) = 6.291, P=0.0005, Fig. 4.4A). SNAP25 cleavage was detected in a 
subpopulation of significantly smaller NF200-positive neurons after 65-hour incubation 
with BiTox/D (23.7 ± 1.2 µm) and BiTox/E (20.6 ± 1.3 µm), compared to BiTox/A (28.2 ± 
1.2 µm) (One-way ANOVA, Dunnett's multiple comparisons test, F (3,120) = 6.291; BiTox/A 
vs BiTox/D P=0.0204; BiTox/A vs BiTox/E P=0.0002, Fig. 4.4A). More notably, the two 
peaks first observed in the frequency distribution histogram of neurons, identified using 




Figure 4.5 Cleaved SNAP25 is detected in a subset of smaller myelinated (Aβ and Aδ) fibre 
sensory neurons after substitution of Rbd/A for the Rbd of alternative serotypes. 10 nM of 
each chimera was added to 2 day old dorsal root ganglion cultures and incubated for a further 65 
hours (BiTox/A, -/C, -/D: N=4, n=3; BiTox/E: N=3, n=3). (A) Quantification of cleaved SNAP25 in 
myelinated neurons, identified using anti-neurofilament 200 antibody (NF200), revealed that 
BiTox/A (28.2 ± 1.2 µm) produced SNAP25 cleavage in a subset of significantly larger myelinated 
neurons compared to BiTox/D (23.7 ± 1.2 µm) and BiTox/ E (20.6 ± 1.3 µm). (B) Expressing the 
number of NF200-positive neurons co-labelled for cleaved SNAP25 as a percentage of the total 
number of NF200-positive neurons per culture revealed no significant differences between 








Figure 4.6 Representative images of cleaved SNAP25 staining in myelinated dissociated 
sensory neurons. (A) An epifluorescent microscope was used to take representative images of 
dorsal root ganglion cultures (BiTox/A, -/C, -/D: N=4, n=3; BiTox/E: N=3, n=3) showing the 
colocalisation of cleaved SNAP25 (red) and Neurofilament 200 (green) after 65 hr incubation of 
2 day old cultures with BiTox/A-E. DAPI (blue) indicates the nucleus of cells. (B) Frequency 
distribution histograms illustrate the distribution of the cell diameter of NF200 positive neurons 
displaying cleaved SNAP25 (dark green) after incubation with the alternative chimeras, compared 
to NF200 positive neurons which were negative for cleaved SNAP25 (light green). The pie charts 
in the top right corner of the histograms illustrate the percentage of the neurons, labelled positively 
for cleaved SNAP25 (black), from the total number of NF200 positive neurons identified. Scale 
bar=50 μm.  
 
replicated in the BiTox/D histogram of NF200-positive neurons (Fig. 4.6B). There was no 
significant difference between the average cell diameter of neurons positively co-labelled 
for both NF200 and cleaved SNAP25, following incubation with BiTox/A and BiTox/C 
(One-way ANOVA, Dunnett's multiple comparisons test, P=0.4625). Furthermore, there 
was no significant difference in the percentage of NF200-positive neurons displaying 
cleaved SNAP25 between BiTox/A and any of the alternative BiTox constructs (One-way 
ANOVA, F (3,11) = 0.7355, P= 0.5524, Fig. 4.5B). 
 
4.2.4 SNAP25 cleavage is not detected in a significantly different subpopulation of 
small diameter neurons after substituting Rbd/A of BiTox/A for the Rbd of 
alternative serotypes. 
Peripherin is a 57 kDa neuron-specific intermediate filament, predominantly expressed 
in the peripheral nervous system (Portier et al., 1983; Parysek and Goldman, 1988). With 
regards to the dorsal root ganglia, peripherin is preferentially expressed in the small, 
unmyelinated neurons and is thus used to characterise this subpopulation of sensory 
neurons (Parysek and Goldman, 1988; Ferri et al., 1990; Goldstein et al., 1991). Anti-
peripherin antibody was therefore used to identify the small, unmyelinated neurons, 
namely the C-fibres nociceptors, after incubation with the alternative BiTox constructs, 
to investigate whether there were any similar, notable trends in the binding of 
unmyelinated neurons, and consequent cleavage of SNAP25, as was previously 
demonstrated in myelinated neurons. 
Substitution of the Rbd/A in BiTox/A did not have a significant effect on the mean cell 
diameter of peripherin-positive neurons in which cleaved SNAP25 was detected (One-
way ANOVA, F (3,59) = 1.806, P= 0.1560, Fig. 4.7A). Incubation with BiTox/C did result in 





Figure 4.7 Substitution of Rbd/A does not influence the detection of cleaved SNAP25 in 
small diameter neurons. 10 nM of each chimera (BiTox/A-E) was added to 2 day old Dorsal root 
ganglion cultures (N=4, n=3) for a 65 hour incubation. (A) Immunolabelling of treated cultures 
using peripherin to identify the unmyelinated sensory neurons did not reveal any significant 
differences in the mean cell diameter of neurons colabelled for peripherin and cleaved SNAP25, 
dependent on treatment with an alternative chimera. (B) The number of neurons colabelled for 
peripherin and cleaved SNAP25 was calculated as a percentage of the total number of peripherin 
positive neurons per culture (N=4). Incubation with alternative chimeras did not significantly affect 
the percentage of colabelled neurons. All data is presented as mean ± S.E.M. 
 
1.3 µm) than BiTox/A (19.3 ± 1.3 µm) but this difference was not shown to be significant 
(One-way ANOVA, F (3,59) = 1.806, P= 0.1040, Fig. 4.7A). Incubation with BiTox/D (19.8 
± 1.9 µm) and BiTox/E (19.7 ± 1.4 µm) produced SNAP25 in a subpopulation of 
peripherin-positive neurons with a very similar mean cell diameter to BiTox/A. Incubation 
with the alternative BiTox chimeras had no significant effect on the percentage of 
peripherin-positive neurons displaying cleaved SNAP25 (One-way ANOVA, F (3,12) 
=0.3058, P= 0.8208, Fig. 4.7B). 
 
4.2.5 Intraplantar injection of BiTox/D is suspected to prolong thermal 
hyperalgesia in Complete Freund’s Adjuvant rat model of inflammatory pain 
Following the observations made in the previous experiments, BiTox/C was not pursued 
any further as it did not produce SNAP25 cleavage in a statistically different population 
of sensory neurons compared to BiTox/A. In contrast, both BiTox/D and -/E produced 








Figure 4.8 Representative images of cleaved SNAP25 staining in unmyelinated dissociated 
sensory neurons. (A) Representative images of dorsal root ganglion cultures were taken using 
an epifluorescent microscope after 65 incubation with chimeras, BiTox/A-/E (N=4, n=3). Cleaved 
SNAP25 (red) is visualised in both peripherin-positive neurons (green) and peripherin-negative 
neurons. DAPI (blue) marks the cell nuclei. (B) Frequency distribution histograms illustrate the 
distribution of the cell diameter of peripherin positive neurons, displaying cleaved SNAP25 (red), 
after incubation with the alternative chimeras, combined with the distribution of peripherin-positive 
neurons which were negative for cleaved SNAP25 (pink). In the inserted pie charts, peripherin-
positive neurons displaying cleaved SNAP25 (black) are expressed as a percentage of the total 
number of peripherin-positive neurons counted. Scale bar=50 μm.  
 
After reviewing the data for both chimeras, BiTox/D and BiTox/E, it was decided that 
BiTox/D would be investigated further. Incubation with BiTox/E consistently produced 
SNAP25 cleavage in a smaller proportion of neurons than the other chimeras, thus 
implying that BiTox/E might not be as efficacious. In contrast, the percentage of neurons 
displaying cleaved SNAP25 after incubation with BiTox/D was very similar to that after 
incubation with BiTox/A. BiTox/D also had the added benefit of cleaving SNAP25 in what 
appeared to be two separate subpopulations of sensory neurons, one subpopulation of 
smaller diameter, myelinated neurons and another subpopulation of larger diameter, 
myelinated neurons. This suggests that BiTox/D may be binding to the large Aβ- neurons 
and the medium sized Aδ-fibre nociceptors.  
It was specifically chosen to trial BiTox/D in an inflammatory pain model given the 
implications of Aδ- and C-fibre nociceptor activation in chronic inflammatory pain. During 
inflammation, inflammatory mediators are released which activate and sensitise the C-
fibre and Aδ-fibre nociceptors, whilst also stimulating them to release their own 
inflammatory mediators (Averbeck et al., 2000; von Hehn et al., 2012). This increased 
excitability and activity of peripheral nociceptors, consequently drives increased firing 
and glutamate release at the central synapse in the dorsal horn, resulting in central 
sensitisation (Latremoliere and Woolf, 2009). Cleavage of SNAP25 in the primary 
afferents should prevent the initial neurotransmission of pain from nociceptors to second 
order neurons, during the acute stage of CFA-induced inflammation, but also, the 
chronification of pain due to changes which occur at the central synapse, secondary to 
the increased firing of primary afferents.  
Consequently, based on this hypothesis, the analgesic effects of BiTox/D were 
investigated in the Complete Freund’s Adjuvant model of inflammatory pain. At baseline, 
prior to injection of either vehicle or BiTox/D, the thermal (Sidak’s multiple comparisons 
test, Baseline, P= 0.9976, Fig. 4.9A) and mechanical (Sidak’s multiple comparisons test, 
109 
 
Baseline, P= 0.8899, Fig. 4.9B) thresholds were not significantly different between the 
two groups of animals. The thermal and mechanical thresholds remained comparable 
between the two groups following intraplantar injection of vehicle and BiTox/D to the left 
hindpaw on day -4 (Sidak’s multiple comparisons test, Thermal Day -3, P= 0.9923, Day 
0, P= 0.5161, Mechanical Day -3 and 0, P> 0.9999). Both vehicle and BiTox/D-injected 
rats developed thermal hyperalgesia (Fig. 4.9A) and mechanical hypersensitivity (Fig. 
4.9B) following intraplantar injection of Complete Freund’s Adjuvant (CFA) to the 
ipsilateral hindpaw on day 0. By day 14-post CFA injection, rats receiving intraplantar 
injection of vehicle showed an almost complete recovery to basal thermal threshold 
values. Rats which received BiTox/D, however, displayed significantly lower thermal 
thresholds compared to vehicle-injected rats (Sidak’s multiple comparisons test, Day 14, 
P= 0.0317, Fig. 4.9A). Further to this, the average thermal threshold for BiTox/D injected 
rats appeared to plateau by day 3 post-CFA with the average withdrawal latency 
remaining stable around 6 s, even at day 14 post-CFA, thus suggesting a prolonged 
period of thermal hyperalgesia.  
Although there was no main effect of treatment on the average thermal threshold (Two-
way ANOVA, Treatment, F (1,10) = 1.362, P= 0.2703, Fig. 4.9A), there was a significant 
interactive effect of treatment over time (Two-way ANOVA, Interaction, F (8, 80) = 2.885, 
P= 0.0071). When taken and analysed separately, treatment with BiTox/D, opposed to 
vehicle, did not influence thermal threshold measurements taken prior to injection of CFA 
(Two-way ANOVA, Treatment: BL - Day 0, F (1,10) = 0.4429, P= 0.5208) but did 
significantly affect thermal threshold after the establishment of the pain model (Two-way 
ANOVA, Treatment: Day 1-14 t F (1,10) = 5.821, P= 0.0365). This demonstrates that whilst 
BiTox/D does not affect basal thermal thresholds, it does affect thermal hypersensitivity 
once a pain phenotype has been induced.  
With regards to the mechanical threshold, there was no main effect of treatment with 
BiTox/D opposed to vehicle (Two-way ANOVA, Treatment, F (1,10) = 0.19, P= 0.6722, Fig. 
4.9B), or overall interactive effect of treatment over time (Two-way ANOVA, Interaction 
F (8, 80) = 0.668, P= 0.7180). The reversal of mechanical hypersensitivity was unaffected 
by injection of BiTox/D with both groups of animals following the same recovery 
trajectory. 
The recovery of the mechanical threshold does, however, appear to be much slower than 
that observed of the thermal threshold. It was attempted to extend the experiment to 
investigate when either sensory threshold would fully recover, however, the experiment 
had to be terminated on day 18 after lacerations were noticed on left hindpaw of two of 
the BiTox/D-injected rats (Fig. 4.9E). This again supports the notion that BiTox/D-injected 




Figure 4.9 BiTox/D potentially prolonged thermal hyperalgesia in a Complete Freund’s 
Adjuvant (CFA) inflammatory pain model. 7 week old Sprague Dawley rats received a 30 μl 
intraplantar injection of either 300 ng of BiTox/D (N=6) or vehicle (N=6), followed by an intraplantar 
injection of 30 μl CFA 4 days later (Day 0). The thermal and mechanical basal thresholds were 
assessed during two separate sessions. Consequently, the Baseline value represents the 
average of the two baseline readings. (A) The average basal withdrawal latency, measured using 
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Hargreaves Plantar test, was not significantly different between BiTox/D- and vehicle-injected 
rats, and was not affected by injection of BiTox/D. A reduced paw withdrawal latency was 
observed 24 hours after CFA injection in both groups, with no significant difference in thermal 
thresholds detected between groups (Day 1). BiTox/D- injected rats consistently displayed lower 
thermal thresholds than vehicle-injected rats following CFA injection. On day 14, this difference 
was shown to be significant. (B) There was no significant difference in mechanical threshold, 
assessed using Electronic von Frey, between groups at baseline. Both groups developed 
mechanical hyperalgesia 24 hours after CFA injection with no significant differences detected in 
mechanical threshold between the two groups at any later time point. (C) Thermals thresholds 
and (D) mechanical thresholds were also measured in the contralateral, uninjected paw. Both 
modalities remained stable in the contralateral paw of both groups and were unaffected by 
injection of CFA or BiTox/D to the ipsilateral paw. (E) On day 18, it was observed that two of 
BiTox/D injected rats had wounds on the foot pad of the CFA-injected hindpaw. Consequently, 
the experiment was terminated meaning that no later time points could be recorded. All data 
points are shown as mean ± S.E.M, * p<0.05. 
 
Importantly, the thermal (Two-way ANOVA, Treatment, F (1,10) = 3159, P= 0.5865, Fig. 
4.9C) and mechanical thresholds (Two-way ANOVA, Treatment, F (1,10) = 1.468, P= 
0.2535, Fig. 4.9D) of the contralateral paw were unaffected by intraplantar injection of 
BiTox/D to the ipsilateral paw.  
 
4.2.6 Cleaved SNAP25 is detected in the ventral horn following intraplantar 
injection of BiTox/D in a rat inflammatory pain model 
Immunohistochemical processing of spinal cord sections revealed SNAP25 cleavage in 
the lateral portion of the ventral horn within the lumbar regions L5 (Fig. 4.10, second 
panel) and L6 (Fig. 4.10, fourth panel), ipsilateral to the intraplantar injection site in 
BiTox/D- injected rats. No SNAP25 cleavage was detected in vehicle-injected animals 
(Fig. 4.10, first and third panel). Higher magnification images of the ventral horn of rats 
that received BiTox/D demonstrate that cleaved SNAP25 is not present within the motor 
neuron soma or at the membrane of motor neurons, but instead, appears to be localised 
within the interneuron terminals, synapsing on to the motor neurons (Fig. 4.11, top 
panel).  
Higher magnification images of the ipsilateral dorsal horn also revealed single neurites 
displaying SNAP25 cleavage extending up to the substantia gelatinosa, the superficial 
laminae of the dorsal horn where the nociceptors terminate (Fig. 4.11, bottom panel). 
These neurites appear to project from the network of interneurons, contained within the 




Figure 4.10 Cleaved SNAP25 is detected in the ventral horn following intraplantar injection 
of BiTox/D in an inflammatory pain rat model. Vehicle-injected rats (N=3) and BiTox/D-injected 
rats (N=3) were perfused with 4% paraformaldehyde on day 15 post-CFA injection and 30 μm 
spinal cord sections were prepared and stained. The spinal cord was marked with an incision to 
the ventral horn, contralateral to the injection site. SNAP25 cleavage (green) was detected 
ipsilateral to the intraplantar injection site at the spinal cord levels, L5 (2nd panel) and L6 (4th 





Figure 4.11 Higher magnification images of the ipsilateral spinal cord reveal cleaved 
SNAP25 within single neurites. Higher magnification epifluorescent microscopy images of 
spinal cord sections isolated from BiTox/D-injected rats revealed that cleaved SNAP25 (green) 
does not colocalise with the motor neurons, marked using NeuN (red), of the ipsilateral ventral 
horn following BiTox/D injection (top). Instead, cleaved SNAP25 is visualised within a network of 
neurites surrounding the motor neurons. Further investigation of the ipsilateral dorsal horn 
(bottom) showed single neurites (white arrowheads), containing cleaved SNAP25, projecting to 




The ability to silence distinct subpopulations of sensory neurons is important for the 
future design of long-lasting analgesics. It presents the opportunity to be able to treat the 
various clinical features of chronic pain conditions. For example, primary thermal 
hyperalgesia occurs due to the peripheral sensitisation of nociceptors at the site of injury, 
the Aδ- and C- fibres. By contrast, secondary hyperalgesia is due to changes in the 
phenotype of Aβ-fibres, such that they begin to produce a noxious response to innocuous 
stimuli (Latremoliere and Woolf, 2009). By discovering therapeutics that can target both 
small and large diameter neurons, it may be possible to prevent both peripheral and 
central sensitisation, and consequently, the establishment and maintenance of certain 
pain conditions. 
Based on the knowledge that the different serotypes of botulinum neurotoxin utilise 
distinct combinations of gangliosides and protein receptors to gain entry into neurons 
(Montal, 2010), and that the composition of these respective gangliosides and proteins 
varies between subtypes of sensory neurons (Ashton et al., 1990), it was hypothesised 
that the different serotypes would preferentially bind to selective subpopulations of 
sensory neurons. To test this hypothesis, the LcTd/A of BoNT/A, containing the zinc-
endopeptidase activity, and thus responsible for cleaving SNAP25, was conjugated to 
the receptor binding domain of BoNT/A, /C, /D and /E, to produce the chimeras, BiTox/A, 
/C, /D and /E, respectively. LcTd/A was specifically chosen as the active domain so that 
the inhouse anti-cleaved SNAP25 antibody could then be used as a reporter to provide 
an indirect measure of the novel chimeras’ activity.  
 
4.3.1 The in vitro binding profile of BiTox/A generates further support for the 
binding profile recognised in vivo 
The in vitro investigation of the binding profile of BiTox/A, conducted in this chapter, 
highlighted that BiTox/A most likely preferentially binds to the larger Aβ-sensory neurons. 
Following incubation with BiTox/A, SNAP25 cleavage was detected in sensory neurons 
with the largest cell diameter as well as in neurons showing the highest level of 
immunoreactivity for NF200, indicative of heavy myelination, associated with the larger 
Aβ-sensory fibres. These observations are consistent with that reported during the in 
vivo investigation of BiTox/A’s sensory binding profile (See 3.2.1). Following intraplantar 
injection of BiTox/A, cleaved SNAP25 was readily detected in both NF200- and IB4- 
positive sensory neurons, located in the glabrous skin of the injected hindpaw, thus 
representing the larger, myelinated, non-peptidergic neurons. Namely, the Aβ- fibres. 
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Additionally, cleaved SNAP25 was visualised in a subset of CGRP-positive neurons 
following intraplantar injection of BiTox/A. Expression of CGRP has been recognised in 
all subclasses of sensory neurons, Aβ-, Aδ- and C- fibres, however, CGRP is 
predominantly expressed in the small, unmyelinated C-fibres (McCarthy and Lawson, 
1990; Lawson et al., 2002; Bae et al., 2015). It is thus possible that this population of 
CGRP-positive nerve fibres, displaying cleaved SNAP25, noted in vivo, could be 
equivalent to the small subpopulation of the peripherin-positive neurons, recognised to 
be unmyelinated, C-nociceptors, that showed SNAP25 cleavage during the present in 
vitro investigation. This, however, remains to be confirmed by further in vitro 
immunolabelling using the anti-CGRP antibody. It is, nevertheless, possible that any 
discrepancies in the predicted binding of BiTox/A could derive from the method of 
investigation, i.e. in vitro investigation performed here, opposed to observations made in 
vivo in the previous chapter. 
 
4.3.2 In vitro investigation of the binding profiles of alternative BiTox chimeras 
confirms that the enzymatic domain of BoNT/A can be retargeted to alternate 
neuronal subpopulations 
Here, it was demonstrated that all four chimeras successfully retained their functionality 
in vitro following conjugation and persisted to cleave SNAP25 in sensory neurons. 
Subsequent staining of dorsal root ganglion cultures with pan-neuronal marker, βIII-
tubulin, proved to be minimally informative due to the skewed size distribution of neurons 
in culture. Although soma size has historically been used to determine cell type, this 
method is flawed as it does not consider the overlap in soma size between large and 
small sensory neurons (Harper and Lawson, 1985). The emergence of neuronal markers 
specific to subtypes of sensory neurons, in combination with soma size, has greatly 
improved the ability to distinguish the classic subtypes: Aβ-, Aδ- and C-fibre sensory 
neurons (Usoskin et al., 2010).  
Consequently, Neurofilament 200 and peripherin were chosen to identify the large, 
myelinated neurons and small, unmyelinated neurons, respectively. This was done with 
the intention that separating the two populations would eliminate the skewness of the 
data and help to elucidate any significant differences in the binding profiles of the 
alternative chimeras (Goldstein et al., 1991). After isolating only the myelinated neurons, 
significant differences were successfully demonstrated between the mean cell diameter 
of neurons in which cleaved SNAP25 was detected following incubation with the four 
chimeras. Both BiTox/A and -/C produced SNAP25 cleavage in myelinated neurons, as 
identified using NF200, with a larger cell diameter, indicative of large diameter Aβ-fibre 
116 
 
neurons. The neurons responsible for normal touch sensation and implicated in the 
development of secondary hyperalgesia. Conversely, following incubation with BiTox/D 
and BiTox/E, SNAP25 cleavage was observed in a subpopulation of significantly smaller 
myelinated neurons, suggestive of the smaller diameter, lightly myelinated Aδ-fibre 
nociceptors.  
There was still no significant difference noted between the mean cell diameter of 
peripherin-positive neurons, identified to be unmyelinated nociceptive neurons, which 
displayed cleaved SNAP25 after incubation with the alternative BiTox chimeras, 
compared to BiTox/A. This finding is not surprising given that the gangliosides found in 
the cell membrane of neuronal axons, which BoNTs utilise during the internalisation 
process, specifically GT1b, GD1a and GM1, are also known to act as ligands for myelin-
associated glycoprotein (MAG) (Ogawa-Goto et al., 1992; Yang et al., 1996; Vinson et 
al., 2001; Vyas et al., 2002). MAG serves as an adhesion molecule, recruiting 
myelinating glial cells, i.e. the Schwann cells, to the axonal membrane, and is thus 
integral for the maintenance of myelination (Posse de Chaves and Sipione, 2010). The 
neuronal membranes expressing the correct ganglioside combinations for the binding of 
BoNTs are, therefore, most likely to be myelinated neurons. It is thus expected that any 
difference in binding profiles between botulinum serotypes would be detected within the 
population of myelinated neurons. Furthermore, this concept is supported by the 
observation that cleaved SNAP25 was consistently detected in a larger percentage of 
neurofilament-positive neurons than peripherin-positive neurons, inferring that BoNTs 
show a higher affinity for myelinated neurons. 
Even with the use of the two antibodies, anti-NF200 and anti-peripherin, to separate the 
two populations of sensory neurons, there was still considerable similarity visible 
between the histograms of peripherin- and NF200- positive neurons. The histograms did, 
however, resemble those depicted by Ferri et al. (1990) who showed all peripherin-
positive neurons to be between 10-40 µm in cell diameter, and all NF200-positive 
neurons be between 20-60 µm in cell diameter, thus highlighting that there is substantial 
overlap between the size distribution of the two populations. Not dissimilarly, here, 
peripherin positive neurons were described to be 10-30 µm and NF200 positive neurons 
10-50 µm in cell diameter. Despite this overlap, the two antibodies have previously been 
shown to be largely mutually exclusive in their expression in dorsal root ganglion neurons 
(Ferri et al., 1990; Goldstein et al., 1991; Fornaro et al., 2008). Accordingly, any similarity 
in the size distributions does not mitigate the validity of the antibodies. 
Contrary to this, in another in vivo study, it was reported that almost a quarter of all 
NF200 positive neurons were actually unmyelinated neurons, and vice versa, that a 
significant proportion peripherin positive fibres were actually large-Aβ myelinated fibres 
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(Bae et al., 2015). These observations were made whilst utilising an in vivo method, 
staining whole sections, and in the absence of any injury. It does,  therefore, question 
the suitability of the two antibodies. Instead, they suggest that Substance P, Calcitonin 
Gene-Related Peptide, and isolectin-IB4 are more appropriate markers when assessing 
subpopulations of neurons.  
The observed differences in the staining of neurons could, however, be due to the nature 
of the tissue used. Bae et al. (2015) specifically examined the localisation of 
neurofilaments in the  trigeminal ganglia whereas, all the aforementioned studies, which 
verified the exclusive nature of NF200 and peripherin, were all conducted on dorsal root 
ganglia. Although not with specific reference to the expression of neurofilaments, RNA 
sequencing has demonstrated significant differences in the protein expression profiles 
between dorsal root and trigeminal ganglion neurons (Kogelman et al., 2017). This 
therefore suggests that although the two antibodies are mutually exclusive in DRG, these 
findings cannot be applied or extrapolated to the trigeminal ganglion neurons. 
The exclusiveness of the two antibodies has, however, been demonstrated whilst 
conducting in vivo staining of whole DRG sections, opposed to in dissociated cultures, 
as was the method used here. With regards to the protocol for producing dissociated 
DRG cultures, it is important to realise that the removal of DRGs requires mutliple 
axotomies, making it, essentially, an in vitro model of neuropathic pain. Interestingly, 
Fornaro et al. (2008) compared the perceived expression of NF200 and peripherin in 
vivo and in vitro, using DRG sections and DRG explant cultures, respectively. The two 
neurofilaments were again shown to be expressed in almost entirely separate 
populations of neurons in vivo. In contrast, whilst neurofilament 200 and peripherin were 
still exclusively detected in two distinct populations of neurons immediately after explant, 
staining 2 days post-explant instead revealed that all neuronal somas were postive for 
peripherin but  yet none were immunoreactive for NF200. Furthermore, by day 10 only a 
small proportion of DRG neurons in the explant were reported to be NF200-positive and 
these were located mostly at the peripheral edge of the explant. Additionally, RNA 
analysis conducted at the same time points indicated that whilst peripherin expression 
was reduced 2 days after explant, its expression levels greatly increased between days 
2 and 10 post-explant, thus suggesting that peripherin has a role in axonal regrowth and 
regeneration in sensory fibres, consistent with other studies (Larivière et al., 2002). 
Conversely, the expression levels of NF200 remained low and, although they did recover 
slightly, the expression levels were not significantly regained.  
This data illustrates that the process of axotomy, even more so a feature in the protocol 
for dissociated dorsal root ganglion cultures, than explants, could greatly disturb the 
normal expression levels of both NF200 and peripherin, and therefore, impact any 
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conclusions made. Similarly, in another study, Ferri et al. (1990) showed that capsaicin 
treatment of rodent neonates increased the percentage of neurons costained for both 
NF200 and peripherin, reiterating, again, that injury impacts the expression of these 
filaments. They specifically suggest that there is a shift in NF200-positive neurons 
towards expressing peripherin after treatment with capsaicin. This could explain why the 
negative skew is still apparent in the NF200 frequency distribution histograms shown 
here.  
In consideration of this, it would be recommended to use cultures which have been 
maintained for longer periods of time before studying the effects of BoNTs. By this time 
point, it would be expected that the axons should have seized growing and that protein 
expression levels should stabilise back to normal physiological levels. For this study, 
chimeras were added 2 days post-culture and cultures were not then collected until 5 
days post-culturing. According to Fornaro et al. (2008), the expression levels should 
begin recovering from 2 days post-culture so, although expression would be low, the 
proteins should be expressed in their correct populations and, therefore, minimally 
impact the data presented here. Furthermore, in contrast to their findings, the data 
presented here clearly shows a substantial proportion of NF200-positive neurons 5 days 
after culturing. This suggests that perhaps there is a quicker recovery of expression 
levels in dissociated cultures than in DRG explants. 
It is also worth noting that there is a slight disparity in cell diameter shown here, 
compared to that described elsewhere. The maximum diameter of peripherin-positive 
and NF200-positive neurons, reported by Ferri et al. (1990), was around 10 µm larger 
than that reported here. This could again be explained by the method used. As discussed 
earlier, the process of trituration during the culturing of dorsal root ganglion cells subjects 
the larger neurons to a great deal of sheer force, potentially rupturing them, and 
consequently mitigating them from the culture. It could, therefore, also be beneficial to 
utilise DRG explant cultures, rather than dissociated cultures, in order to avoid the loss 
of the larger diameter neurons. Dissociated cultures do, however, have the added 
advantage of allowing equal, as well as increased penetration of all neurons. Hence why 
they were selected for the screening of BoNTs in this study (Passmore, 2005).  
Another consideration to make is the age of the animals used. The majority of studies 
collected DRGs from rats weighing 300-350 g which suggests that they were 
approximately 8-11 weeks old, and would thus be considered young adults (McCutcheon 
and Marinelli, 2009; Brower et al., 2015). In this current work, the rats used were 3-4 
week old, weighing less than 100 g, and equivalent to pubescents (McCutcheon and 
Marinelli, 2009). This could account for the overall smaller cell diameter noted. It has 
previously been documented that neurons continue to increase in soma size with age, 
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as well as there being a shift noted in the proportion of large versus small diameter 
neurons (Hatai, 1902). The use of pubescent rats was jusitified as it achieved a 
compromise between the ease of imaging and the increased viability of neurons taken 
from animals of a younger age (Manfridi and Forloni, 1992; McCutcheon and Marinelli, 
2009) versus the maturity of neurons and expression profiles associated with adult 
cultures, compared to embryonic neurons (Melli and Höke, 2009). 
In summary, NF200 and peripherin are reliable markers for separating the respective 
populations of myelinated and unmyelinated sensory neurons, when isolated from dorsal 
root ganglia, and have therefore been used appropriately in this study. Furthermore, the 
size distribution of both peripherin- and NF200-positive neurons shown here are 
analogous to that reported previously in vivo (Ferri et al., 1990). It was therefore 
acceptable to reach the conclusion that BiTox/D and BiTox/E do bind to a subpopulation 
of significantly smaller NF200- positive neurons and to proceed on this basis.  
 
4.3.3 Pursuing BiTox/D as a potential analgesic 
Upon reflection of the data, BiTox/D was chosen to be investigated as a potential 
analgesic. Although both BiTox/D and BiTox/E produced SNAP25 cleavage in a 
subpopulation of significantly smaller myelinated neurons than BiTox/A, incubation with 
BiTox/D led to cleaved SNAP25 being detected in a greater proportion of neurons 
compared to Bitox/E. This was shown on both Western Blot and following quantification 
of all neurons, marked using βTubulin III. Furthermore, the observation was made that 
BiTox/D consistently cleaved SNAP25 in two distinct subpopulations of sensory neurons, 
one subpopulation of smaller diameter, myelinated neurons, around 18 µm in cell 
diameter, and another of larger diameter, myelinated neurons, around 28 µm in cell 
diameter. This suggests that BiTox/D may be binding to both the myelinated large Aβ- 
neurons and the smaller, more thinly myelinated Aδ-fibre nociceptors.  
It is not surprising, however, that BiTox/D displays the most distinct binding profile 
compared to the other chimeras investigated. BoNT/D displays the least homology in its 
amino acid sequence compared to other serotypes (Rummel et al., 2009; Strotmeier et 
al., 2010) and its method of internalisation remains the most contested. One theory 
states that, unlike other serotypes, Rbd/D does not utilise gangliosides but instead binds 
to the phospholipid, phosphatidylethanolamine (Tsukamoto et al., 2005). Conflicting 
evidence, however, claims that whilst Rbd/D is missing key residues in the ganglioside 
binding pocket, conserved between the other serotypes, it instead contains two 
carbohydrate binding pockets, one believed to have affinity for sialic acid, similar to 
tetanus, and another for which the ligand has yet to be identified (Strotmeier et al., 2010). 
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Accordingly, it has also been reported that Rbd/D binds to the b-series of gangliosides, 
GT1b and GD1b, comparable to the other serotypes, as well as GD2 (Strotmeier et al., 
2010; Kroken et al., 2011). Additionally, there is no known protein receptor for BoNT/D. 
It is however, agreed that BoNT/D must utilise some component of the synaptic vesicles 
as its uptake is greatly increased upon stimulation of the neurons (Rummel et al., 2009; 
Kroken et al., 2011).  
Overall, the internalisation method of Rbd/D remains relatively unclear. The unique 
neuronal binding profile determined here for BiTox/D does, however, support the notion 
that BoNT/D displays affinity for, and interacts with, alternate lipids, and possibly 
proteins, compared to the other serotypes. 
 
4.3.4 Neuronal blockade of Aδ nociceptors potentially causes prolonged thermal 
hyperalgesia in inflammatory pain 
BiTox/A is hypothesised to bind to the larger Aβ fibres based on its ability to successfully 
reduce secondary hyperalgesia in inflammatory pain conditions and its lack of 
effectiveness at treating primary hyperalgesia, localised to the site of injury (Mangione 
et al., 2016). Correspondingly, here it was shown that following incubation of cultures 
with BiTox/A, cleaved SNAP25 was detected in the larger myelinated neurons. Most 
noticeably, all NF200-positive neurons with a cell diameter greater than 30 µm displayed 
positive SNAP25 cleavage.  
It was therefore speculated that incubation with BiTox/D, similar to BiTox/A, would 
continue to block the activity of the larger Aβ low-threshold mechanoreceptors that 
innervate the area adjacent to site of injury and are responsible for the phenomenon of 
secondary hyperalgesia, as well as the Aδ nociceptors, located at the site of 
inflammation. The additional action at Aδ-nociceptors would thus block 
neurotransmission from these neurons and consequently prevent primary hyperalgesia 
and the development of neurogenic inflammation (Latremoliere and Woolf, 2009). It was 
therefore believed that BiTox/D would effectively treat both clinical features, primary and 
secondary hyperalgesia, of inflammatory pain conditions.  
Unfortunately, it was instead suspected that pre-treatment with BiTox/D might prolong 
thermal hyperalgesia at the site of inflammation. Only partial recovery of the thermal 
threshold was seen. Interestingly, immunotherapy treatment of neuroblastoma using 
anti-GD2 antibodies, whilst being very successful at treating neuroblastoma, is 
associated with severe visceral pain, requiring management with morphine (Cheung et 
al., 1987; Handgretinger et al., 1992, 1995). This perceived pain has been attributed to 
the activation of the complement cascade system which acts to heighten an inflammatory 
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response (Sorkin et al., 2010). GD2 has previously been demonstrated to be one of the 
possible interactive partners of BoNT/D (Kroken et al., 2011). If correct, it is therefore 
possible that the binding of BiTox/D to GD2 could augment the inflammatory response 
to CFA, by activating the complement system, thus maintaining the inflammatory state 
in BiTox/D-injected animals, whilst vehicle-injected animals recover.  
Administration of anti-GD2 antibodies in rats is, however, more associated with 
producing mechanical hyperalgesia, consistent with a neuropathic pain phenotype, 
opposed to thermal hyperalgesia, which is affected here, and is more characteristic of 
inflammatory pain conditions (Sorkin et al., 2002). Nevertheless, induction of pain by 
bolus injection of anti-GD2 antibodies results in a lower mechanical threshold being 
required for the activation of Aδ- fibres specifically, compared to saline-treated animals. 
Contrarily, no significant difference in mechanical activation threshold for C-fibres is 
noted (Xiao et al., 1997). This suggests a preference of anti-GD2 antibodies to target 
Aδ- nociceptors, presumably due to GD2 expression. Together with the data presented 
here, indicating that BiTox/D is targeting Aδ-nociceptors, this proposes that BiTox/D and 
anti-GD2 antibodies could display similar binding patterns and thereby supports the 
theory that they could potentially share similar pathophysiologic mechanisms.  
Furthermore, Weng et al. (2012) showed that only C-fibre firing and excitability is altered 
in CFA-induced inflammatory pain. This therefore negates the involvement of Aδ- 
nociceptors in primary hyperalgesia. The ineffectiveness of BiTox/D at treating thermal 
hyperalgesia consequently supports the notion that BiTox/D specifically binds the Aδ-
nociceptors because, if these findings are correct, then only blockade of 
neurotransmission in the C-fibres would be expected to produce analgesia.  
Regardless, the retargeting of LcTd/A to the smaller myelinated neurons, hypothesised 
to be Aδ -fibre nociceptors, using Rbd/D, did not affect the development of mechanical 
or thermal hyperalgesia following injection of CFA, thus implying that these neurons are 
not implicated in the establishment of chronic inflammatory pain conditions. The 
observation that thermal hyperalgesia persisted past the normal recovery experienced 
by vehicle-injected rats suggests that Aδ-nociceptors may, however, be important for the 
resolution of inflammation, and the subsequent reversal of thermal hyperalgesia. 
 
4.3.5 SNAP25 cleavage within the spinal cord suggests that BiTox/D could have a 
centrally mediated effect 
Comparable to that demonstrated following intraplantar injection of BiTox/A, cleaved 
SNAP25 was detected at the level of the spinal cord in animals that received intraplantar 
injection of BiTox/D, thus confirming that BiTox/D successfully retains the enzymatic 
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activity of LcTd/A in vivo. It also indicates that BiTox/D must be retrogradely transported 
from the peripheral injection site to the spinal cord. Retrograde transport of both BoNT/A 
and BoNT/B has previously been demonstrated in vivo (Antonucci et al., 2008; Restani 
et al., 2011; Matak et al., 2012). This retrograde transport was shown to be essential for 
the analgesic effect of BoNT/A in formalin-induced pain (Bach-Rojecky and Lacković, 
2009) and acidic saline-induced hyperalgesia (Matak et al., 2011), after the observed 
analgesia was eliminated by intraneural injection of colchicine, an axonal transport 
blocker, to the sciatic nerve. With regards to BiTox/D, this could mean that the prolonged 
thermal hyperalgesia, suspected to occur, might not be due to the actions of BiTox/D at 
the sensory afferents in the periphery, as so far discussed, but could instead, at least in 
part, be due to changes in spinal cord processing.  
A central mechanism for the analgesia produced by BoNT/A was first demonstrated in 
the formalin inflammatory pain model. Treatment with intraplantar BoNT/A injection, prior 
to formalin challenge, was ineffective against the first phase of inflammation, however, 
significantly reduced pain behaviour during the second phase (Cui et al., 2004). The first 
phase of inflammation represents the direct chemical activation of nociceptors by 
formalin at the periphery, whereas the second phase reflects changes in excitability, 
resulting from peripheral and central sensitisation. Similarly, BoNT/B was shown to 
reduce substance P release in the ipsilateral dorsal horn, subsequent to intrathecal 
injection of capsaicin (Marino et al., 2014), as well as preventing phosphorylation of 
pGluA1 and Akt, known markers of central sensitisation, following intrathecal injection of 
the glutamate receptor agonist, N-methyl-D-aspartate (NMDA) (Sikandar et al., 2016). 
BoNT/B did not, however, reduce local edema in the carrageenan-injected paw 
(Sikandar et al., 2016). Again, this suggests that the main analgesic effect of BoNTs is 
mediated at the level of the spinal cord by preventing the increase in neuronal excitability 
associated with central sensitisation. The evidence presented, however, explains a pro-
analgesic effect, whereas, here, BiTox/D has been described to be pro-hyperalgesic. 
Nevertheless, this effect could likewise be due to a centrally mediated mechanism.  
Specifically, cleaved SNAP25 is visualised in close proximity to the motor neurons in the 
ipsilateral ventral horn of the lumbar spinal cord, isolated from BiTox/D-injected rats. 
However, it is absent in the soma and at the membrane of motor neurons. Again, this is 
reminiscent of the SNAP25 cleavage noted after peripheral injection of BiTox/A. It is 
important to note that there were no signs of motor paralysis or motor deficits visible in 
either vehicle- or BiTox/D injected rats. Both groups were able to suspend from an 
inverted wire mesh for prolonged periods of time, indicative of normal motor function and 
tone (Marino et al., 2014; Mangione et al., 2016). This consequently questions the 
significance of the SNAP25 cleavage observed in the ventral horn.  
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Cleaved SNAP25 was also found present in a few single neurites which extended up to 
the substantia gelatinosa, the superficial laminae of the dorsal horn, where the Aδ- and 
C- fibre nociceptors terminate (Todd, 2010). It is unclear whether the SNAP25 cleavage 
present in the dorsal horn is being detected in fibres projecting up from the main network 
of cleaved SNAP25-positive fibres, originating in the ventral horn, possibly from 
interneurons or fibres involved in proprioception (Betley et al., 2009) or nocifensive spinal 
motor reflexes to noxious stimuli (Sivilotti and Woolf, 1994), or whether it is being 
detected in a remote population of dorsal horn neurons, secondary to anterograde 
transport in the peripheral afferents. Matak et al. (2012) likewise detected small amounts 
of cleaved SNAP25 in the dorsal horn after intramuscular injection of BoNT/A, but 
attributed this to the axonal transport of BoNT/A in spinal sensory neurons. The cleavage 
was consequently used to explain BoNT/A’s observed analgesic effects. 
Further investigation is still required to confirm whether this staining is indeed contained 
within interneurons, and if so, to determine the nature of these neurons, specifically, 
whether they are excitatory or inhibitory. It is thus possible that if cleaved SNAP25, 
produced by BiTox/D, is localised within GABAergic interneurons, specifically in the 
dorsal horn, that it could then suggest that BiTox/D is leading to the disinhibition of the 
pain signalling pathway, thereby augmenting the pain response, and subsequently 
maintaining central sensitisation. All claims remain purely speculative at present and 
require further investigation.  
 
4.3.6 Conclusion 
Based on the behavioural evidence provided, BiTox/D was not further pursued for testing 
in other pain models. BiTox/A thus currently remains the most promising analgesic. 
Provided the lack of success in generating a chimera specifically for treating 















There is currently a large amount of interest in utilising tetanus toxin, as well as other 
clostridial neurotoxins, as a drug delivery tool to treat diseases of the central nervous 
system (Toivonen et al., 2010). Native tetanus toxin binds to the presynaptic motor 
neuron terminals at the neuromuscular junction. Tetanus then undergoes retrograde 
transport to the motor neuron soma, located in the ventral horn of the spinal cord (Surana 
et al., 2017). By selectively expressing only the binding domain of tetanus toxin (Tbd), 
and conjugating or fusing this to a potential therapeutic, for example, a small molecule 
drug, a protein of interest or a gene for expression, the binding domain can be used to 
navigate the conjugated therapeutic to the motor neuron presynaptic terminals. The Tbd 
can consequently chaperone the conjugated therapeutic to the motor neuron soma in 
the spinal cord, via axonal transport. This mechanism of drug delivery circumvents the 
blood-spinal cord barrier to penetrate the central nervous system. Its specificity of binding 
also prevents off-target effects thus making it an attractive tool for application in central 
nervous system diseases. Specifically, those involving the motor system, such as 
Amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) (Figueiredo et 
al., 1997; Francis et al., 2004; Ciriza et al., 2008; Chian et al., 2009). 
These investigations so far, have focused on the attachment of a single Tbd to a single 
therapeutic molecule, using a simple one to one ratio. The attachment of a second 
binding domain should augment the efficacy of Tbd during drug delivery. The binding of 
a ligand to a receptor is determined by specific binding kinetics, most notably including 
on- and off-rate constants (Peuker et al., 2013). During binding, the ligand and receptor 
associate (the on-rate) and dissociate (the off-rate) several times (Corzo, 2006; Peuker 
et al., 2013). The presence of two binding domains would imply that as one receptor 
binding domain dissociates away from the receptor, the other binding domain which, as 
part of the same chimera, would be in close proximity to the receptor, would then be 
available to associate with the now vacant receptor. This hence increases the overall 
association time of the chimera with the receptor, and prevents the chimera from drifting 
away from the receptor during dissociation. In principle, this should increase the binding 
of the chimera to its receptor, thus improving its availability for, and overall rate of, 
internalisation, subsequently increasing the chimera’s efficacy. 
There are, however, concerns for the immunogenicity associated with tetanus toxin when 
pursuing it as a potential drug delivery tool. It is estimated that over 80% of the English 
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population under 40 years of age, and 53% of those over 60 years of age, are immunised 
against tetanus toxin (Maple et al., 2000). This means that a chimera containing Tbd 
could potentially be attacked and removed by immune cells before being able to produce 
any therapeutic effect. Only if the Tbd- containing chimera is internalised rapidly by 
neurons before eliciting an immune response, will the chimera be able to provide any 
therapeutic benefit (Toivonen et al., 2010). For this reason, here, the alternate toxin, 
Cholera toxin, was also investigated for use in drug delivery. 
Similar to Tbd, the b subunit of cholera toxin is capable of undergoing both anterograde 
and retrograde transport after peripheral application, and is subsequently used as a well-
established, effective neuronal tracer (Stoeckel et al., 1977; Angelucci et al., 1996; Conte 
et al., 2009). The majority of humans are not immunised against cholera toxin due to its 
low prevalence in developed countries, as a result of increased sanitation (Azurin and 
Alvero, 1974), thus making it an ideal candidate for development.  
Consequently, in this chapter, it will be investigated whether the attachment of a second 
receptor binding domain can improve the efficacy of protein delivery to the central 
nervous system. Additionally, it will be determined whether cholera toxin does offer an 
efficacious alternative to Tbd for drug delivery.  
 
5.2 Results 
5.2.1 Tbd-Cy3 is retrogradely transported to the motor neurons in the ventral horn 
of the lumbar spinal cord following intraplantar injection  
Tbd-Cy3 was prepared by Dr C. Leese, using the established stapling technique. Briefly, 
Tbd was fused to synaptobrevin whilst Cy3 was conjugated, via maleimide chemical 
conjugation, to the SNARE peptide SNAP25. Following the addition of syntaxin, the 
staple, a stable fluorescent chimera was produced (Mavlyutov et al., 2016). The 
attachment of the fluorescent label, -Cy3, enabled the location of Tbd to be inferred. 
Following intraplantar injection of 7.5 µg Tbd-Cy3 to the left hindpaw, Cy3 
immunofluorescence was detected in the soma of motor neurons, located in the ventral 
horn of the lumbar spinal cord, ipsilateral to the injection site. Specifically, at the L5 region 
of the spinal cord (Fig. 5.1). No Cy3 immunofluorescence was observed in the 
contralateral ventral horn.  
 
5.2.2 The penetration of the lumbar spinal cord motor neurons by Tbd-Cy3 is 




Figure 5.1 Tbd-Cy3 is visualised in the motor neurons of the ventral horn of the lumbar 
spinal cord following intraplantar injection. Male 5 week old Sprague-Dawley rats received 
intraplantar injection of 7.5 µg/ 50 µl Tbd-Cy3 (N=2). Rats were perfused 7 days post-injection 
and the spinal cord was collected and cryosectioned. Representative images taken on a Nikon 
A1 TIRF confocal microscope show -Cy3 immunofluorescence (red) detected in the ipsilateral 
ventral horn of the lumbar spinal cord, specifically within the motor neurons marked by NeuN 
(green). Cy3 immunofluorescence was absent in the contralateral ventral horn. Scale bar= 20 μm  
 
The previous experiment confirms that Tbd remains functional after attachment of a 
fluorescent label. It was demonstrated that Tbd can still effectively internalise into 
neurons and undergo retrograde transport to the spinal cord, resulting in detectable 
immunofluorescence in the ventral horn. Consequently, the amount of 
immunofluorescence in the motor neurons of the spinal cord was utilised to provide an 
indirect measure of internalisation and retrograde transport.  
To investigate whether the attachment of a second receptor binding domain could 
significantly enhance the binding of a protein, a second Tbd was attached to the 
fluorescent Tbd-Cy3 chimera. In short, the first Tbd and the -Cy3 label both remained 
fused to the same SNARE peptides. The second Tbd was expressed fused to the 
syntaxin peptide which was originally utilised as the “staple” peptide. Accordingly, no 
additional staple was required as all components of the SNARE complex were now 
contained within the individual subunits. Additionally, at this stage, the efficacy of cholera 
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toxin subunit B was also studied using a commercially available recombinant Cholera 
Toxin Subunit B Alexa Fluor 488 Conjugate (CTB-488) to determine whether cholera 
might provide a possible alternative delivery tool to tetanus toxin. 
All three chimeras were administered via intraplantar injection. Rats received a single 
injection of either 7.5 µg of Tbd-Cy3, 7.5 µg of 2xTbd-Cy3 or 20 µg of CTB-488 to left 
hindpaw. Quantification of immunofluorescence in the motor neuron soma in the spinal 
cord revealed that injection of the different compounds did significantly affect the amount 
of immunofluorescence detected in the motor neuron soma located in the ipsilateral 
ventral horn to the injected hindpaw (One-way ANOVA, F (2,15) =11.43, P=0.001, Fig. 
5.2C). Specifically, attachment of the second Tbd resulted in an almost ten-fold increase 
in the amount of immunofluorescence detected in motor neurons compared to Tbd-Cy3, 
consisting of only a single binding domain (Tukey’s  multiple comparisons test, P <0.001, 
Fig. 5.2A and 5.2C). Additionally, significantly more immunofluorescence was observed 
after injection of 2xTbd-Cy3 compared to CTB-488 (Tukey’s multiple comparisons test, 
P<0.05, Fig. 5.2A, 5.2B and 5.2C). CTB-488 did produce more immunofluorescence than 
Tbd-Cy3 in the motor neurons, however, this difference was not shown to be significant.  
 
5.2.3 Attachment of a second tetanus binding domain to TetBot increases the 
efficacy of the BoNT/A enzymatic domain to cleave SNAP25 in the spinal cord. 
Next, it was important to determine whether Tbd can deliver a large protein or enzyme 
to the spinal cord, and whether this ability to deliver a large protein is once more improved 
by the attachment of a second binding domain. Fluorescent probes such as Cy3 are 
usually very small in comparison to fully functional proteins. Cyanine fluorescent dyes 
specifically have a molecular weight below 1 kDa (Southwick et al., 1990; Mujumdar et 
al., 1993). Consequently, fluorescent probes do not largely impact the motility or binding 
of the proteins to which they are fused. In contrast, the enzymatically-active LcTd/A has 
a molecular weight of 100 kDa and can therefore greatly perturb the native binding and 
transportation of a targeting protein.  
To test this hypothesis, two separate chimeras were prepared. In the first chimera, 
LcTd/A was conjugated to a single Tbd, and in the second, LcTd/A was conjugated to 
two Tbds, using a similar method to that previously described in this chapter. The two 
chimeras were thus referred to as TetBot and 2xTetBot, respectively. The inclusion of 
LcTd/A meant that the cleaved SNAP25 antibody could again be used to provide a 
reliable reporter for LcTd/A enzymatic activity. It could therefore be easily recognised 
where LcTd/A had been active, and from this, then surmise where the LcTd/A had been 
transported to, and how effectively.  
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consisting of only a single binding domain (Tukey’s  multiple comparisons test, P <0.001,  
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Figure 5.2 The penetration of the lumbar spinal cord motor neuron soma by Tbd-Cy3 is 
increased by the attachment of a second tetanus binding domain. Male 5 week old Sprague-
Dawley rats received an intraplantar injection to the left hindpaw of either 7.5 µg/ 50 µl Tbd-Cy3 
(N=2), 7.5 µg/ 50 µl 2xTbd-Cy3 (N=2) or 20 µg/ 30 µl CTB-AlexaFluor488 (N=2). Animals were 
then perfused 7 days later. The fixated spinal cord was taken and cryosectioned for 
immunohistochemistry. Images were acquired using a Nikon A1 TIRF confocal microscope. (A) 
Immunolabelling of ipsilateral lumbar spinal cord sections revealed -Cy3 (red) 
immunofluorescence colocalised with the NeuN stain, used to visualise the motor neurons 
(green), after injection of both Tbd-Cy3 and 2xTbd-Cy3. Scale bar= 20 μm (B) Spinal cord 
sections isolated from CTB-AlexaFluor488-injected animals similarly displayed Alexa-488 
immunofluorescence (green) contained within the ipsilateral motor neurons (red). Scale bar= 20 
μm (C) Quantification of the resultant immunofluorescence, using a thresholding technique, 
showed that injection of 2xTbd-Cy3 produced significantly more detectable immunofluorescence 
than injection of either Tbd-Cy3 and CTB-AlexaFluor488. All data presented as mean ± S.E.M., * 
p<0.05, *** p<0.001. 
 
Western blot analysis of dorsal root ganglion cultures incubated with increasing 
concentrations of both TetBot and 2xTetBot demonstrated that cleaved SNAP25 can be 
readily detected following 65 hour incubation with 2xTetBot at concentrations as low as 
3.2 pM. In contrast, SNAP25 cleavage was only visualised following incubation with 
concentrations of 80 pM TetBot and above (Fig. 5.3C). This therefore implies that 
2xTetBot has a higher efficacy than TetBot. 
Similarly, quantification of the cleaved SNAP25 staining following intraplantar injection 
of 300 ng TetBot and 300 ng 2xTetBot into separate groups of animals, revealed that a 
significantly larger area of the spinal cord displayed positive SNAP25 cleavage following 
administration of 2xTetBot compared to TetBot (Unpaired t-test, t (4) =4.775, P=0.009, 
Fig. 5.3B). SNAP25 cleavage was visible in the ipsilateral ventral horn of the lumbar 
spinal cord following injection of both 2xTetBot and TetBot (Fig. 5.3A). Lumbar spinal 
cord sections prepared from 2xTetBot injected rats, however, showed a much greater 
medial spread of SNAP25 cleavage. Dense cleaved SNAP25 staining was seen reaching 
to the central canal of the spinal cord with additional projections decussating to the 
contralateral spinal cord (Fig. 5.3A). Furthermore, following intraplantar injection of 
2xTetBot, the dense SNAP25 cleavage staining was observed as far dorsal as laminae 
V and VI of the dorsal horn. Additionally, single cleaved SNAP25-positive neurites were 
also seen extending more sparsely through to the superficial dorsal horn (Fig. 5.3A). In 
contrast, spinal cord sections prepared from TetBot injected rats displayed SNAP25 
cleavage in a smaller area which was concentrated around laminae IX of the ventral 
horn, and was restricted to the ipsilateral spinal cord (Fig. 5.3A).  
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LcTd/A meant that the cleaved SNAP25 antibody could again be used to provide a 
reliable reporter for LcTd/A enzymatic activity. It could therefore be easily recognised  
131 
 
Figure 5.3 Greater penetration of the lumbar rat spinal cord is observed after intraplantar 
injection of 2xTetBot. Male 6 week old Sprague-Dawley rats received an intraplantar injection 
to the left hindpaw of either 300 ng/ 50 µl TetBot (N=3) or 300 ng/ 50 µl 2xTetBot (N=3). After 6 
days, the animals were culled and the spinal cord was isolated. The spinal cord was marked by 
an incision to the contralateral ventral horn before sectioning. (A) Images were acquired using 
the Leica epifluorescence microscope. Cleaved SNAP25 (green) was visualised in the ipsilateral 
ventral horn of both TetBot- and 2xTetBot-injected rats but was absent in the neuronal soma, 
labelled using NeuN (red). Scale bar= 0.5 mm (B) Quantification of the staining at L5 of the spinal 
cord revealed that 2xTetBot (N=3, n=2) resulted in a significantly larger area of cleaved SNAP25 
staining relevant to the total section area (44.7 ± 5.4%) than single TetBot (N=3, n=2) (15.6 ± 
2.8%) (C) Western blot (N=1) of dorsal root ganglion cultures following 65 hr incubation with 
TetBot and 2xTetBot were probed with a cleaved SNAP25 antibody. SNAP25 cleavage was 
clearly detectable at concentrations as low as 3.2 nM after incubation with 2xTetBot, in 
comparison to 80 pM TetBot. (D) Staining of the thoracic lumbar region revealed bilateral SNAP25 
cleavage in 2xTetBot-injected rats. This staining was absent in TetBot-injected rats. Scale bar= 
0.5 mm. All data presented as mean ± S.E.M. ** p<0.01. 
 
Moreover, cleaved SNAP25 was detected at the thoracic level of the spinal cord after 
intraplantar injection of 2xTetBot (Fig. 5.3D) but not after intraplantar injection of TetBot. 
This suggests that the attachment of a second Tbd encourages transcytosis into second 
order projections neurons meaning that 2xTetBot may have transcytosised twice.  
As was observed after injection of BiTox/A and BiTox/D, neither TetBot- or 2xTetBot- 
injected animals exhibited any visible signs of muscular paralysis, such as lameness or 
inability to grasp, despite the widespread SNAP25 cleavage observed at the level of the 
spinal cord. This is particularly surprising given the great expanse of SNAP25 cleavage 
detected in 2xTetBot injected animals, specifically. 
 
5.2.4 Cleaved SNAP25 is not readily detected in the lumbar spinal region following 
intraplantar injection of ChoBot 
The utility of Cholera Toxin Subunit B to deliver proteins of interest to the spinal cord was 
still investigated despite that CTB-488 was not shown to be more efficacious than single 
Tbd-Cy3 at internalising to neurons and undergoing retrograde transport, and remained 
less efficacious than 2xTbd-Cy3, due to the concerns over the immunogenicity predicted 
to occur when using tetanus toxin.  
LcTd/A was again used as the protein of interest to study the ability of cholera binding 
domain to deliver proteins to the spinal cord. In this instance, LcTd/A was conjugated to 
the AB5 domain of cholera toxin (for a more in-depth description, see 6.2.1). Briefly, AB5 
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contains the receptor binding domain of cholera, the previously investigated B subunit, 
which interacts in a pentameric arrangement (B5) with the rod-like structure, the A2 
domain (A). The A1 domain which mediates the enzymatic active of cholera toxin was 
purposely excluded from the chimera. Resultantly, the chimera includes five binding 
domains.  
In contrast to TetBot and 2xTetBot, immunohistochemical staining of the lumbar spinal 
cord showed few single fibres containing cleaved SNAP25 in the ipsilateral ventral horn 
after intraplantar injection of ChoBot (Fig. 5.4A). Staining of spinal cord sections using 
anti-CTB antibody, however, revealed positive CTB staining in the motor neurons of the 
ipsilateral ventral horn (Fig. 5.4B). This consequently suggests that CTB is unable to 
effectively chaperone LcTd/A to the central spinal cord. 
 
5.3 Discussion 
The blood-brain barrier remains a major obstacle for the delivery of therapeutic proteins 
to the central nervous system. Clostridial neurotoxins gain entry to the central nervous 
system via retrograde transport within nerve fibres, thereby circumventing the blood-
brain barrier (Caleo and Schiavo, 2009). Consequently, clostridial neurotoxins represent 
one avenue being explored to achieve neuronal drug delivery. Here, it has been 
demonstrated that tetanus toxin can be used to effectively deliver both small fluorescent 
compounds, and much larger functional enzymes, to neuronal soma, situated within the 
central nervous system. Furthermore, it has been shown that the established stapling 
technique can be successfully used to enhance the efficacy of chimeras by constructing 
a chimera comprising of two receptor binding domains. 
 
5.3.1 Attachment of a second targeting domain successfully augments the efficacy 
of chimeras 
Here, the attachment of a second Tbd to the Tbd-Cy3 construct resulted in an almost 
ten-fold increase in the amount of fluorescence detected in the motor neuron soma in 
the ventral horn. Similarly, the conjugation of a second binding domain to the active 
chimera, TetBot, produced nearly three times as much SNAP25 cleavage in the lumbar 
spinal cord. The evidence from both experiments clearly supports the hypothesis that the 
presence of two targeting domains significantly increases the binding of chimeras. As a 
result, more material is being internalised into neurons and is consequently then reaching 
the central nervous system, following retrograde transport. Hence, enhancing the 





Figure 5.4 Limited SNAP25 cleavage is visualised in the lumbar spinal cord after 
intraplantar injection of ChoBot. 4 weeks old male Sprague-Dawley rats (N=2) received 
intraplantar injection of 200 ng/ 30 µl ChoBot. (A)  Imaging of the lumbar spinal cord was 
conducted using a Nikon A1 TIRF confocal microscope. Lumbar spinal cord sections isolated 
from ChoBot-injected rats (N=2) show only single fibres positive for cleaved SNAP25 (green) 
within the ipsilateral ventral horn. No SNAP25 cleavage was detected in the contralateral ventral 
horn. Motor neurons are labelled using NeuN (red). Scale bar= 20 μm (B) Low magnification 
images of the spinal cord were acquired using the Leica epifluorescence microscope. Anti-CTB 
antibody (red) was used to detect the Cholera B subunit (CTB) at the level of the spinal cord whilst 
NeuN (green) was used to label all neuronal soma. Positive staining in the lumbar spinal cord for 
CTB (red) colocalised with the motor neurons of the ventral horn, following intraplantar injection, 
demonstrating that the B-subunit of ChoBot is retrogradely transported to the spinal cord. Scale 




This is most likely due to an increased interaction time between the chimera and the 
receptor of interest. As described earlier, the theory of binding kinetics depicts an on- 
(association) and off- (dissociation) rate constant for ligand-receptor interactions (Corzo, 
2006; Peuker et al., 2013). The presence of a second binding domain would greatly 
increase the probability of the chimera continuing to interact with the receptor. As one 
binding domain dissociates away from the receptor, the other binding domain would be 
immediately available to bind to the now vacant receptor. This would thus prevent drift 
and would increase the overall chimera-to-receptor interaction time, henceforth, 
improving the internalisation rate. A similar finding has been demonstrated in native 
proteins that naturally contain two binding domains. For example, fibronectin-binding 
proteins, F1 and F2, of the bacterium, streptococcus, require both binding domains for 
optimal binding of the proteins to their targets (Jaffe et al., 1996). 
The attachment of a second binding domain to a functional enzyme was important to 
demonstrate that Tetanus toxin could be used to deliver large cargo, opposed to small 
fluorescent markers. The SNAP25 cleavage detected confirmed that the attachment of 
two separate binding domains did not interfere with the enzymatic activity of LcTd/A. In 
contrast, the presence of a second binding domain greatly augmented the perceived 
catalytic activity of the chimera, as demonstrated by the large expanse of SNAP25 
cleavage, both dorsally and medially, visualised in the spinal cord of rats injected 
intraplantar with 2xTetBot. Conversely, SNAP25 cleavage was mostly contained within 
the ipsilateral ventral horn following injection of TetBot. Noticeably, cleaved SNAP25 was 
detected in fibres extending to the contralateral spinal cord and into the ipsilateral dorsal 
horn of the lumbar spinal cord. Additionally, cleaved SNAP25 was detected at the higher 
thoracic level of the spinal cord in rats receiving intraplantar injection of 2xTetBot. 
Together, the evidence suggests that the presence of the double binding domain, aids 
the transcytosis of the LcTd/A into second order neurons. In its native form, tetanus is 
retrogradely transported, via motor neurons, to the ventral horn, where it transcytoses 
into interneurons (Surana et al., 2017). The SNAP25 cleavage observed in the thoracic 
region implies that the chimera may be capable of transcytosing across multiple 
synapses, after the addition of a second Tbd, whereas the transcytosis of the single 
binding domain TetBot appears to be more restricted. 
 
5.3.2. The potential evidence for transcytosis introduces the possibility of 
delivering therapeutics to higher central nervous system regions 
Moreover, the fact that SNAP25 cleavage was detected in the thoracic region generates 
interest as to whether peripheral injection of 2xTetBot could be used to deliver 
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therapeutic proteins to higher regions of the central nervous system, for example, the 
brainstem. Cleaved SNAP25 appears to be visualised in the lateral reticulospinal tract, 
a descending motor pathway, important for locomotion (Watson and Harvey, 2009). It is 
therefore possible that cleaved SNAP25 would be detected in the reticular formation in 
the brainstem, where this tract orginates. Tissue from the brainstem was not analysed 
on this occasion, however, this staining would be conducted if this experiment was to be 
repeated.  
Although likely, it has not yet been confirmed that the cleaved SNAP25, detected in the 
thoracic spinal cord, is specifically contained within the lateral reticulospinal tract. The 
intermediolateral nucleus, which contains preganglionic sympathetic neurons, is located 
proximal to the lateral reticulospinal tract. It is thus possible that the SNAP25 cleavage 
visualised could instead be contained within the preganglionic sympathetic neurons of 
the intermediolateral nucleus, that innervate the abdominal viscera. This would thus 
suggest that 2xTetBot had somehow enterred the systemic circulation, from the 
peripheral injection site, to gain access to the abdomen.  
It is important that this matter is resolved before further developing double tetanus 
binding domain as a delivery tool. One way to achieve this would be to retrogradely label 
the preganglionic neurons by injection of Fluorogold to the abdomen, and then 
investigate whether the cleaved SNAP25 staining colocalises with the tracer (Appel and 
Elde, 1988; Clemens et al., 2005). Alternatively, tyrosine hydroxylase could be used to 
label the sympathetic neurons, again looking for colocalisation with the cleaved SNAP25 
marker. Notably, the cleaved SNAP25 staining demonstrated here does appear very 
similar to the tyrosine hydroxylase labelling of the IML, reported by Clemens et al. (2005), 
who described this labelling to be descending inhibitory dopaminergic axonal 
arborisations. Notably, the descending pathways regulating the activity of the 
sympathetic neurons project from the ventrolateral medulla (Zagon and Smith, 1993), 
again suggesting that it is possible that LcTd/A could reach the brainstem, after 
peripheral injection of 2xTetBot, albeit, via an alternative pathway to that previously 
considered.  
 
5.3.3 Tetanus chimeras do not produce motor paralysis despite high levels of 
SNAP25 cleavage detected in the ventral horn 
One of the most suprising findings, following intraplantar injection of 2xTetBot, was the 
absence of any signs of motor paralysis or motor impairment despite the large amount 
of SNAP25 cleavage detected in the ventral horn of the lumbar region. Laminae IX, 
located in the lateral ventral horn of the spinal cord, is responsible for the motor 
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innervation of the distal flexor muscles and appears to be the centre point of the SNAP25 
cleavage in both the 2xTetBot- and TetBot- injected rats. Native tetanus toxin 
transcytoses from motor neurons into synapsing inhibitory interneurons where it cleaves 
the SNARE protein, synaptobrevin, thus blocking the release of inhibitory 
neurotransmitters, and consequently producing spastic paralysis (Surana et al., 2017). 
Accordingly, it would be expected that both TetBot and 2xTetBot would likewise produce 
spastic paralysis provided that the Tbd should target the chimera to the neurons natively 
targeted by tetanus, the inhibitory interneurons. This, however, remains to be confirmed 
by immunostaining.  
In support of the observations made here, Ferrari et al. (2013) likewise did not observe 
any signs of motor paralysis in mice, even after intramuscular injection of 500 ng TetBot, 
equivalent to 100,000 times the lethal dose of native BoNT/A. It is, however, possible 
that while no obvious muscle paralysis was perceived, that the rats could have 
experienced compromised function of the hindpaw. In future, a grip test should be used 
to discriminate whether rats have any less obvious muscular paralysis. 
 
5.3.4 Utilising tetanus chimeras to treat lysosomal disorders 
The potential for motor paralysis associated with drug delivery to the interneurons and 
higher motor pathways by Tbd would not be a concern if the aim was to deliver a 
therapeutic protein, such as a neuroprotective factor, to neurons rather than a functional 
enzyme. It remains to be investigated whether Tetanus toxin can be used to deliver other 
proteins, rather than another clostridial subunit, as shown here. Tbd has previously been 
used to target the enzyme, beta-hexosaminidase, responsible for the degradation of the 
ganglioside GM2 in neurons, to the lysosomes of neurons to treat GM2 gangliosidosis, 
a neurodegenerative lysosomal storage disease (Dobrenis et al., 1992). A reduction in 
the accumulation of GM2 was noted after the incubation of neuronal cultures with the 
Tbd-beta-hexosaminidase construct. It was thus concluded that Tbd had successfully 
chaperoned the enzyme to the lysosome, to enable effective degradation of GM2. The 
stapling technology could therefore conceivably be applied to enhance drug delivery for 
the treatment of lysosomal disorders.  
 
5.3.5 The cholera toxin-derived targeting domain is not suitable for delivery of 
therapeutics to the central nervous system 
In contrast, potentially undetected motor effects remain an issue with regards to the other 
objective of this thesis, to design a neuronal blocker to be used as a novel analgesic, as 
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this would require the inclusion of the LcTd/A catalytic domain. Although a greater 
amount of fluorescence was visualised in the motor soma of the ventral horn following 
intraplantar injection of CTB-488, than single Tbd-Cy3, the cholera targeting subunit, 
AB5, was largley unsuccessful at chaperoning and delivering LcTd/A to the spinal cord. 
The lack of retrograde transport demonstrated could prove beneficial, however, when 
developing an analgesic for pain conditions where the pain is restricted to a peripheral 
site. If the catalytic activity of ChoBot is equally confined to the peripheral injection site 
then this would greatly reduce the risk of off-target, central effects.  
It is worthwhile to note, however, that although more fluorescence was detected after 
intraplantar injection of CTB-488, compared to TetBot, a larger amount of CTB-488 than 
Tbd-Cy3 was injected, almost three times as much (20 µg CTB-488 opposed to 7.5 µg 
Tbd-Cy3), in line with recommendations gathered from previous studies (Conte et al., 
2009; Mantilla et al., 2009). Accordingly, there was approximately a 3.5 fold increase in 
the amount of fluorescence detected, thus implying that, overall, cholera CTB subunit 
did not offer a huge advantage over single Tbd, with regards to the delivery of fluorescent 
dyes. Additionally, CTB was conjugated to AlexaFluor488, opposed to Cy3. The 
AlexaFluor dyes provide much greater photostability than the traditional fluorophores 
(ThermoFisher, n.d.; Mahmoudian et al., 2011) and are therefore more resistant to 
photobleaching. This could prove particularly advantageous when using confocal 
microscopy and thus might haved biased the perceived fluorescence.  
It should also be acknowledged that CTB-488 was not constructed using the SNARE 
stapling technology used to produce Tbd-Cy3 and 2xTbd-Cy3. It was instead purchased 
as a recombinantly expressed protein, whereby the genes encoding CTB and 
AlexaFluor488 were fused, prior to expression (ThermoFisher, 2003). The ChoBot 
chimera used later in the experiment was, however, constructed using the stapling 
technology. It would therefore be of benefit to construct AB5-Cy3, using the SNARE-
stapling approach, to determine whether fluorscence can still be detected in the spinal 
cord when using the same method of conjugation, and the same fluorophore. 
Notably, in contrast to the CTB-488 conjugate, when constructing ChoBot, the LcTd/A 
was conjugated to the AB5 domain, rather than directly to the B subunit. It has been 
reported that the B subunit dissociates from the pentameric structure at low pH, typically 
lower than pH 4.0 (De Wolf et al., 1987). BoNT/A must enter acidic vesicles, upon 
internalisation, to permit the unfolding of the translocation domain, in order for the 
enzymatic light chain to escape to the cytosol (Pirazzini et al., 2011). There are therefore 
two possible theories for the perceived lack of SNAP25 cleavage in the spinal cord. 
Firstly, ChoBot could have entered the acidic vesicles, consequently causing the 
targeting domain, CTB, to dissociate away from the chimera. This would have resulted 
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in LcTd/A being left at the peripheral terminal whilst CTB continued to be retrogradely 
transported to the central synapse, hence explaining the immunoreactivity for CTB 
detected in the motor soma post-intraplantar injection of ChoBot, and the absence of 
SNAP25 cleavage. Conversely, the AB5 domain could have chaperoned LcTd/A into 
neutral vesicles, resulting in the catalytic light chain being unable to escape the vesicle, 
and therefore, the Lc would have been delivered to the central motor neuron soma but 
remained trapped inside the endosome, rendering LcTd/A inactive. This again provides 
valid explanation for the positive CTB staining, despite the lack of cleaved SNAP25. 
 
5.3.6 Conclusion 
In conclusion, it has been shown that tetanus toxin is an efficacious tool for drug delivery 
to the central nervous system. The in vivo data collected from TetBot and 2xTetBot 
injected-rats highlights that the pioneered stapling technique can be successfully used 
to enhance the efficacy of chimeras by attachment of a second targeting domain. 
2xTetBot remains a proof of principle due to the associated immunogenicity of tetanus 
toxin in humans (Maple et al., 2000). The transferability of the technology to other 
chimeras still requires further investigation but appears promising. Moreover, the 
opportunity exists to attach another binding domain, or therapeutic protein, by splitting 
the SNARE complex into 4 individual peptides. Each of SNARE peptides could, in theory, 
be recombinantly expressed with an attached protein, creating a 4-domain SNARE-
stapled chimera.  
Separately, Cholera toxin was investigated as an alternative toxin for development as a 
drug delivery tool but failed to deliver large proteins to the central nervous system. The 
suspected limited penetration of the central nervous system by ChoBot could, however, 
prove beneficial in the development of analgesics. Although no motor paralysis following 
injection of either TetBot or 2xTetBot was observed, the long-term effects of SNAP25 
cleavage within the motor area of the spinal cord are unknown and should thus be 
avoided when developing a future analgesic. Furthermore, if SNAP25 cleavage is only 
observed in the periphery following intraplantar injection of ChoBot, it could help to 
resolve the earlier questions of whether the therapeutic effect of BoNT/A is due to its 
peripheral or central catalytic activity. The use of ChoBot as a novel analgesic will 





Chapter 6. New bacterial chimera for the alleviation of post-operative pain 
and chemotherapy-induced peripheral neuropathy 
 
6.1 Introduction 
Two aforementioned novel clostridial chimeras, BiTox/A (Mangione et al., 2016) and 
TetBot (Ferrari et al., 2013), have been shown to be analgesic against mechanical 
hypersensitivity in separate pain conditions. Further investigation here has demonstrated 
that both chimeras produce large amounts of SNAP25 cleavage at the level of spinal 
cord, thus indicating that they must undergo retrograde transport from the periphery to 
the spinal cord. Consequently, although no signs of motor paralysis or compromised 
well-being were observed, there are concerns about any possible long-distance, off-
target adverse effects, associated with the retrograde transport of these chimeras.  
By comparison, ChoBot, containing the binding domain of Cholera Toxin (AB5) and the 
light chain translocation domain of Botulinum Neurotoxin A (LcTd/A), produced negligible 
amounts of cleaved SNAP25 in the spinal cord following intraplantar injection. This 
therefore implies that there is minimal retrograde transport of LcTd/A to the central spinal 
cord and that the catalytic activity of LcTd/A is instead restricted to the peripheral 
injection site. Not only is this beneficial to prevent off target effects but, if ChoBot was 
similarly shown to be analgesic, it would help to further elucidate whether the therapeutic 
benefit of SNAP25 cleavage by LcTd/A is due to a peripheral or central mechanism 
(Mangione et al., 2016).  
Firstly, this chapter aims to confirm whether ChoBot does retain the catalytic activity of 
LcTd/A in vivo, and, if so, determine whether this catalytic activity is largely constrained 
to the injection site. If shown to be true, it will next be pursued whether ChoBot can 
similarly provide analgesia in pain models. Thus, either generating support for, or 
negating, the hypothesis that the analgesic effect of LcTd/A is peripherally mediated.  
 
6.2 Results 
6.2.1 ChoBot retains the enzymatic activity of Botulinum Neurotoxin A in vitro 
As described in the previous chapter, the novel chimera, ChoBot, was constructed from 
a truncated version of the AB5 cholera toxin, which was then stapled to the LcTd/A, by 
the addition of a SNARE peptide staple.  
The native Cholera Toxin A subunit is expressed as a single polypeptide consisting of 
two domains, A1 and A2, which are joined by a disulphide bond. The A1 domain contains 
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the catalytic activity of cholera toxin (Beddoe et al., 2010). Consequently, the truncated 
A subunit used here to form the chimera contained only the rod-like, linker portion of the 
A subunit, the A2 domain, fused to the SNARE peptide, synaptobrevin. Specifically, the 
A2 domain is an α-helix which associates with the B subunit, via the central pore. There 
is a total of five B subunits which assemble into a pentameric arrangement, around the 
A2 domain, hence the name, AB5. The removal of the A1 subunit eliminated the catalytic 
activity associated with Cholera toxin. Instead, here, the chimera’s catalytic activity was 
inferred by the addition of the LcTd/A, which facilitates the cleavage of SNAP25. LcTd/A 
was fused to the SNARE- peptide, α-SNAP25, which, with the addition of the staple, 
syntaxin, enabled the formation of a SNARE complex between the two separate 
components of the chimera, the truncated AB5-synaptobrevin and LcTd/A-αSNAP25, to 
form an irreversibly conjugated chimera (Fig. 6.1A). 
The stability of the chimera is highlighted during the running of a coomassie-stained 
SDS-PAGE gel. In the unboiled sample, the chimera is seen as a single band and does 
not dissociate back into the separate LcTd/A-αSNAP25 and A2-synaptobrevin domains, 
showing that the SNARE-complex is SDS-page resistant (Fig. 6.1A). The A2-
synaptobrevin band represents excess material that was unable to conjugate to LcTd/A-
αSNAP25 due to there being no more available to conjugate to, hence the absence of  
 
Figure 6.1 ChoBot successfully cleaves SNAP25 in rat cortical neuron cultures (A) A 
coomassie-stained SDS-PAGE gel showing the assembly of the chimera, ChoBot. (B) Western 
blot showing cleavage of SNAP25 in rat cortical neuron cultures following 65 hour incubation with 
0.64 pM- 10 nM ChoBot (N=2). Complete cleavage of SNAP25 is observed at concentrations of 
2 nM and greater. Quantification of the western blot data displayed in the dose-response curve 
shows that the EC50 for SNAP25 cleavage was 71.58 pM. Data provided courtesy of Dr C. Leese. 
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a LcTd/A-αSNAP25 band in the unboiled sample. Conversely, in the boiled sample, all 
components can be seen in their individual bands. It is noted on the gel, however, that 
the pentameric and singular B-subunits dissociate from the A subunit in all lanes, 
including in the unboiled sample. This is because the A2 subunit is non-covalently bound 
to the B-pentamer meaning that the two easily dissociate with the addition of SDS-page. 
Hence, also explaining the B-pentamer and singular B-subunit bands visible in each lane 
(Fig. 6.1A) (Beddoe et al., 2010). 
After demonstrating the successful assembly of the chimera, the functionality of ChoBot 
was assessed in vitro to ensure that ChoBot remained capable of binding and 
internalising into neurons, as well as effectively retaining the catalytic activity of BoNT/A. 
ChoBot was added to dissociated cortical neuron cultures in varying concentrations. 
Complete cleavage of SNAP25 was shown in rat cortical neurons after 65 hour 
incubation with concentrations of 2 nM ChoBot and higher. Moreover, SNAP25 cleavage 
was produced by concentrations as low as 16 pM, thus demonstrating that ChoBot can 
effectively bind and internalise into neurons, and cleave SNAP25, in vitro (Fig. 6.1B). 
 
6.2.2 ChoBot produces SNAP25 cleavage in myelinated sensory neurons in vitro 
The ultimate intention is to design a chimera to be used as an analgesic. ChoBot’s 
enzymatic activity was therefore further assessed in dorsal root ganglion cultures to 
determine whether ChoBot is able to preferentially bind to, and consequently cleave 
SNAP25 in, a subset of sensory neurons, specifically nociceptive neurons. For this 
purpose, we compared the binding profile of ChoBot to the two chimeras which have 
previously been demonstrated to produce analgesia in animal models, TetBot and 
BiTox/A (Ferrari et al., 2013; Mangione et al., 2016). 
After 65 hour incubation with 10 nM ChoBot, cleaved SNAP25 was observed in a subset 
of sensory neurons with an average cell diameter of 21.0 ± 1.0 µm, again identified using 
the pan-neuronal marker, βTubulin III (Fig. 6.2A). According to the frequency distribution 
histogram, cleaved SNAP25 was most often visualised in neurons with a cell diameter 
between 18-20 µm. Another peak was noted at 28 µm cell diameter, (Fig. 6.2B), 
reminiscent of the frequency distribution histograms associated with incubation of 
cultures with BiTox/D (Fig. 4.4B). 
Similarly, incubation with TetBot resulted in detectable SNAP25 cleavage in a subset of 
neurons with a mean cell diameter of 22.1 ± 1.1 µm (Fig. 6.2A). Again, two peaks were 
noted in the frequency distribution histogram, one peak at 16-20 µm cell diameter, and 
the other at 26 µm cell diameter (Fig. 6.2B). There was no significant difference between  
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Figure 6.2 ChoBot cleaves SNAP25 in a subpopulation of cultured sensory neurons. (A)  
Epifluorescent images of SNAP25 cleavage (red) in dissociated dorsal root ganglion neurons, 
identified using pan-neuronal marker, βTubulin III (BTIII) (green) after 65 hour incubation of 
cultures with 10 nM ChoBot (N=3, n=3), 10 nM TetBot (N=3, n=3) and 10 nM BiTox/A (N=5, n=3). 
The health of sensory neurons was confirmed by identification of an intact nucleus using DAPI 
(blue). Cleaved SNAP25 immunoreactivity was not detected in vehicle or untreated neuronal 
cultures (data not shown). (B) Images were quantified to produce frequency distribution 
histograms showing the number and diameter of neurons displaying both BTIII and cSNAP25 
staining (black) compared to neurons displaying BTIII staining only (grey). Inserted pie charts (top 
right) show the percentage of the total neurons identified, that displayed SNAP25 cleavage 
(black). Scale bar = 50 μm. (C) The data points plotted represent the identified neurons positive 
for cleaved SNAP25 after incubation with each of the chimeras. Incubations with BiTox/A (27.6 ± 
1.3 µm) resulted in cleaved SNAP25 being detected in neurons with a significantly higher mean 
cell diameter compared to ChoBot (21.0 ± 1.0 µm) and TetBot (22.1 ± 1.1 µm). All data is 
presented as mean ± S.E.M.** P=0.01, *** P=0.001. 
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the average cell diameter of neurons displaying cleaved SNAP25 after incubation of 
ChoBot compared to TetBot (One-way ANOVA, F (2,100) = 9.355, P=0.8158, Fig 6.2C). 
In contrast, incubation with BiTox/A produced cleaved SNAP25 in a subpopulation of 
neurons with significantly larger mean cell diameter (27.6 ± 1.3 µm) than following 
incubation with ChoBot (One-way ANOVA, F (2,100) = 9.355, P=0.0005) and TetBot (One-
way ANOVA, F (2,100) = 9.355, P=0.0045, Fig 6.2C). This is well exemplified by the 
frequency distribution histogram were the neurons displaying positive cleaved SNAP25 
can be seen distributed across the upper values of the histogram. There was no 
significant difference in the percentage of neurons showing positive-cleaved SNAP25 
staining between the three chimeras (One-way ANOVA, F (2, 8) = 0.34433, P=0.7187, Fig. 
6.2B). 
The neuronal markers, Neurofilament 200 and peripherin, were subsequently used to 
distinguish whether this difference in binding between BiTox/A and the two other 
chimeras, ChoBot and TetBot, occurred within the population of larger, myelinated Aβ- 
and thinly myelinated Aδ- sensory neurons, or within the population of smaller 
unmyelinated neurons. Labelling the larger, myelinated neurons, using anti-NF200 
antibody, likewise revealed that the neurons displaying positive cleaved SNAP25 
staining after incubation with BiTox/A had a significantly larger mean cell diameter (28.2 
± 1.2 µm) in comparison to those showing cleaved SNAP25 after addition of ChoBot 
(20.9 ± 1.3 µm; One-way ANOVA, F (2,90) = 10.68, P=0.0004) and TetBot (21.5 ± 1.3 µm; 
One-way ANOVA, F (2,90) = 10.68, P=0.0015) (Fig. 6.3C). For both ChoBot and TetBot, 
the frequency distribution histogram indicated that the peak in the number of neurons 
displaying SNAP25 cleavage occurred below 20 µm (Fig. 6.3B). BiTox/A again produced 
a histogram were the neurons displaying cleaved SNAP25 spanned the upper values of 
the histogram, with a peak specifically observed at 30 µm cell diameter (Fig. 6.3B). There 
was, however, no perceived difference in the percentage of neurons displaying cleaved 
SNAP25, dependent on the treatment of cultures with the different chimeras (One-way 
ANOVA, F (2,7) = 0.1389, P=0.8727, Fig 6.3B). 
In contrast, identification of the unmyelinated, peripherin-positive neurons did not 
indicate any significant differences in either the mean cell diameter of the neurons co-
labelled for cleaved SNAP25 (One-way ANOVA, F (2,27) = 0.3012, P=0.7423; Fig. 6.4C), 
or in the percentage of peripherin-positive neurons displaying cleaved SNAP25 (One-
way ANOVA, F (2,6) = 0.6665, P=0.5478, Fig. 6.4B), following incubation with the different 
chimeras. All three chimeras produced cleaved SNAP25 in a subpopulation of 




Figure 6.3 ChoBot cleaves SNAP25 in a subpopulation of myelinated sensory neurons. (A)  
Representative images of cleaved SNAP25 (red) in myelinated sensory neurons, defined using 
anti-neurofilament 200 (NF200) antibody (green), following 65 hour incubation of dissociated 
dorsal root ganglion cultures with 10 nM ChoBot (N=3, n=3), TetBot (N=3, n=3) and BiTox/A (N=4, 
n=3). The nucleus is indicated by DAPI (blue). Scale bar= 50 μm. (B) Quantification of images 
was used to generate frequency distribution histograms which show the distribution of NF200-
labelled neurons displaying cleaved SNAP25 (black), dependent on cell diameter, compared to 
NF200-positive neurons negative for cleaved SNAP25 (grey). Pie charts (top right) display the 
percentage of total NF200-positive neurons that were colabelled for cleaved SNAP25 (black). (C) 
Plotting the cell diameter of individual neurons colabelled for NF200 and cleaved SNAP25, after 
incubation with each of the chimeras, revealed that BiTox/A cleaves SNAP25 in myelinated 
sensory neurons with a larger mean cell diameter (28.2 ± 1.2 µm) than ChoBot (20.9 ± 1.3 µm) 




Figure 6.4 ChoBot cleaves SNAP25 in a small proportion of unmyelinated sensory neurons 
in vitro. (A) Representative epifluorescent images of cleaved SNAP25 (red) in unmyelinated 
sensory neurons, marked using anti-peripherin antibody (green), taken after 65 hour incubation 
of 2 day old dissociated dorsal root ganglion cultures with 10 nM ChoBot (N=2, n=3), 10 nM TetBot 
(N=3, n=3) and 10 nM BiTox/A (N=4, n=3). DAPI (blue) marks the cell nuclei. Scale bar = 50 μm. 
(B) Frequency distribution histograms show the distribution of peripherin-positive neurons 
displaying cleaved SNAP25 (black), dependent on cell diameter, compared to peripherin marked 
neurons, negative for cleaved SNAP25 (grey). Pie charts (top right) illustrate the number of 
neurons colabelled for peripherin and cleaved SNAP25 (black) expressed as a percentage of the 
total number of peripherin-positive neurons. (C) The cell diameter of neurons colabelled for 
peripherin and cleaved SNAP25 was plotted to reveal no significant difference in the mean cell 
diameter of unmyelinated neurons displaying cleaved SNAP25 after incubation with each of the 
chimeras. All data is presented as mean ± S.E.M. 
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6.2.3 Cleaved SNAP25 is detected in the peripheral sensory neurons of the 
glabrous skin following intraplantar injection of ChoBot 
Subsequent in vivo investigations were used to evaluate whether the in vitro binding 
profile of ChoBot could be replicated in vivo. The pan-neuronal marker, βIII-Tubulin, was 
firstly used to label the neuronal fibres, innervating the glabrous skin. βIII-Tubulin 
recognises all nerve fibres and subsequently stains both motor and sensory neurons. 
The location of the nerve terminals was therefore used to distinguish the sensory nerve 
fibres from the motor nerve fibres. Sensory neurons terminate inside the dermis, proximal 
to the epidermis. Conversely, motor neurons project directly to the muscle fibres which 
are located much deeper in the dermis and are easily identified by their striated 
appearance.  
Subsequent immunostaining using anti βIII-Tubulin antibody, revealed positive cleaved 
SNAP25 staining in the sensory neurons of the glabrous skin of the ipsilateral paw, 
following intraplantar injection of 200 ng ChoBot (Fig. 6.5A). SNAP25 cleavage was not 
detected in the sensory neurons of contralateral paw of ChoBot-injected animals (Fig. 
Fig. 6.5A). Likewise, cleaved SNAP25 was not observed in the ipsilateral paw of vehicle-
injected or naïve rats.  
Further staining was next conducted to elucidate which subtype of sensory neurons, 
specifically, contained cleaved SNAP25. Comparable to the in vitro labelling, cleaved 
SNAP25 was visualised in the larger, myelinated NF200 positive-neurons, however, it 
was not present in all NF200-stained neurons (Fig. 6.5B). SNAP25 cleavage was also 
seen in neurons expressing CGRP, described to be peptidergic neurons (Fig. 6.5B). 
 
6.2.4 ChoBot significantly reduced KCl-evoked CGRP release in cultured sensory 
neurons   
Consequent to the evidence that ChoBot can internalise into peptidergic neurons, it was 
investigated whether ChoBot could modulate neuropeptide release. Peptidergic neurons 
are heavily involved in neurogenic inflammation and are implicated in inflammatory pain 
conditions (Kilo et al., 1997; Benemei et al., 2009). In a CGRP release ELISA assay, 
conducted by Dr Marta L.A. Simoes, 65 hour incubation of dissociated mouse dorsal root 
ganglion cultures with 10 nM ChoBot significantly reduced KCl-evoked CGRP release 
(Fig. 6.5C). Incubation with ChoBot did not, however, significantly impact either basal or 
capsaicin-induced CGRP release, although there was a trend for both to be reduced. 
This therefore confirms that, in vitro, ChoBot has a functional effect on the sensory 






Figure 6.5 ChoBot cleaves SNAP25 in peripheral sensory neurons in vivo and prevents 
KCl-evoked CGRP release in vitro. ChoBot-injected rats (200 ng/ 30 µl, N=2) and vehicle-
injected rats (30 µl 0.4% OG in Buffer A, N=2) were perfused with 4% paraformaldehyde 7 days 
post-injection. Naïve rats were also perfused but received no prior treatment. (A) Epifluorescent 
images of 30 µm glabrous skin sections, isolated from the plantar surface of the hindpaw, reveal 
cleaved SNAP25 (red) in the sensory neurons, marked using βIII-Tubulin (green), within the 
dermis of the ChoBot-injected paw (ipsilateral paw, N=2). Cleaved SNAP25 was absent in the 
paw contralateral to the ChoBot-injected paw (N=2), in the ipsilateral hindpaw of vehicle-injected 
rats (N=2) and in naïve animals (N=2). Autofluorescence is generated by the dermal layer and is 
visible at the top of all of the images. It can thus be ignored. Scale bar = 100 µm (B) Cleaved 
SNAP25 colocalised with both CGRP-positive and NF200-positive neurons (N=2). Scale bar = 50 
µm. (C) 65 hour incubation with 10 nM ChoBot significantly attenuated KCl-evoked CGRP release 
from dissociated mouse dorsal root ganglion neuron cultures (N=3). Reduced capsaicin-evoked 
CGRP release was also noted but was not significant. All data presented as mean ± S.E.M, *** 
P<0.001. ELISA data provided courtesy of Dr. M.L.A. Simoes. 
 
6.2.5 Cleaved SNAP25 is detected at the neuromuscular junction in the glabrous 
skin of the hindpaw following intraplantar injection of ChoBot 
It was also of importance to determine whether ChoBot would display any affinity for 
motor neurons, provided the paralytic nature of native BoNT/A. Visualisation of the 
neuromuscular junction, using α-Bungarotoxin-488, showed cleaved SNAP25 localised 
to the neuromuscular junction, as well as in some of the motor nerve fibres innervating 
the synapse (Fig. 6.6). Cleaved SNAP25 was absent at the neuromuscular junction in 
the contralateral paw. Expectedly, cleaved SNAP25 was not detected at the 
neuromuscular junction in vehicle-injected rats or in naïve animals (Fig. 6.6). 
 
6.2.6 Pre-emptive intraplantar injection of ChoBot attenuates the development of 
mechanical hypersensitivity following surgery 
The identification of SNAP25 cleavage in the peripheral sensory neurons combined with 
the overall absence of cleaved SNAP25 in the ventral lumbar spinal cord, or the 
contralateral paw, suggests that the catalytic activity of ChoBot is largely restricted to the 
peripheral injection site. The analgesic potential of ChoBot was consequently 
investigated as it would circumvent the concerns over the long-distance effects of BoNT 
chimeras, resulting from the retrograde transport, and possible transcytosis, routinely 
observed with these chimeras. ChoBot was primarily trialled in an incisional post-
operative pain model. Briefly, 200 ng ChoBot was administered via intraplantar injection 
to the left hindpaw of rats, five days prior to the induction of the incisional post-operative 
pain model. Post-operative pain was induced by performing a longitudinal incision to the 




Figure 6.6 Cleaved SNAP25 is detected at the neuromuscular junction after intraplantar 
injection of ChoBot. α-Bungarotoxin-488 was used to identify the neuromuscular junction 
(green) in glabrous skin sections, cryosectioned from the plantar surface of the hindpaw. Cleaved 
SNAP25 (red) was found colocalised to neuromuscular junction in the ipsilateral ChoBot-injected 
hindpaw, 7 days post intraplantar injection (N=2). Cleaved SNAP25 was not detected at the 
neuromuscular junction of contralateral hindpaw (N=2), in the ipsilateral paw of vehicle injected 
rats (N=2), or naïve rats (N=2).  
 
Injection of ChoBot did not influence either thermal (Two-way ANOVA, Treatment: 
Baseline - Day -1: Ipsilateral paw, F (1, 8) =0.4712, P= 0.5118, Fig. 6.7B; Contralateral 
Paw, F (1, 8) =0.0060, P= 0.9404, Fig. 6.7D) or mechanical basal thresholds (Two-way 
ANOVA, Treatment: Baseline - Day -1: Ipsilateral paw, F (1, 8) =1.275, P= 0.2915, Fig. 
6.7A; Contralateral Paw, F (1, 8) = 0.0358, P= 0.8546, Fig. 6.7C). Pre-treatment with 
ChoBot did, however, significantly attenuate the development of mechanical 
hypersensitivity in the ipsilateral paw following incision, compared to rats that received 
vehicle injection (Two-way ANOVA, Treatment: Day -1 – Day 7, F (1, 8) = 23.6, P= 0.0013, 
Fig. 6.7A). ChoBot-injected rats maintained a significantly higher mechanical withdrawal 
threshold in the ipsilateral paw, than vehicle-injected rats, between days 1-3 post-incision 




Figure 6.7 Pre-emptive intraplantar injection of ChoBot prevents the development of 
mechanical hypersensitivity following surgery. 5 week old male Sprague-Dawley rats 
received intraplantar injection of 200 ng/ 30 µl ChoBot (N=5) or vehicle (N=5) 5 days prior to the 
induction of the incisional post-operative pain model (A) Injection of ChoBot partially prevented 
the development of mechanical hypersensitivity in the ipsilateral paw, as shown by the increased 
mechanical withdrawal threshold, assessed using Electronic von Frey, between days 1 and 3 
post-surgery compared to vehicle-injected rats. (B) The paw withdrawal latency, measured using 
Hargreaves Plantar test, revealed that ChoBot had no effect on thermal hyperalgesia produced 
in the ipsilateral paw following incision. (C) The mechanical threshold and (D) the thermal 
threshold of the contralateral hindpaw remained unaffected by either incision and intraplantar 
injection of ChoBot to the ipsilateral paw. All data presented as mean ± S.E.M, ** P<0.01. 
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7 post-incision, the mechanical threshold had returned to basal levels for both ChoBot- 
and vehicle-injected rats and there was no longer a significant difference in mechanical 
threshold between the two groups (Sidak’s multiple comparisons test, Day 7, P= 0.5056). 
By comparison, ChoBot had no effect on the development of thermal hypersensitivity in 
the ipsilateral paw following incision (Two-way ANOVA, Treatment: Day -1 – Day 7, F (1, 
8) = 0.1672, P= 0.6933, Fig. 6.7B). Additionally, it was evident that the mechanical 
threshold (Two-way ANOVA, Interaction, F (7, 56) = 0.6173, P= 0.7393, Fig. 6.7C) and 
thermal threshold (Two-way ANOVA, Interaction, F (7, 56) = 0.4969, P= 0.8328, Fig. 6.7D) 
of the contralateral paw remained stable throughout the experiment and were unaffected 
by either injection of ChoBot or incision to the opposing hindpaw.  
 
6.2.7. Post-operative intraplantar injection of ChoBot does not reverse mechanical 
hypersensitivity in a post-operative pain model 
Encouraged by these results, it was next investigated whether ChoBot could be 
administered post-incision to reverse the mechanical hypersensitivity normally 
developed. In contrast, ChoBot injected intraplantar 1 day post-incision failed to 
significantly reduce the mechanical hypersensitivity developed in the ipsilateral paw 
(Two-way ANOVA, Treatment: Day 1 – Day 4, F (1, 7) = 1.339, P= 0.2852, Fig. 6.8A) and 
remained ineffective against the thermal hypersensitivity component (Two-way ANOVA, 
Treatment: Day 1 – Day 4, F (1, 7) = 0.1988, P= 0.6692, Fig. 6.8B). Again, the mechanical 
threshold (Two-way ANOVA, Interaction, F (5, 35) 0.7433, P= 0.5964, Fig. 6.8C) and 
thermal threshold (Two-way ANOVA, Interaction, F (5, 35) = 1.594, P= 0.1876, Fig. 6.8D) 
of the contralateral paw remained unaffected throughout the experiment.  
 
6.2.8 Pre-emptive intraplantar injection of ChoBot does not prevent the 
development of mechanical hypersensitivity in females following surgery  
Over more recent years, there has been an increased emphasis placed on the need to 
include female subjects in pain studies (Mogil and Chanda, 2005). A large volume of 
evidence has shown that females not only experience more severe clinical pain, but also 
differ in their responsiveness to analgesic drugs (Greenspan et al., 2007; Fillingim et al., 
2009; Hurley and Adams, 2009). With specific reference to post-operative pain, it has, 
however, been demonstrated that both male and female rodents develop mechanical 
hypersensitivity to an equal degree in the incisional post-operative pain model (Kroin et 
al., 2003; Banik et al., 2006). Consequently, the analgesic potential of ChoBot was 




Figure 6.8 Post-operative intraplantar injection of ChoBot does not reverse mechanical 
hypersensitivity in an incisional pain model. 5 weeks old male Sprague-Dawley rats received 
intraplantar injection of either 30 µl vehicle (N=4) or 200 ng/ 30 µl ChoBot (N=5) one day post 
incision, after day 1 behavioural testing had been conducted. Injection of ChoBot post-incision did 
not significantly reverse the observed (A) mechanical hypersensitivity or (B) thermal 
hypersensitivity in the ipsilateral hindpaw. (C) The mechanical threshold and (D) the thermal 
threshold of the contralateral hindpaw remained stable and were unaffected by either incision or 
intraplantar injection to the ipsilateral paw. All data presented as mean ± S.E.M. 
 
model, to evaluate whether ChoBot was similarly as efficacious at attenuating the 
development of mechanical hypersensitivity in females, as was demonstrated in males.  
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There was no significant difference observed in either the mechanical (Two-way ANOVA, 
Sex, F (1,16) = 0.2569, P= 0.6191) or thermal threshold (Two-way ANOVA, Sex, F (1, 16) = 
3.034, P= 0.1007) of the ipsilateral hindpaw between males and females, recorded at 
baseline. Again, intraplantar injection of ChoBot did not significantly affect either the 
basal mechanical threshold of the contralateral paw (Two-way ANOVA, Treatment: 
Baseline 1 - Day -1, F (1, 6) = 0.2291, P= 0.6491, Fig. 6.9C) or the thermal threshold of the 
contralateral or ipsilateral paw in female rats (Two-way ANOVA, Treatment: Baseline 1 
- Day -1: Ipsilateral paw, F (1, 6) = 0.8546, P= 0.3909, Fig. 6.9B; Contralateral Paw, F (1, 6) 
= 3.316, P= 0.1185, Fig. 6.9D). A significant effect on the mechanical threshold of the 
ipsilateral hindpaw was detected (Two-way ANOVA: Baseline 1 - Day -1: Ipsilateral paw, 
F (1, 6) = 6.12, P=0.0482, Fig. 6.9A), however, this was due to differences observed in the 
initial baseline measurement of the ipsilateral paw between the two treatment groups, 
prior to injection of either vehicle or ChoBot. Once this data point was removed, injection 
of ChoBot was no longer shown to have a significant effect on the basal mechanical 
threshold of the ipsilateral hindpaw (Two-way ANOVA, Treatment: Baseline 2 - Day -1: 
Ipsilateral paw, F (1, 6) = 1.438, P=0.2756, Fig. 6.9A). 
In contrast to that observed in male rats, pre-emptive intraplantar injection of ChoBot in 
female rats did not hinder the development of mechanical hypersensitivity in the 
ipsilateral paw, following plantar incision (Two-way ANOVA, Treatment, F (1, 6) = 0.9955, 
P= 0.3569, Fig. 6.9A). Again, ChoBot did not significantly alter the thermal 
hypersensitivity observed post-incision (Two-way ANOVA, Treatment, F (1, 6) = 3.744, P= 
0.1012), although a trend for a reduced thermal threshold was noted in the ipsilateral 
paw of ChoBot-injected females (Fig. 6.9B). There does, however, appear to be a much 
larger variation in the paw withdrawal latency in female rats, compared to male rats, 
which could explain the observed trend.  
Once more, neither injection of ChoBot, nor the establishment of the post-operative pain 
model, had any significant effect on the mechanical threshold of the contralateral paw 
(Two-way ANOVA, Interaction, F (8, 48) = 1.051, P= 0.4123, Fig. 6.9C) or the thermal 
threshold (Two-way ANOVA, Interaction, F (8, 48) = 0.8011, P= 0.6046, Fig. 6.9D). 
 
6.2.9. Intraplantar injection of ChoBot does not reverse the thermal or mechanical 
hypersensitivity observed in Complete Freund’s Adjuvant inflammatory pain 
model  
Post-operative pain encompasses clinical features from a range of different pain 
conditions including nociceptive pain, inflammatory pain and neuropathic pain (Kehlet et 




Figure 6.9 Pre-emptive intraplantar injection of ChoBot does not prevent incision-induced 
mechanical hypersensitivity in female rats. Intraplantar injection of 30 µl vehicle (N=4) or 200 
ng/ 30 µl ChoBot (N=4) was administered to the left hindpaw of 6 week old female Sprague-
Dawley rats 5 days prior to plantar incision of the ipsilateral paw. (A) Pre-emptive injection of 
ChoBot did not attenuate the development of mechanical hypersensitivity in the ipsilateral 
hindpaw. (B) ChoBot was also ineffective against the development of thermal hyperalgesia in the 
ipsilateral paw. ChoBot- injected rats remained hyperalgesic to thermal stimuli 7 days post-
incision whereas the thermal threshold of vehicle-injected recovered to approximately basal 
values. (C) The mechanical threshold and the (D) the thermal threshold of the contralateral paw 
were unaffected by injection of vehicle or ChoBot or incision to the ipsilateral paw. All data 
presented as mean ± S.E.M, * P<0.05. 
basal pain thresholds indicates that ChoBot is not affecting acute nociception and 




Figure 6.10 Intraplantar injection of ChoBot does not reverse thermal or mechanical 
hypersensitivity in Complete Freund’s Adjuvant (CFA) inflammatory pain model. 
Intraplantar injection of either 30 µl vehicle (N=2) or 200 ng/ 30 µl ChoBot (N=3) was delivered to 
the left hindpaw of 6 week old male Sprague-Dawley rats 24 hours after injection of 15 µl CFA to 
the ipsilateral hindpaw. Day 1 behavioural testing was conducted prior to injection of ChoBot and 
vehicle. Injection of ChoBot failed to reverse CFA-induced (A) mechanical hypersensitivity or (B) 
thermal hypersensitivity in the ipsilateral hindpaw. (C) The mechanical threshold and (D) the 
thermal threshold remained consistent in the contralateral hindpaw in both groups, regardless of 
treatment. All data presented as mean ± S.E.M.  
neuropathic component of postoperative pain. To elucidate whether the perceived 
analgesic effect of ChoBot was due to an effect on inflammation, ChoBot was injected 
intraplantar in the Complete Freund’s Adjuvant inflammatory pain model to determine 
whether it would similarly reverse the pain phenotype.  
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ChoBot administered to the hindpaw 1 day after intraplantar injection of CFA did not 
influence the recovery of either the mechanical (Two-way ANOVA, Treatment, F (1, 3) = 
0.9798, P= 0.3952, Fig. 6.10A) or the thermal threshold (Two-way ANOVA, Treatment, 
F (1, 3) = 0.1846, P= 0.6964, Fig. 6.10B) compared to rats which instead received vehicle. 
Mechanical (Two-way ANOVA, Time, F (6, 18) = 0.387, P= 0.8777, Fig. 6.10C) and thermal 
thresholds (Two-way ANOVA, Time, F (6, 18) = 2.017, P= 0.1163, Fig. 6.10D) measured in 
the contralateral paw remained consistent throughout the experiment and were therefore 
unaffected by either injection of CFA or ChoBot to the ipsilateral paw.  
 
6.2.10 Intraplantar injection of ChoBot reduces mechanical hypersensitivity in 
paclitaxel-induced peripheral neuropathy 
The lack of effect of ChoBot observed on both acute nociception and inflammatory pain 
suggests that ChoBot might instead be mediating its therapeutic effect against the 
possible neuropathic component of post-operative pain. Consequently, it was 
investigated whether ChoBot would produce analgesia in a neuropathic pain model.  
Repeated intraperitoneal injection of Paclitaxel (2 mg/ml/kg), a chemotherapy drug, was 
successfully used to establish paclitaxel-induced peripheral neuropathy (PIPN), the 
chosen neuropathic pain model (Polomano et al., 2001). Rats who received repeated 
injection of paclitaxel displayed significant mechanical hypersensitivity in both paws 
compared to rats that received intraperitoneal injection of the vehicle control (Two-way 
ANOVA, Treatment: Ipsilateral Hindpaw, F (1, 8) = 38.02, P= 0.0003; Treatment: 
Contralateral Hindpaw, F (1, 8) = 91.48, P< 0.0001 Fig. 6.11A).  
The perceived mechanical hypersensitivity in paclitaxel-treated rats was significantly 
reversed by intraplantar injection of ChoBot to left hindpaw, subsequently referred to as 
the ipsilateral paw (Two-way ANOVA, Treatment: Day 14 - 28, F (1, 10) = 13.47, P= 0.0043, 
Fig. 6.12A). A significant overall reduction in mechanical hypersensitivity following 
injection of ChoBot was also observed in the contralateral paw (Two-way ANOVA, 
Treatment: Day 14 - 28, F (1, 10) = 9.227, P= 0.0125, Fig. 6.12B). The mechanical threshold 
of ChoBot-injected PIPN animals was, however, only shown to be significantly higher 
than vehicle-injected PIPN animals at one time point (Sidak’s multiple comparisons test, 
Day 17, P= 0.0296). The analgesic effect was apparent in both paws by day 17 and 
persisted until the experiment was terminated on day 28 (Fig. 6.12A and Fig. 6.12B).  
Although thermal hyperalgesia has previously been described in the PIPN model, it was 
only observed in animals treated with lower doses of paclitaxel and was absent in 
animals receiving the higher dosage of 2 mg/ kg Paclitaxel (Polomano et al., 2001). 




Figure 6.11 Repeated intraperitoneal injection of paclitaxel successfully produces 
paclitaxel-induced peripheral neuropathy (A) 6 week old male Sprague-Dawley rats received 
four intraperitoneal injections of either vehicle (1:1 ethanol:kolliphor) (N=4) or 2 mg/ml/kg 
Paclitaxel (N=6) on four alternate days (Day 0, 2, 4, 6). Repeated IP injection of paclitaxel (Px) 
successfully established paclitaxel-induced peripheral neuropathy (PIPN), as demonstrated by 
the development of mechanical hypersensitivity (decreased paw withdrawal threshold) in both the 
ipsilateral and contralateral paw of paclitaxel-injected rats, apparent by day 6. The mechanical 
threshold was not affected by intraplantar injection of vehicle (30 µl 0.4% OG in Buffer A) to the 
left hindpaw (ipsilateral paw) of both groups on day 15. (B) Plotting the mean weight per treatment 
group, including Px + ChoBot (N=6), revealed no significant difference in the average weight gain 
dependent on treatment group. Repeated injection of Px did not produce robust (C) thermal 
hypersensitivity or (D) cold allodynia, as assessed by acetone test. All data presented as mean ± 
S.E.M. Significance between groups for the ipsilateral paw: * P<0.05, ** P<0.01, *** P<0.001, **** 
P<0.0001; Significance between groups for the contralateral paw: # P<0.05, ## P<0.01, ### 
P<0.001, #### P<0.0001. 
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mg/kg paclitaxel treatment (Two-way ANOVA, Treatment: Ipsilateral Hindpaw, F (1, 2) = 
4.341, P= 0.1726; Treatment: Contralateral Hindpaw, F (1, 2) = 10.36, P= 0.0845, Fig. 
6.11C). In contrast, cold allodynia has been reported by previous studies were rats 
received 2 mg/kg paclitaxel (Polomano et al., 2001; Flatters and Bennett, 2004). This 
pain phenotype was not, however, replicated in this current study (Fig. 6.11D). All data 
points were shown to be statistically insignificant, except for day 13 when paclitaxel-
treated rats displayed a significantly higher score in the contralateral paw during the 
acetone test, compared to vehicle-treated rats, implying the development of cold 
allodynia (Mann–Whitney unpaired t-test, Day 13, P= 0.0095). Yet, this result was not 
reproduced at the succeeding time point, highlighting major inconsistency in the acetone 
test scores. The lack of overall significance could therefore be due to the high level of 
variation in the test scores as well as inadequate power due to limited N numbers. As a 
result, the acetone test was abandoned in subsequent experiments. 
 
 
Figure 6.12 Intraplantar injection of ChoBot reduces mechanical hypersensitivity in 
paclitaxel-induced peripheral neuropathy (PIPN). 6 week old male Sprague-Dawley rats 
received four intraperitoneal injections of 2 mg/ml/kg Paclitaxel (N=6) on four alternate days (Day 
0, 2, 4, 6). Maximal mechanical hypersensitivity was observed in the ipsilateral (left) hindpaw and 
contralateral (right) hindpaw by day 10. On day 15, rats received intraplantar injection of either 30 
µl vehicle (N=6) or 200 ng/ 30 µl ChoBot (N=6) to the ipsilateral hindpaw. (A) Injection of ChoBot 
reversed the paclitaxel-induced mechanical hypersensitivity whereas vehicle-injected PIPN rats 
remained hypersensitive. (B) ChoBot also reversed mechanical hypersensitivity in the 
contralateral paw, compared to vehicle-injected PIPN rats, but with a less pronounced effect than 




Notably, the three groups of rats all continued to gain weight normally throughout the 
experiment, regardless of the induced-neuropathy or treatment condition (Two-way 
ANOVA, Treatment, F (2, 13) =0.7047, P= 0.5122, Fig. 6.11B). Neither group displayed any 
signs of ill-health, decreased well-being or motor impairment. 
 
6.2.11 Female rats experiencing paclitaxel-induced peripheral neuropathy show a 
trend towards a reduction in mechanical hypersensitivity following intraplantar 
injection of ChoBot 
After the earlier post-operative pain experiment revealed that ChoBot was efficacious at 
preventing the development of mechanical hyperalgesia following surgical incision in 
males, but not females, and furthermore, after confirming that ChoBot was again 
analgesic in a neuropathic pain model, it was deemed important that the current 
neuropathic pain model should be repeated in female rats, to determine whether the 
effects of ChoBot are indeed gender-specific.  
It has previously been demonstrated that there are no sex-differences in the 
development of PIPN between male and female Sprague-Dawley rats (Hwang et al., 
2012). Similarly, here, no significant difference in the paw withdrawal threshold between 
male and female rats who received vehicle treatment (Two-way ANOVA, Sex, F (1, 5) = 
5.408, P= 0.0676) or paclitaxel treatment was detected (Two-way ANOVA, Sex, F (1, 7) 
=0.4492, P= 0.512, Fig. 6.13). Likewise to the male rats, the female rats which received 
repeated injection of paclitaxel showed a reduced mechanical withdrawal threshold 
compared to female rats that received repeated injection of vehicle. This trend, however, 
was not shown to be significant (Two-way ANOVA, Treatment: Ipsilateral Hindpaw, F (1, 
4) = 2.183, P= 0.2136; Treatment: Contralateral Hindpaw, F (1, 4) = 6.605, P= 0.062, Fig. 
6.14A). Furthermore, following injection of ChoBot on day 15 post-first paclitaxel 
injection, a recovery of the mechanical threshold was observed. Again, however, this 
was not shown to be significant (Two-way ANOVA, Treatment Day 14 - 28, F (1, 4) = 4.94, 
P= 0.0903, Fig. 6.14C). This lack of significance is most likely due to low n numbers 
rather than a lack of effect.  
The analgesic effect observed in the contralateral hindpaw following injection of ChoBot 
to the ipsilateral paw was not as clear in female rats (Two-way ANOVA, Treatment Day 
14 - 28, F (1, 4) = 0.3788 P= 0.5715, Fig. 6.14D). Only one timepoint indicated an increased 
mechanical threshold in the contralateral paw of ChoBot-injected rats compared to 
vehicle-injected rats. Conversely, in male rats, a higher mechanical withdrawal threshold 
was consistently measured in the contralateral paw at every time point, subsequent to 
ChoBot injection in comparison to vehicle-injected rats (Fig. 6.12B). 
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Figure 6.13 Male and female rats similarly 
develop mechanical hypersensitivity after 
repeated injection of Paclitaxel. 6 week old 
male and 7 week old female Sprague-Dawley 
rats received four intraperitoneal injections of 
either vehicle (1:1 ethanol:kolliphor) (Male, N=4; 
Female, N=3) or 2 mg/ml/kg Paclitaxel (Px) 
(Male, N=6; Female, N=3) on four alternate days 
(Day 0, 2, 4, 6). Reduced mechanical withdrawal 
threshold was observed in left hindpaw following 
repeated IP injection of Px in both male and 
female rats. No significant difference in the 
mechanical withdrawal threshold of the left 
hindpaw between male and female vehicle-
injected rats, or between male and female Px-injected rats was detected. Intraplantar injection of 
vehicle (30 µl 0.4% OG in Buffer A) to the ipsilateral (left) paw of all groups on day 15 did not 
affect mechanical withdrawal threshold. All data presented as mean ± S.E.M. 
 
As previously demonstrated, all three groups of female rats continued to gain weight 
normally throughout the experiment (Two-way ANOVA, Treatment, F (2, 22) = 0.1609, P= 
0.8523, Fig. 6.14B). No signs of decreased well-being or motor impairment were 
detected in any of the animals.  
 
6.2.12 The combined behavioural results of male and female PIPN rats highlights 
an analgesic effect of ChoBot against Paclitaxel-induced mechanical 
hypersensitivity 
Subsequently, after confirming that the mechanical pain thresholds were not significantly 
different between male and female rats undergoing the PIPN pain model, and after 
observing similar trends in the pain thresholds of female rats to those observed in male 
rats, it was decided that the data collected from both male and female rats could be 
effectively combined to increase the number of subjects, and consequently increase the 
statistical power of the data analysis.  
Combining the results from both the male and female rats once more highlighted a 
significant decrease in the mechanical withdrawal threshold of both the ipsilateral and 
the contralateral hindpaw in animals that received repeated injection of paclitaxel, 
opposed to vehicle control (Two-way ANOVA, Treatment: Ipsilateral Hindpaw, F (1, 14) = 
22.8, P= 0.0003; Treatment: Contralateral Hindpaw, F (1, 14) = 49.25, P< 0.0001, Fig.  
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Figure 6.14 A trend towards reduced Paclitaxel-induced mechanical hypersensitivity is 
observed in female rats after intraplantar injection of ChoBot. 7 week old female Sprague-
Dawley rats received four intraperitoneal injections of either vehicle (1:1 ethanol:kolliphor) (N=3) 
or 2 mg/ml/kg Paclitaxel (N=3) on four alternate days (Day 0, 2, 4, 6). (A) Repeated injection of 
(Px) resulted in a reduced mechanical threshold in the ipsilateral and contralateral paw of Px-
injected rats which was maximal by day 14. This reduction was not shown to be significant when 
compared to vehicle-injected females. The mechanical threshold was not affected by intraplantar 
injection of vehicle (30 µl 0.4% OG in Buffer A) to the left (ipsilateral) hindpaw on day 15. (B) The 
mean weight of each treatment group, including Px + ChoBot (N=3), was plotted to reveal no 
significant difference in the average weight gain between treatment groups. (C) Injection of 
ChoBot appeared to reverse the paclitaxel-induced mechanical hypersensitivity. Treatment was 
not shown to have an overall significant effect on mechanical threshold (P= 0.09), however, the 
mechanical withdrawal threshold was consistently higher in ChoBot-injected females and 
significance was reported on day 24. (D) The mechanical withdrawal threshold was also 
measured in the contralateral hindpaw. A reduced mechanical threshold is visualised by day 10 
but does not show a clear recovery after intraplantar injection of ChoBot to the ipsilateral hindpaw. 
All data presented as mean ± S.E.M, Significance between groups for the ipsilateral paw: * 
P<0.05; Significance between groups for the contralateral paw: # P<0.05, ## P<0.01. 
162 
 
6.15A). Intraplantar injection of ChoBot, 15 days after the first paclitaxel injection, 
reversed the mechanical hypersensitivity associated with PIPN in the ipsilateral paw 
such that the mechanical threshold returned to basal values (Two-way ANOVA, 
Treatment, F (1, 16) = 20.4, P= 0.0004, Fig. 6.15C). Intraplantar injection of ChoBot to the 
ipsilateral hindpaw was furthermore shown to significantly reduce mechanical 
hypersensitivity in the contralateral paw, compared to rats injected with vehicle (Two-
way ANOVA, Treatment, F (1, 16) = 8.531, P= 0.01, Fig. 6.15D). This was shown despite 
that the mechanical threshold of contralateral hindpaw was only significantly increased 
in the ChoBot-injected rats, compared to the vehicle-injected rats, at day 20 (Sidak’s 
multiple comparisons test, Day 20, P= 0.015). 
 
6.3 Discussion 
Throughout this project, widespread SNAP25 cleavage has been visualised in the ventral 
horn of the lumbar spinal cord after peripheral injection of the clostridial chimeras so far 
tested, namely BiTox/A (Chapter 3), BiTox/D (Chapter 4) and TetBot (Chapter 5). In the 
absence of any perceived motor impairments, the SNAP25 cleavage in the ventral horn 
has raised concerns about the possible off-target effects of the clostridial chimeras and 
has further stimulated discussion about whether any associated analgesic effects are 
centrally or peripherally mediated. In contrast, data collected in the previous chapter 
suggested that the novel chimera, ChoBot, lacked catalytic activity at the central motor 
synapse, and from this, it was surmised that ChoBot might exclusively act at the 
peripheral terminal. Here, it was shown that ChoBot does successfully cleave SNAP25 
in peripheral neurons, located at the intraplantar injection site. Consequent evaluation of 
the analgesic potential of ChoBot, across multiple pain models, revealed that, like 
BiTox/A, ChoBot produces analgesia specifically in pain conditions comprising a 
neuropathic component, and is ineffective against inflammatory pain conditions. 
 
6.3.1 ChoBot cleaves SNAP25 at the peripheral injection site 
The identification of cleaved SNAP25 in the sensory neurons of the hindpaw, following 
intraplantar injection, confirmed that ChoBot was able to internalise into sensory neurons 
in vivo and successfully cleave SNAP25. Immunolabelling in vivo largely agreed with the 
data gathered after in vitro incubation of dorsal root ganglion cultures with ChoBot. 
Cleaved SNAP25 was detected within a subset of NF200-positive, myelinated neurons, 
both in vivo and in vitro. In vitro data specified that ChoBot was enzymatically active in 
myelinated neurons of a significantly smaller average cell diameter than those neurons 
displaying cleaved SNAP25 after incubation with BiTox/A. This was repeatedly shown 
when labelling with both pan-neuronal marker, βIII-Tubulin, and with NF200.  
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Figure 6.15  The combined behavioural results of male and female PIPN rats highlights an 
analgesic effect of ChoBot against Paclitaxel-induced mechanical hypersensitivity. (A) 
Rats received four intraperitoneal injections of either vehicle (1:1 ethanol: kolliphor) (N=7, 4 male, 
3 female) or 2 mg/ml/kg Paclitaxel(Px) (N=9, 6 male, 3 female) on four alternate days. Repeated 
Px injection produced mechanical hypersensitivity in both the ipsilateral and contralateral 
hindpaw. Intraplantar injection of vehicle (30 µl 0.4% OG in Buffer A) on day 15 had no effect on 
the observed mechanical hypersensitivity. (B) Weight gain was not affected by treatment group. 
(C) Intraplantar injection of 200 ng/ 30 μl ChoBot to the left (ipsilateral) hindpaw on day 15 (N=9, 
6 male, 3 female), reversed the paclitaxel-induced mechanical hypersensitivity observed. Vehicle-
injected PIPN rats maintained mechanical hypersensitivity until the experiment was terminated 
on day 28. (D) Injection of ChoBot to the ipsilateral paw also attenuated mechanical 
hypersensitivity displayed in the contralateral paw with ChoBot-injected animals demonstrating a 
significantly higher mechanical withdrawal threshold compared to vehicle-injected PIPN rats on 
day 20. All data presented as mean ± S.E.M. Significance between groups for the ipsilateral paw: 
* P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001; Significance between groups for the contralateral 
paw: # P<0.05, ## P<0.01, ### P<0.001, #### P<0.0001. 
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Notably, however, there were fewer larger diameter neurons present in the cultures that 
were incubated with ChoBot and TetBot, than those incubated with BiTox/A. This could 
potentially bias the mean cell diameter of neurons displaying cleaved SNAP25, after 
incubation with ChoBot and TetBot, to a smaller value. Importantly, however, there was 
a consistently large increase in the number of small diameter neurons in cultures 
incubated with BiTox/A, compared to ChoBot and TetBot, indicating that there was no 
overall difference in the distribution of the cell diameter of neurons between the cultures. 
This is clearly demonstrated by the consistency of the median cell diameter between the 
different culture conditions. For example, with regards to the βIII-Tubulin staining, all 
three median cell diameters were 17 µm -18.1 µm. Consequently, there would have been 
an equal opportunity for both BiTox/A, TetBot and ChoBot to enter neurons of varying 
cell diameters, thus implying that the mean cell diameter should not have been drastically 
influenced by the number of large diameter neurons present. This is well demonstrated 
in the frequency histogram for neurons, identified using βIII-Tubulin, where only one 
larger neuron with a cell diameter greater than 30 µm displayed cleaved SNAP25 after 
incubation with ChoBot. The other five large neurons available remained negative for 
cleaved SNAP25. The mean cell diameter therefore remains a true representation of the 
neurons in which the chimeras preferentially cleave SNAP25.  
The presence of cleaved SNAP25 in myelinated neurons agrees with previous studies 
that demonstrated immunofluorescence in laminae III-V of the dorsal horn, where the 
myelinated Aβ fibres terminate, following intraneural injection of labelled-cholera subunit 
B (Woolf et al., 1992; Tong et al., 1999; Shehab et al., 2003). Minimal CTB labelling was 
detected in lamina I and II where the unmyelinated neurons terminate. Accordingly, here, 
cleaved SNAP25 is visualised in a much smaller percentage of peripherin-labelled 
unmyelinated neurons, than NF200- labelled myelinated neurons, following incubation 
with ChoBot, similarly demonstrating that ChoBot has a greater affinity for myelinated 
neurons.  
In contrast here, however, ChoBot produced cleaved SNAP25 in a subset of smaller 
myelinated neurons, more suggestive of Aδ-nociceptors, rather than Aβ low-threshold 
mechanoreceptors. Nevertheless, following nerve transection, previous studies did 
characterise increased immunoreactivity in lamina I-II of the dorsal horn, where the C- 
and Aδ-neurons project, and reported increased CTB labelling in smaller neurons  (Woolf 
et al., 1992; Tong et al., 1999; Shehab et al., 2003). This was suggested to be due to the 
increased uptake of CTB by undamaged unmyelinated and lightly myelinated neurons, 
post-nerve injury. This possibly results from the increased expression of the ganglioside 
to which CTB binds, GM1, which is associated with nerve repair and regeneration 
(Toffano et al., 1983; Leon et al., 1984). As described earlier, the protocol for producing 
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dissociated DRG cultures involves mutliple axotomies, required to excise DRGs. Again, 
this methodological process could perturb the expression levels of gangliosides and 
consequently impact the perceived in vitro binding profile of ChoBot.  
The presence of cleaved SNAP25 in CGRP-positive neurons following intraplantar 
injection of ChoBot, however, negates that the in vitro binding profile is solely a product 
of the culturing process. Although CGRP can be expressed by all subpopulations of 
sensory neurons, its expression is most prevalent in the smaller neurons, the C- and Aδ 
nociceptors  (Ferri et al., 1990; McCarthy and Lawson, 1990; Lawson et al., 2002; Bae 
et al., 2015). Cleaved SNAP25 was detected in both NF200- positive and CGRP-positive 
neurons in vivo, again suggesting that ChoBot could be catalytically active in Aδ 
nociceptors as this neuronal subtype would be most likely to produce immunoreactivity 
to both markers. Additional triple immunolabelling is, however, still required to confirm 
this.  
 
6.3.2 ChoBot demonstrates potential as a future analgesic 
Regardless, together, the verification of the catalytic activity of ChoBot in the peripheral 
sensory neurons, presumed to be Aδ-nociceptors, and the lack of activity noted at the 
central terminal, supported the decision to investigate ChoBot as a potential analgesic. 
ChoBot was shown to significantly attenuate the development of mechanical 
hypersensitivity following surgical incision to the hindpaw. Post-operative pain occurs in 
10–50% of surgical cases, for example, following breast surgery, amputation, and major 
heart surgery (Kehlet et al., 2006). Effective management of post-operative pain is 
essential to increase early mobilisation, reduce hospital stay length and to lessen the 
associated medical costs (Gupta et al., 2010).  
This analgesic effect was only observed when ChoBot was delivered pre-emptively, prior 
to surgery. Provided that cleaved SNAP25 was detected in the peripheral sensory 
neurons, this suggests that ChoBot could be preventing the initial sensitisation of 
peripheral afferents, which occurs around the incision site, and potentially the central 
sensitisation which occurs secondary to the increased nociceptive input from the 
peripheral afferents, by blocking neurotransmission (Pogatzki-zahn et al., 2017). The 
inefficacy of ChoBot post-incision suggests that once this hypersensitivity has been 
established, ChoBot is unable to reverse these changes. 
Pre-emptive analgesia is highly desirable from a clinical perspective as it reduces the 
need for post-operative pain management, for example, with the use of opioids which 
are prone to abuse. It has also been suggested that pre-emptive treatments are more 
effective methods for treating postoperative pain  (Møiniche et al., 2002). There is a huge 
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emphasis placed on the need for pre-emptive analgesia to be preventative, meaning that 
the treatment must stop peripheral and central sensitisation which leads to the 
chronification of post-operative pain, rather than simply blocking the initial perioperative 
nociceptive signalling. 
Unfortunately, this analgesic effect was not reproduced in females. Clinical studies show 
that female patients experience more severe post-operative pain than males, according 
to reported visual analogue scale (VAS) pain scores, and require more frequent 
analgesics to manage their pain (Logan and Rose, 2004; Uchiyama et al., 2006; Pereira 
and Pogatzki-Zahn, 2015). These sex differences have so far not been replicated in 
rodents. Instead, there were no perceived differences in the development of either 
mechanical or thermal hypersensitivity between male and female rodents in the incisional 
post-operative pain model, and both sexes responded equally to analgesic interventions 
(Kroin et al., 2003; Banik et al., 2006).  It is therefore unclear why male and female rats 
responded differently to incision following intraplantar injection of ChoBot 
Notably, here, the stage of the menstrual cycle was not measured. Recently, in light of 
mixed reports on the significance of the estrous cycle on pain thresholds, it has been 
shown that the estrous cycle in females does not introduce any additional variability in 
pain measurements, compared to male rodents, thus negating the need to record the 
stage of the estrous cycle (Mogil and Chanda, 2005; Prendergast et al., 2014; Becker et 
al., 2016). Instead, both studies suggest that males display their own intrinsic variability 
resulting from fighting, aggressive behaviours and instinctive hierarchy, behaviours 
which are largely absent in females. Therefore, the frequency of these behaviours should 
be equally considered when making a case for measuring the hormone levels in females. 
Although the menstrual cycle itself has been revealed to have little impact on pain 
thresholds, the mechanisms for the establishment of chronic pain have, however, been 
found to differ greatly between males and females (Mapplebeck et al., 2016). It has been 
shown that the development of mechanical allodynia in males relies upon the activation 
of microglia post-injury. This was demonstrated after the inhibition of, and the depletion 
of, microglia both significantly reversed mechanical allodynia in males separately 
subjected to the spared nerve injury model and the CFA model (Sorge et al., 2015). 
Conversely, although similar levels of microgliosis were observed in females, microglia 
were not implicated in the establishment of mechanical hypersensitivity in females as 
depletion and inhibition of microglia had no effect on mechanical pain thresholds. 
Consequently, this highlights that the difference in the efficacy of ChoBot, between the 
sexes, could potentially arise from a mechanism for the establishment of chronic pain 
which might only be active in males.  
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Despite the inflammatory component apparent in post-operative pain, ChoBot failed to 
induce analgesia in the Complete Freund’s Adjuvant inflammatory pain model in male 
rats, thus demonstrating a lack of effectiveness of ChoBot in inflammatory pain 
conditions. It was hypothesised that ChoBot would have an analgesic effect in 
inflammatory conditions after in vitro incubation of DRG cultures with ChoBot caused a 
reduction in CGRP release, a process which occurs in neurogenic inflammation and 
contributes to both peripheral and central sensitisation (Benemei et al., 2009). It would 
thus be useful to repeat this assay, using rat DRG cultures, to ascertain whether the 
results are reproducible or are indeed species-dependent.  
Conversely, when ChoBot was investigated in a neuropathic pain model, ChoBot had a 
profound analgesic effect. Interestingly, ChoBot was able to reverse the mechanical 
hypersensitivity observed in male and female PIPN rats. A full reversal of mechanical 
hypersensitivity was observed in the ipsilateral paw. Additionally, a partial, yet significant, 
recovery of the mechanical withdrawal threshold was demonstrated in the contralateral 
paw.  
A bilateral analgesic effect has previously been shown following unilateral injection of 
BoNT/A, including after intraplantar injection specifically. This was reported in two 
separate neuropathic pain models, in the streptozotocin-induced model of diabetic 
peripheral neuropathy (Bach-Rojecky et al., 2010) and in the paclitaxel-induced 
peripheral neuropathy model, as used here (Favre-Guilmard et al., 2009). In a separate 
study, the bilateral analgesic effect, produced after intraplantar injection of BoNT/A in a 
saline-induced model of muscular hyperalgesia model, was abolished by intraneural 
injection of colchicine, a blocker of axonal transport, to the sciatic nerve (Bach-Rojecky 
and Lacković, 2009). Thus, highlighting that the observed analgesia was due to a central 
effect of BoNT/A, subsequent to retrograde transport. This was further accredited in a 
subsequent follow-on study whereby axonal transport within the sensory nerves 
specifically, was demonstrated (Matak et al., 2011).  
In contrast, here, a negligible amount of cleaved SNAP25 was detected at the level of 
the spinal cord. This therefore opposes the theory for a central cause for the bilateral 
analgesia associated with peripherally-injected ChoBot. Due to the expansive cleavage 
of SNAP25 normally observed in the spinal cord after intraplantar injection of the other 
chimeras, it could be that investigation of the dorsal horn was neglected and that 
observations of cleaved SNAP25 were subsequently missed. This seems unlikely due to 
the thorough investigation of the tissue. Instead, the data suggests that ChoBot has a 
peripheral action, resulting in the blockade of neurotransmission in presumably the Aδ-
nociceptors, although it is unclear how this would provide analgesia in the contralateral 
paw. To ascertain that there is no role for retrograde transport in the analgesic effect of 
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ChoBot, colchicine could be injected intraneurally at the same time, or prior to, injection 
of ChoBot. If analgesia was still produced in the contralateral hindpaw then this would 
prove that it was due to another mechanism, other than a centrally-mediated effect of 
ChoBot.  
It is not yet clear why ChoBot produced an analgesic effect in both sexes experiencing 
PIPN but was only efficacious in males with regards to post-operative pain. Of note, 
however, the analgesic effect in the contralateral hindpaw was not as pronounced in 
female rats. There was only one data point that demonstrated a noticeably higher 
mechanical withdrawal threshold in the contralateral paw of ChoBot-injected PIPN 
females, compared to those receiving vehicle. It would be of interest to repeat this 
experiment, with a higher number of females, to allow a comprehensive comparison to 
made between the PIPN pain phenotype, and responsiveness to ChoBot, between males 
and females, to fully ascertain whether any subtler sex-differences do exist.  
Given the therapeutic benefit of ChoBot administered pre-emptively in post-operative 
pain, it raises the additional question of whether ChoBot injected before repeated 
Paclitaxel exposure might similarly prevent the development of mechanical hyperalgesia. 
64% of patients complain of chemotherapy-induced peripheral neuropathy whilst still 
receiving chemotherapy treatment. For 27% of these patients, this peripheral neuropathy 
develops into a long-lasting chronic neuropathic pain condition (Reyes-Gibby et al., 
2009). From this perspective, an earlier interventive treatment could be beneficial to 
block the development of the neuropathy. Consequently, another promising future 
experiment to conduct would be to inject ChoBot in the days before paclitaxel injection, 
to determine whether ChoBot would similarly prevent the development of the neuropathic 
pain condition. 
 
6.3.3 Justification of the behavioural assessment method utilised  
All of the observations made above relied upon the use of an electronic von Frey 
aesthesiometer to assess the mechanical withdrawal threshold. Electronic von Frey has 
been highlighted as a sensitive test by which to assess mechanical hypersensitivity 
(Ängeby Möller et al., 1998; Vivancos et al., 2004). The major advantage associated with 
using electronic von Frey is the reduced experimental time. Each animal requires a 
maximum of 4 applications of the electronic von Frey aesthesiometer compared to the 
repeated applications of single filaments, during manual von Frey testing. This lead can 
to the sensitisation of the paw, as well as learnt behaviours to subsequent von Frey 
filament applications (Deuis et al., 2017).  
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The accuracy and suitability of electronic von Frey for the evaluation of mechanical 
threshold, compared to manual methods, specifically in neuropathic pain models has, 
however, been questioned. It was found that electronic von Frey was unable to produce 
reliable readings of the mechanical threshold in neuropathic pain models which feature 
severe deformity of the hindpaw, resulting from denervation. For example, in the chronic 
constriction injury model were all three branches of the sciatic nerve are damaged (Nirogi 
et al., 2012). In the partial sciatic nerve ligation model, however, were the hindpaw 
maintains postural control due to the partial innervation that remains, electronic von Frey 
provided consistent readings. From this perspective, electronic von Frey would be able 
to reliably assess the mechanical threshold in the PIPN model as this model does not 
produce a motor deficit and does not feature any degeneration of the motor fibres, 
meaning that the posture and form of the hindpaws are unaffected (Polomano et al., 
2001). Furthermore, Electronic von Frey has already been successfully used to 
investigate mechanical threshold in both the incisional post-operative pain model 
(Whiteside et al., 2004) and the PIPN model (Rahn et al., 2008). Importantly, the values 
generated here, match those previously reported in the literature whilst using an 
electronic von Frey aesthesiometer, highlighting the high reproducibility between 
investigators (Moalem et al., 2004; Papers et al., 2004; Rahn et al., 2008). Furthermore, 
specifically, in this study, electronic von Frey has produced consistent results and its’ 
use is therefore justified. 
 
6.3.4 Considerations for the use of ChoBot as an analgesic  
For a novel chimera to be used as an analgesic, it is important that it can be easily 
administrated, and that the method of delivery is minimally invasive. The previously 
designed chimera, TetBot, produced analgesia in an inflammatory pain model (Ferrari et 
al., 2013), however, this effect was only noted after intrathecal injection and could not be 
replicated following peripheral injection (data unpublished). In humans, intrathecal 
injection is a complicated procedure that requires administration by a trained anaesthetist 
and is associated with serious adverse complications such as persistent parathesias, 
arachnoiditis, and, more rarely, temporary respiratory depression (Goodman et al., 
2008). The analgesic effects of ChoBot were reported after intraplantar injection. ChoBot 
could therefore be easily delivered by subcutaneous injection to a chosen peripheral site. 
Subcutaneous injection would not require highly specialist medical personnel, thus 
reducing any associated medical costs. Furthermore, whilst TetBot contains the receptor 
binding domain of Tetanus toxin, which the majority of humans are immunised against 
(Maple et al., 2000), most humans are not immunised against cholera toxin meaning that 
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it can be developed into a therapeutic intervention for humans. By contrast, TetBot is 
essentially redundant for human use. 
Unfortunately, however, ChoBot was no more efficacious at producing analgesia in 
inflammatory pain conditions than BiTox/A. Thus far, TetBot is the only chimera which 
has been demonstrated to be analgesic in inflammatory pain conditions. Notably, the 
clostridial toxins bind to specific gangliosides expressed within the cell membrane. As 
described in Chapter 4, specific gangliosides, including GT1b, GD1a and GM1, associate 
with myelin-associated glycoprotein (MAG), which is essential for the stability of the 
myelin sheath of neurons (Yang et al., 1996; Schnaar, 2010). Expression of these 
gangliosides is hence, more associated with myelinated neurons. Therefore, in order to 
target the unmyelinated c-fibres which are more commonly implicated in chronic 
inflammatory pain conditions (Weng et al., 2012), it may be important to expand the 
search for a targeting domain, away from toxins, and perhaps towards neuropeptides. If 
this was successful, then LcTd/A could, in theory, be targeted to neurons which normally 
become sensitised following neuropeptide release from peptidergic neurons, for 
example, during neurogenic inflammation (Xanthos and Sandkühler, 2014). 
Before further pursuing the use of ChoBot as an analgesic, it will be important to fully 
determine the stability of the chimera in vivo. During SDS-page, ChoBot can be seen to 
dissociate into LcTd/A-SNARE-A2 and the singular and pentameric B subunit. In 
contrast, the previous chimeras, BiTox/A (Ferrari et al., 2011) and TetBot (Ferrari et al., 
2013) remained stable following SDS-page, demonstrating that an irreversible assembly 
of the individual components had occurred. Moreover, immunoreactivity for the CTB 
subunit was still detected in the ventral spinal cord in the absence of any SNAP25 
cleavage. It is thus possible that the B subunit had dissociated away from the chimera, 
whilst in the periphery, before retrogradely transporting to the soma, leaving LcTd/A-
SNARE-A2 in the peripheral terminals, hence explaining why cleaved SNAP25 was only 
detected in the peripheral neurons. From this perspective, it might be necessary to 
conjugate LcTd/A directly to the singular CTB subunit, to avoid any potential adverse 
effects associated with any dissociated CTB subunits.  
Further to this, there were additional concerns about the significance of cleaved SNAP25 
detected at the neuromuscular junction. Rats injected with ChoBot were observed for 
any signs of stress or compromised wellbeing. Specifically, they were observed for 
indications of dehydration, such as weight loss, symptomatic of cholera, and for flaccid 
muscle paralysis, indicative of botulism. The ChoBot-injected rats continued to gain 
weight after receiving the injection of ChoBot and did not exhibit any visible signs of 
muscular paralysis, such as lameness or inability to grasp during the inverted wire mesh 
test. Furthermore, it has repeatedly been demonstrated that the engineered clostridial 
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chimeras do not cause muscular paralysis. For example, in Chapter 3 it was shown that 
BiTox/A produces cleaved SNAP25 at both the NMJ, as well as in the ventral horn, but 
fails to elicit muscular paralysis (Ferrari et al., 2011, 2013; Mangione et al., 2016). This 
suggests that the lethality and toxic effects associated with the two native toxins were 




In summary, it has been demonstrated that ChoBot can be effectively assembled using 
the established protein-stapling technology. The novel chimera, ChoBot, successfully 
retained the catalytic activity of LcTd/A, both in vitro and in vivo. Here, ChoBot is 
highlighted as a promising analgesic for pre-emptive use in post-operative pain and for 
the management of chemotherapy-induced neuropathies. It would be of great interest to 
investigate whether ChoBot can similarly reverse the mechanical hypersensitivity, 
characteristic of other neuropathic pain conditions. Importantly, considering that cleaved 
SNAP25 was largely absent at the level of the spinal cord, the analgesia associated with 
ChoBot provides evidence for a peripheral action, namely at the peripheral afferents, 
















Chapter 7. General Discussion 
 
The primary objective of this project was to identify a novel analgesic to provide long-
lasting pain relief in a variety of chronic pain conditions. Botulinum Neurotoxin A was 
chosen as the ideal biologic for development because of its well-known ability to silence 
neurons and effectively block neurotransmission. The multidomain structure of BoNT/A, 
combined with the expertise and knowledge of biochemistry and protein modification in 
the laboratory, made BoNT/A highly suitable for protein engineering. By exploiting protein 
modification techniques, it was hypothesised that BoNT/A would be safely retargeted to 
the sensory neurons, selectively involved in pain signalling pathways, whilst 
simultaneously excluding its entry to the neuromuscular junction to remove the flaccid 
motor paralysis, normally associated with botulism.  
Previous efforts to reengineer BoNT/A have resulted in the chimera, BiTox/A. For the 
chimera, BiTox/A, the LcTd/A, responsible for the enzymatic activity of BoNT/A, was 
reassembled to the receptor binding domain of BoNT/A, using the pioneered stapling 
technology, to produce an elongated version of native BoNT/A (Ferrari et al., 2011). 
Subsequent behavioural investigations had demonstrated that BiTox/A is analgesic in 
certain pain conditions, and is especially effective at reducing the mechanical 
hypersensitivity developed in neuropathic pain (Mangione et al., 2016). A significant 
portion of this project focused on the investigation of the in vivo behaviour of the 
published chimera, BiTox/A, to elucidate the mechanisms by which it might mediate its 
analgesic effect, subsequent to peripheral delivery (Mangione et al., 2016). 
 
7.1 The in vivo activity of clostridial chimeras 
Despite that, previously, Mangione et al. (2016) had failed to detect SNAP25 cleavage 
at either the peripheral injection site or in the lumbar dorsal horn after intraplantar 
injection of BiTox/A using western blot, here, immunohistochemical staining successfully 
revealed cleaved SNAP25 at both locations. This consequently provides the first 
evidence for both a peripherally- and centrally- mediated mechanism for the analgesia 
produced by BiTox/A. 
 
7.1.1 Cleaved SNAP25 is consistently detected in the peripheral sensory afferent 
terminals following intraplantar injection of clostridial chimeras 
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Specifically, cleaved SNAP25 staining was visualised in the peripheral sensory afferents 
following intraplantar injection of BiTox/A and colocalised with Neurofilament 200, the 
marker of myelinated neurons, and IB4, indicative of non-peptidergic neurons. This 
binding profile, established in vivo, was subsequently replicated in vitro, following 
immunolabelling of dissociated DRG cultures. In vitro, BiTox/A produced cleavage in the 
larger, myelinated neurons, suggestive of Aβ sensory neurons. Interestingly, in vivo, 
cleaved SNAP25 also partially colocalised with CGRP, a neuropeptide released by 
sensory afferents which contributes to pain signalling and neurogenic inflammation 
(Benemei et al., 2009). This was reminiscent of the peripherin-positive subpopulation of 
sensory neurons that were identified to contain cleaved SNAP25 in BiTox/A-incubated 
cultures, given that CGRP is primarily expressed by the unmyelinated C-fibre nociceptors 
(McCarthy and Lawson, 1990; Lawson et al., 2002).  
Likewise, ChoBot, investigated in chapter 6, was shown to produce SNAP25 cleavage 
in the peripheral sensory afferents, specifically within a subset of NF200 and CGRP-
positive afferents. This thus suggests that this peripheral action at the sensory afferents 
is conserved across the clostridial chimeras.  
 
7.1.2 Clostridial chimeras do not produce muscular paralysis despite cleaving 
SNAP25 at the neuromuscular junction 
Despite successfully demonstrating the enzymatic activity of BoNT/A in the peripheral 
sensory afferents, the issue with all the chimeras so far tested, including ChoBot, is the 
unexpected presence of cleaved SNAP25, repeatedly detected at the neuromuscular 
junction of the glabrous skin. It has, however, been consistently reported that animals 
injected with clostridial chimeras, do not display any visible signs of motor paralysis or 
impaired motor function of the hindlimb. More thorough assessments are, however, 
required to effectively disprove this concern before developing the chimeras for use in 
humans. As explained earlier, CatWalk gait analysis could elucidate any more subtle 
change in gait as a result of less obvious motor paralysis (Kappos et al., 2017). 
Electromyography recordings would also be recommended to ensure that there is no 
change in the electrical activity of the skeletal muscle, as this would likely be the most 
convincing argument to confirm that there is no motor effect.  
It is, however, possible that the function of the hindpaw muscles could be preserved, 
despite the cleavage of SNAP25 at the neuromuscular junction, if a suboptimal amount 
of SNAP25 has been cleaved. Keller and Neale (2001) depicted a model which predicted 
that for each percentage of SNAP25 cleaved, there is a two times equivalent reduction 
in the percentage of neurotransmitter released. The model illustrates that cleaved 
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SNAP25 is a competitive antagonist of full length SNAP25. In accordance with this, it 
has previously been described that half of the SNAP25 present is required to be cleaved 
to effectively block glutamate release from synaptosomes (Otto et al., 1995). 
Consequently, this shows that the negative effect of cleaved SNAP25 can be overcome 
if there is enough full length cleaved SNAP25 available to out-compete the cleaved, non-
functional SNAP25. These observations are therefore consistent with the proposed 
hypothesis that BiTox/A displays reduced penetration of the neuromuscular junction 
(Darios et al., 2010; Ferrari et al., 2011). If a lower level of SNAP25 is cleaved by BiTox/A, 
due to the reduced penetration and internalisation rate compared with native BoNT/A, 
then the limited amount of cleaved SNAP25 present could be successfully out-competed, 
and thus compensated for, by the full-length SNAP25. This could thereby justify the lack 
of motor impairment observed, despite the SNAP25 cleavage which occurs.  
 
7.1.3 The relevance of sensorimotor connectivity for the SNAP25 cleavage 
observed within the lumbar spinal cord following peripheral injection 
Further to the SNAP25 cleavage detected at the neuromuscular junction, the significance 
of the large area of SNAP25 cleavage reported in the ventral spinal cord, surrounding 
the motor neurons, following peripheral injection of not only BiTox/A, but also BiTox/D, 
TetBot and 2xTetBot, remains to be elucidated. As suggested previously, this could 
represent SNAP25 cleavage in the sensorimotor pathways within the spinal cord, which 
modulate motor output and are important for proprioception (Cai et al., 2017). For 
example, there are sensory neurons, namely the Ia sensory afferents, which respond to 
muscle stretch and project from the dorsal horn to then form synapses directly with the 
proximal dendrites and soma of the motor neurons in laminae IX (Snider et al., 1992). 
These afferents could thus provide direct access for BiTox/A, to the dorsal horn, via 
retrograde axonal transport, and could potentially represent the single fibres of SNAP25 
cleavage in the dorsal horn. Furthermore, there are also GABAergic interneurons, 
present in the spinal cord, which modulate the sensory input to motor neurons, both by 
presynaptic inhibition of sensory neurotransmitter release to motor neurons, as well as 
inhibition of the motor neurons post-synaptically to reduce excitability (Betley et al., 
2009). Again, this emphasises the interconnectivity which exists between the dorsal and 
ventral horn, even beyond direct contacts.  
Additionally, there is also the corticospinal tract which projects from the somatosensory 
and motor cortices to both the dorsal and ventral horn of the spinal cord. It is important 
for the execution of voluntary motor movements and sensory feedback (Scheibel and 
Scheibel, 1966; Moreno-López et al., 2016). The corticospinal tract thus represents yet 
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another interface between the sensory and motor systems, and collectively illustrates 
how well interconnected these two systems are. This hence demonstrates that even if 
the BiTox/A protease is solely transported by the motor neurons to reach the central 
spinal cord, considering that cleaved SNAP25 cannot be detected in the DRG, the 
protease could still gain indirect access to the neurons which constitute the sensory 
system, in order to impact sensory processing. 
In view of this, future experiments will be required to identify the neuronal subtypes which 
contain cleaved SNAP25, indicating the presence of active BiTox/A protease in the spinal 
cord to effectively delineate the neuronal networks by which BiTox/A might mediate its 
possible central effect. Two methods by which to achieve this would firstly be the use of 
neuronal tracers, such as Dil and DiA, that can be injected using a microelectrode to 
either the DRG or the dorsal root to label the sensory neurons, or to the ventral root to 
separately label the motor neurons (Snider et al., 1992). Alternatively, neuronal subtypes 
can be identified by immunolabelling, using specific markers. For example, vGlut1 can 
be used to selectively label the sensory terminals in the spinal cord, whilst parvalbumin 
can be used to label the motor neurons (Betley et al., 2009). Furthermore, vGlut2 and 
GAD65 can be used to identify the excitatory and inhibitory interneurons, respectively 
(Betley et al., 2009). Both techniques should label the entirety of the neuron, including 
the axonal and dendritic projections, rather than being confined to the neuronal nucleus 
and cytoplasm as is seen with the NeuN marker, used here. This will help to conclude 
whether the cleaved SNAP25 detected in the dorsal and ventral horn, is present within 
the dendritic arborisations of the motor neurons or within the spinal interneurons. 
Interestingly, the synaptic bouton labelling of sensory terminals, produced by vGlut1 
(Betley et al., 2009), resembles the cleaved SNAP25 staining observed immediately 
adjacent to the motor neurons, following intraplantar injection of BiTox/A, which was 
hypothesised to represent synaptic end-feet. This theory contrasts Cai et al. (2017) who 
claimed that the cleaved SNAP25 stain, resultant from peripheral injection of BoNT/A, 
remained contained within motor neurons. The two techniques detailed could be used to 
effectively disprove this theory if cleaved SNAP25 staining was found colocalised with 
either a tracer, or a respective neuronal marker, used to label the sensory afferents. If 
shown to be true, this experiment would further determine whether BiTox/A might enter 
the sensory afferents directly, or whether it instead enters connective interneurons.  
It will also be important to conduct an experiment whereby colchicine, a blocker of axonal 
transport, is injected intraneurally prior to intraplantar injection of BiTox/A (Bach-Rojecky 
and Lacković, 2009; Matak et al., 2012). This will delineate whether it is necessary for 
BiTox/A to reach the central spinal cord, regardless of which neuronal subtype it is active 
in, in order to elicit its analgesic effect. It will also verify that the SNAP25 cleavage 
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detected distal from the injection site, for example at the spinal cord and in the 
contralateral paw, results from axonal transport of the BiTox/A protease and not from 
systemic diffusion. 
Nevertheless, the lack of penetration of the spinal cord by ChoBot does, however, make 
it an attractive candidate for future development as an analgesic. Restricting the 
enzymatic activity of BoNT/A protease to the periphery greatly reduces the likelihood of 
any adverse off-target effects and improves the chimera’s safety profile, accordingly. 
 
7.2 The development and behavioural assessment of novel chimeras 
In addition to attempting to elucidate the in vivo activity of clostridial chimeras, an effort 
was made to produce a chimera efficacious against thermal hyperalgesia. Consequently, 
it was investigated whether chimeras produced by combining LcTd/A with the binding 
domains of other botulinum serotypes, namely Rbd/C, -/D and -/E, would show specificity 
for other sensory neuron subpopulations. If shown to be correct, this method would 
enable the targeting of separate sensory neuron subpopulations, whilst maintaining the 
long-duration blockade, characteristic of BoNT/A (Eleopra et al., 1998). It was 
hypothesised that the novel chimeras would then preferentially silence other distinct 
subpopulations of sensory neurons, and thus, be more efficacious against other pain 
conditions, such as inflammatory pain. 
Two of the novel chimeras, BiTox/D and -/E, did actively target LcTd/A to a different 
subpopulation of sensory neurons, however, when further pursued in a behavioural 
model of inflammatory pain, BiTox/D was unfortunately suspected to be pro-
hyperalgesic. Specifically, the behavioural assessment of BiTox/D in CFA-injected rats 
suggested that it might instead prolong the period of thermal hyperalgesia. This is not, 
however, to say that this stapling technology, or this approach, is therefore redundant. 
Recent research in collaboration with the Hunt lab at the University College London, 
investigated the conjugation of LcTd/A to neuropeptides, implicated in pain signalling, 
such as substance P, again using the stapling technique described (Maiarù et al., 2016). 
Given intrathecally, LcTd/A conjugated to Substance P successfully reduced mechanical 
hypersensitivity in both a chronic inflammatory pain model, induced by CFA injection, 
and in the spared nerve injury model of neuropathic pain. 
 
7.2.1 Methodological considerations for the perceived lack of analgesic effect of 
chimeras in inflammatory pain models  
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Here, in this project, the stapling technology was used to construct the chimera, ChoBot. 
Again, ChoBot consisted of the LcTd/A which was then attached to the AB5 cholera toxin 
binding domain. ChoBot was similarly shown to be analgesic. However, like with BiTox/A, 
this therapeutic effect was specifically observed against the mechanical component of 
pain conditions. Specifically, ChoBot was effective at attenuating the mechanical 
hypersensitivity experienced in the incisional pain model for post-operative pain and in 
the PIPN model of neuropathic pain. ChoBot was not, however, shown to relieve thermal 
hyperalgesia or to produce analgesia in purely inflammatory conditions, i.e. the CFA-
induced inflammatory pain model. This finding was demonstrated despite that, in vitro, 
ChoBot produced SNAP25 cleavage in a subpopulation of neurons which, based on their 
size distribution and myelination, were significantly distinct from the subpopulation in 
which BiTox/A cleaves SNAP25. Instead, the subpopulation of sensory neurons 
appeared very similar to that which TetBot is catalytically active in. Notably, TetBot was 
previously shown to reduce mechanical hypersensitivity in CFA-induced inflammatory 
pain (Ferrari et al., 2013). It is thus surprising that ChoBot did not also display an anti-
nociceptive effect in an inflammatory pain model. This could, nevertheless, result from 
the method of administration.  
The analgesic effect of TetBot was observed after intrathecal injection whereas, for this 
project, ChoBot was injected intraplantar. Similarly, the aforementioned BoNT/A-
Substance P construct, which reduced mechanical hypersensitivity in the CFA 
inflammatory pain model, was delivered via intrathecal injection (Maiarù et al., 2016). 
The method of administration could thus be essential for the observed therapeutic effect 
of clostridial chimeras in inflammatory pain conditions as, noticeably, all of BiTox/A 
behavioural experiments likewise utilised intraplantar injection (Mangione et al., 2016). 
Besides which, interestingly, immunolabelling of spinal cord sections, isolated from 
ChoBot-injected rats, showed minimal immunoreactivity for cleaved SNAP25 in the 
spinal cord, thereby suggesting that there had been insufficient transport of the BoNT/A 
protease to the spinal cord. Together, this suggests that clostridial chimeras might 
require direct access to the central terminal in order to elicit an analgesic effect in 
inflammatory pain conditions. Given the consistency of the results, dependent on the 
method of delivery, this might occur regardless of the targeting domain utilised.  
An alternative explanation regards the timing of the delivery of the chimeras. Both of the 
peripherally-injected chimeras, BiTox/A and ChoBot, were administered to the hindpaw 
one day after CFA injection. At this time point, one day post-CFA injection, significant 
oedema is already observed in the CFA-injected hindpaw, indicative of an inflammatory 
response (Iadarola et al., 1988; Stein et al., 1988). Accordingly, in both behavioural 
experiments, pain behaviour was maximal after 24 hours, consistent with previous 
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reports (Fehrenbacher et al., 2012; Mangione et al., 2016). The heightened immune 
response in the hindpaw at this time, and the infiltration of immune cells could result in 
the quick removal of the injected chimera before it is able to internalise into the sensory 
neurons that innervate the site of inflammation, thus leading to a diminished analgesic 
effect.  
Interestingly, BiTox/A administered to the hindpaw one day post-CFA injection elicited a 
very transient relief of mechanical hypersensitivity in the CFA-inflammatory pain model 
between days 2-3 post CFA-injection. Although the difference was shown to be 
significant, the improvement in the mechanical threshold was minimal. By comparison, 
when CFA was instead injected into the ankle joint, intraplantar injection of BiTox/A, 3 
days after CFA induction, resulted in a more significant, sustained reversal of the 
mechanical hypersensitivity, observed in the hindpaw. In this instance, BiTox/A was 
injected distal to the site of inflammation and would thus be less vulnerable to immune 
cells clearance which, consequently, could explain the improved analgesic effect 
observed. 
 
7.3 Additional methodological considerations 
7.3.1 The use of the in-house anti-cleaved SNAP25 antibody 
One of the major limitations of this project is the reliance of the conclusions made on the 
validity of the in-house anti-cleaved SNAP25 antibody. Rhéaume et al. (2015) previously 
questioned the specificity of some of the commercially available anti-cleaved SNAP25 
antibodies. Consequently, they tested the validity of these antibodies alongside their own 
in-house anti-cleaved SNAP25 antibodies. It was found that the validity of the 
commercial antibodies depended on the assay in which they were used, whether that be 
western blot or immunohistochemistry, and moreover, with specific reference to 
immunohistochemistry, the type of tissue used. The presence of immunoreactivity in 
vehicle-treated samples was regarded as evidence that the antibody lacked specificity 
and was instead binding both cleaved and full length SNAP25. The in-house anti-cleaved 
SNAP25 used here did not produce an immunofluorescent signal in tissue taken from 
either vehicle-injected or naïve animals or in vehicle or untreated DRG cultures, thus 
validating the antibody used here. It can thus be confirmed that the conclusions made 
are valid and based upon reliable evidence. It would, however, be recommended to 
ensure that these findings can replicated using an alternative anti-cleaved SNAP25 




7.3.2 The inclusion of the SNAP25 linker when generating clostridial chimeras  
With regards to the cleaved SNAP25 immunoreactivity, it has repeatedly been 
questioned whether the chimeras themselves would contribute to the positive cleaved 
SNAP25 signal. The chimeras have all been constructed using the SNARE stapling 
approach which involves the assembly of a SNARE complex at the centre of the 
conjugated subunits (Darios et al., 2010; Ferrari et al., 2011, 2013; Mangione et al., 2016; 
Mavlyutov et al., 2016). Consequently, all the chimeras contain the SNAP25 peptide, the 
cleavage target of BoNT/A protease. The presence of the BoNT/A protease within the 
chimera can thus result in self-cleavage. As detailed by Rhéaume et al. (2015), the 
amount of BoNT/A injected to elicit therapeutic effects is fairly negligible and therefore it 
would be extremely difficult to detect BoNT/A directly. This is why the proteolytic product 
is instead labelled as this provides signal amplification and acts as a reporter for the 
location of the BoNT/A protease. Similarly, the positive cleaved SNAP25 staining, 
generated directly by the cleaved SNAP25 linker-peptide contained within the chimeras, 
should be insignificant, perhaps even undetectable, compared to the signal produced by 
the cleavage of cellular SNAP25, the intended proteolytic product of the chimeras, due 
to the nanogram amounts injected.  
The other concern generally expressed regards the ability of the chimera to form in 
addition to its subsequent stability, following self-cleavage. Interestingly, SNAP25 which 
has been cleaved by BoNT/A, fully retains the ability to assemble into the SNARE-
complex (Hayashi et al., 1994; Otto et al., 1995). Once BoNT/A-cleaved SNAP25 enters 
the SNARE-complex, however, the complex is rendered non-functional and is 
consequently unable to fuse the vesicular and the plasma membrane, hence explaining 
why cleaved SNAP25 acts as a competitive antagonist to full length SNAP25 (Keller and 
Neale, 2001). Likewise, in the context of the SNARE-stapling technique, self-cleavage 
of the SNAP25 linker does not interfere with the assembly of the SNARE complex, and 
thus, does not impact chimera formation (Darios et al., 2010). Additionally, BoNT/A is 
unable to access and cleave SNAP25 once it is already engaged in a SNARE complex 
(Hayashi et al., 1994). Therefore, if the chimera assembles before self-cleavage occurs 
then the chimera will comprise full-length SNAP25 thus making the above justification 
inconsequential. 
 
7.4 Versatility in the SNARE-stapling technology 
Apart from demonstrating novel chimeras as potential future analgesics, this project also 
illustrated how advancements can be made to the stapling technology to successfully 
increase the efficacy of chimeric proteins. At this time, the project moved away from the 
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original aim of developing a novel pain therapeutic and instead concentrated on spinal 
cord delivery. It was shown that instead of using syntaxin solely as a staple, syntaxin 
could equally be utilised to attach an additional domain to the chimeric protein, via 
recombinant expression, comparable to that demonstrated with the other SNARE 
components. The additional subunit, here, an extra binding domain, did not interfere with 
the normal activity of the chimera but, instead, augmented it. One of the other linker 
peptides, α-SNAP25 is in fact composed of two individual helixes and could thus be split 
to enable the attachment of another additional domain. In theory, the potential exists to 
join a total of 8 individual subunits, if both ends of each of the four helices of the 
tetrahelical SNARE complex were utilised (Darios et al., 2010).  
 
7.5 Conclusions 
In conclusion, this project has demonstrated the ability of the SNARE-stapling technology 
to produce safer, novel analgesics for use in a range of chronic pain conditions. During 
this project, ChoBot, specifically, has been highlighted as a promising analgesic for pre-
emptive use in post-surgical pain and for the management of neuropathic pain 
conditions. Meanwhile, the potential mechanisms by which BiTox/A might mediates its 
analgesic effect have been elucidated. All chimeras were administered without producing 
motor paralysis or compromising the wellbeing of animals.  
This project has also emphasised the versatility of the stapling technology. In chapter 4, 
it was shown how the stapling technology allows for the combinatorial engineering of 
proteins. This enabled the efficient substitution of receptor binding domain of the BiTox 
chimera and consequently, allowed for the exploration of the differential binding profiles 
resulting from the alternative targeting of the BoNT/A protease. Furthermore, it has been 
demonstrated that the stapling technology is not restricted to use with clostridial 
neurotoxin subunits, exclusively. ChoBot utilised the binding domain of an alternative 
bacterial toxin, cholera toxin. Additionally, the stapling technology has also been used to 
conjugate BoNT/A protease to neuropeptides implicated in pain signalling (Maiarù et al., 
2016), as well as to surrogate targeting domains intended to target the protease to 
neuroblastoma cell lines, for the treatment of cancer (Rust, 2016; Hart, 2017).This further 
demonstrates the multiple disease applications for the stapling technology.  
In this project, the use of chimeras for spinal cord delivery was investigated. With further 
development, chimeras could provide a therapeutic delivery tool for use in central 
nervous system conditions, including amyotrophic lateral sclerosis (ALS) and spinal 
muscular atrophy (SMA), which, with the aid of advancements to the stapling technology 
such as the attachment of additional targeting domains, could lead to an augmented 
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therapeutic effect. The most promising application does, however, remain the use of 
clostridial chimeras in chronic pain.  
Multiple chimeras have now been tested across multiple pain models to successfully 
produce analgesia (Ferrari et al., 2013; Maiarù et al., 2016; Mangione et al., 2016). 
These chimeras have the capability to selectively target and provide long-term silencing 
of pain signalling pathways. With the aid of future experiments to further validate the 
safety profile of clostridial chimeras, they offer a potential solution to the inadequacy of 
current pharmacological intervention for chronic pain and could provide the first 
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